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Abstract 
 
 
 
This thesis presents two novel approaches for performing subgroup analyses or 
identifying subgroups in an individual patient data (IPD) meta-analyses setting. The 
work contained in this thesis originated from an important research priority in the 
area of low back pain (LBP); identifying subgroups that most (or least) benefit from 
treatment. Typically, a subgroup is evaluated by applying a statistical test for 
interaction between a baseline characteristic and treatment. A systematic review found 
that subgroup analyses in the area of LBP are severely underpowered and are of a 
rather poor quality (Chapter 4). IPD meta-analyses provide an ideal framework with 
improved statistical power to investigate and identify subgroups. However, 
conventional approaches to subgroup analyses applied in both a single trial setting and 
an IPD setting have a number of issues, one of them being that subgroups are typically 
investigated one at a time. As individuals have multiple characteristics that may be 
related to response to treatment, alternative statistical methods are required to 
overcome the associated issues. Tree based methods are a promising alternative that 
systematically search the entire covariate space to identify subgroups defined by 
multiple characteristics. In this work, a number of relevant tree methods, namely the 
Interaction Tree (IT), Simultaneous Threshold Interaction Modelling Algorithm 
(STIMA) and Subpopulation Identification based on a Differential Effect Search (SIDES), 
were identified and evaluated in a single trial setting in a simulation study. The most 
promising methods (IT and SIDES) were extended for application in an IPD meta-
analyses setting by incorporating fixed-effect and mixed-effect models to account for 
the within trial clustering in the hierarchical data structure, and again assessed in a 
simulation study. Thus, this work proposes two statistical approaches to subgroup 
analyses or subgroup identification in an IPD meta-analysis framework. Though the 
application is based in a LBP setting, the extensions are applicable in any research 
discipline where subgroup analyses in an IPD meta-analysis setting is of interest. 
xv 
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Chapter 1 
 
Brief Introduction  
 
 
1.1 Introduction 
 
The main purpose of this thesis is to develop and evaluate an innovative approach for 
identifying subgroups in individual patient data (IPD) meta-analyses within the area of 
low back pain (LBP). Although this is the ultimate goal, there are several important 
steps that need to be taken along the way to help achieve this goal. These steps include 
a systematic review of the quality of subgroup analyses in LBP randomized controlled 
trials (RCTs), a review of the methods used to perform subgroup analyses in general 
and the comparison of identified relevant subgroup analysis methods in a single trial 
setting. Evaluating candidate methods in a single trial setting will help select the best 
method(s) to take forward and extend to an IPD subgroup meta-analyses setting. 
 
At the outset, it is important to put this PhD project into context and make it clear as to 
where this work originated from and why it was funded. Therefore, this chapter will 
start by briefly detailing the background for the overall project and origins of the PhD 
funding. The primary and secondary research objectives of this thesis will then be 
presented. Finally, an overview of the thesis structure will be given. 
 
3 
 
1.2 Project Background 
 
The funding for this PhD comes from a National Institute of Health Research (NIHR) 
programme grant applied for by both the supervisors of this PhD; Professor Martin 
Underwood (Principal Investigator) and Professor Nigel Stallard (Co-applicant). The 
funding was for a programme grant on the identification of subgroups of patients that 
most benefit from therapist delivered interventions for the management of LBP. This 
project involved collecting a repository of individual patient data from the several 
existing RCTs that have tested similar therapist delivered interventions, and then 
performing subgroup analyses of the pooled trial dataset. The outcome of the subgroup 
analyses would determine whether or not patients presenting with non-specific low 
back pain can be matched to a treatment that is best suited to them. Any identified 
subgroups that most benefit will have increased effectiveness compared to the average. 
 
The programme grant also funded this PhD to look into the development of subgroup 
analysis methodology specifically in the area of low back pain research. The work, 
therefore, sits clearly within the field of back pain research, but with a strong focus on 
methodological development in statistical analysis.  
 
1.3 Research Objectives 
 
The work in this thesis is motivated by research priorities in the LBP community; in 
particular, identifying subgroups of patients who most benefit from therapist delivered 
interventions. Typically single trials are designed such that the sample size will provide 
sufficient power for a main effect to be detected in the primary outcome only. 
Therefore splitting the total sample into smaller subgroups will severely under-power 
any secondary subgroup analyses for detecting true subgroup effects i.e. more likely to 
yield false negative findings. Despite lacking power, subgroup analyses can still be 
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performed as a purely exploratory piece of work to generate hypotheses to be tested in 
future research.  
 
There are plenty of LBP data from positive studies that test similar interventions and 
use similar outcome measures. Thus a cost-effective way of performing subgroup 
analyses that substantially improves the issue of power is by pooling the IPD from 
these trials and performing subgroup meta-analyses. Ordinary meta-analyses that 
synthesize aggregated data from several similar studies are a popular form of analysis. 
It has been used for many years; hence its methodology is very well established. IPD 
meta-analyses on the other hand use the original individual patient data from each of 
the studies, which makes the analyses rather more complex. However, of the two 
approaches, the advantage of IPD meta-analyses is that patient level covariates can be 
fully investigated which is therefore ideal for performing subgroup analyses. 
Performing IPD meta-analyses has only recently become popular and therefore its 
methods are not as well established. Typically, subgroup analyses in both single trials 
and in IPD meta-analyses use interaction tests and only test for one interaction at a 
time; they do not consider the multiple characteristics of patients. Thus, there is a need 
to develop IPD subgroup meta-analyses methodology that incorporates the multiple 
characteristics of patients when defining and identifying subgroups. This highlights the 
primary research objective of the work in this thesis.  
 
Primary research objective: The primary research objective of this thesis is to 
develop and evaluate an innovative approach or approaches for identifying subgroups 
in IPD meta-analyses within the area of low back pain.  
 
Secondary research objectives: In order to attain the primary research objective, a 
number of important steps in the form of secondary research questions were 
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addressed. These steps are primarily to do with evaluating both the clinical and 
statistical aspects of subgroup analyses in a single trial setting. By doing so, this helps 
develop a firm understanding of subgroup analyses as a whole before moving forward 
to think about methodological extensions to an IPD subgroup meta-analyses setting. To 
be more precise, the secondary research questions were: 
 
1) What are the current recommendations for performing subgroup analyses in 
RCTs? 
2) What is the quality, conduct and reporting like of secondary subgroup analyses 
performed of RCTs of therapist delivered interventions for the management of 
non-specific LBP? 
3) What alternative methods can be used to perform subgroup analyses in RCTs? 
 
These secondary research questions helped to systematically work towards meeting 
the primary objective. These questions were answered in the above order and thus 
formed the structure of this thesis. 
 
1.4 Thesis Structure 
 
Due to the multidisciplinary nature of this project, the content of this thesis has been 
separated into three parts with the intention of maintaining clarity and focus. More 
specifically, this was done to make the statistical and clinical aspects more distinct, at 
the same time allowing the statistical component to be presented in a more general 
setting. The three parts of this thesis are as follows: 
 
Part 1: Context and Current Practice 
 
Chapter 1 - Brief introduction 
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Chapter 2 – Background 
Chapter 3 – Review of current subgroup analysis guidance for trials 
Chapter 4 – Systematic review of subgroup analyses performed in LBP RCTs 
 
Part 2: Statistical Methodology 
 
Chapter 5 – Review of generic subgroup methodology 
Chapter 6 – Introduction to recursive partitioning methodology 
Chapter 7 – Simulation study comparing existing tree based methods based on 
recursive partitioning methodology 
Chapter 8 - Development of tree based method using recursive partitioning 
methodology to identify subgroups in individual patient data meta-analyses 
Chapter 9 – Further development of tree based methods 
 
Part 3: Application and Summary 
 
Chapter 10 – Application of proposed method to real data 
Chapter 11 – Discussion, further work and conclusions 
 
Chapters in Part I of the thesis will focus more on the clinical aspect of the project. At 
first, it is important to develop a firm understanding about what LBP is, what the 
current recommendations are for the management of LBP, how LBP is currently 
measured and why the identification of subgroups is a high research priority in the 
area of LBP. Thus, a detailed background of the clinical problem will be given in 
Chapter 2. Although several secondary subgroup analyses have been performed in the 
LBP literature, it is important to review the quality of these reported analyses. 
However, prior to doing so, it is necessary to understand the statistical challenges faced 
when performing subgroup analyses e.g. lack of power, multiplicity issue, and learn 
what recommendations have been made to ensure that the reported results are 
credible. For this reason, a review of the statistical challenges and current 
recommendations for performing subgroup analyses in RCTs in general is presented in 
Chapter 3. Thereafter, the final chapter in Part I will present a systematic review of 
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subgroup analyses performed in RCTs of therapist delivered interventions for the 
management of non-specific LBP. The content of this systematic review has been 
published in the Spine Journal (1). 
 
Chapters in Part II of the thesis focus on the statistical aspects of the project. This part 
of the thesis will initially review subgroup analysis methodology in general in Chapter 
5, where a host of methods that can be used to perform subgroup analyses will be 
described. Chapter 5 identifies tree based approaches that are based on recursive 
partitioning methodology as a promising approach to subgroup analyses in the context 
of RCTs. Chapter 6 will therefore go on to introduce the recursive partitioning 
methodology along with a description of several advanced variants that use this 
methodology to identify subgroups that moderate treatment effect. A simulation study 
will then be performed in Chapter 7 to compare the tree based methods described in 
Chapter 6 in a single trial setting. The candidate methods identified from Chapter 7 will 
then be developed for application to individual patient data. Therefore, Chapter 8 will 
detail the development of the proposed statistical method for identifying subgroups in 
an IPD subgroup meta-analysis including a simulation study. Finally in Part II of the 
thesis, further development of the proposed extensions evaluated in Chapter 8 will be 
described and assessed.  
 
Finally, in Part III I will focus on applying the proposed methodology to real data 
collected for the main funded project. The application of the proposed methods will be 
presented in Chapter 10. A detailed discussion, recommendations for further work and 
the final conclusions will be presented thereafter in Chapter 11. 
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Chapter 2 
 
Background 
 
 
2.1 Introduction 
 
Low back pain (LBP) is a musculoskeletal disorder that is extremely common and 
experienced by most adults at some point in their life (2, 3). It is common for a person 
with LBP to experience recurring episodes over time which in turn will affect their 
quality of life as well as their well-being (4, 5). Consequently, it has a big health and 
social impact, causing an enormous economic burden on those in search of treatment, 
their families and to society as a whole (6-8). The effective management of LBP is 
therefore a major concern. This chapter will initially define non-specific LBP along with 
its epidemiology and costs. The available recommended treatments and the most 
commonly used outcome measures of LBP will then be described. Finally, the effect 
sizes in positive studies will be discussed highlighting subgroup analyses as an 
important research priority. 
 
2.2 Definition 
 
In general, LBP is defined clinically as the occurrence of pain and discomfort located in 
the lower region of the back (also referred to as the lumbosacral area), that is, the area 
between the bottom of the rib cage and the buttock creases (9). In some instances, pain 
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in the upper legs may also be experienced in addition to the LBP. Here the term ‘pain’ is 
commonly defined as being an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage (10). The term ‘non-specific’ LBP simply refers to when pain is experienced in 
the lower back region but it is not possible to pin-point the exact cause of the LBP or 
attribute it to a known pathology (e.g. fracture, infection, malignancy specific cause 
etc). The set of symptoms for non-specific LBP include tension, soreness and/or 
stiffness in the lower back region attributed to a combination of several structures in 
the back, including the discs, joints and connective tissues (9). Even though non-
specific LBP is typically defined in this way, there is a clear misconception as to what it 
actually means. It is defined here as being a disease or a condition when in actual fact it 
is a set of symptoms. 
 
The duration of an episode of non-specific LBP can be classified as being acute, sub-
acute or chronic. Conventionally, acute LBP is when the duration of an episode 
continues for no more than six weeks, sub-acute LBP is when the duration of an 
episode lasts between six and twelve weeks and finally chronic LBP is when the 
duration of an episode lasts for more than 12 weeks (11). Although classifying patients 
in this manner may help with the diagnosis and management of LBP, it is possible that 
the approach in itself may not help with treatment decisions. For example, it might just 
be that the duration of symptoms is not a strong predictor of outcome and does not 
predict response to treatment at all (12). Also the symptoms of LBP may vary over time 
therefore making it difficult to classify the patient as being either an acute case or a 
chronic case of LBP. Applying such artificial constructs to patient symptoms may just 
be an oversimplification of what is happening in reality. Instead, it may be more useful 
to investigate diagnostic classification criteria whereby the large population of non-
specific LBP patients are further separated into smaller more homogeneous subgroups 
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based on some valid criteria e.g. history, muscular stability and flexibility. Such an 
approach may allow patients to be treated more effectively. 
 
2.3 Epidemiology  
 
Non-specific LBP is a common problem that can be quite disabling and is experienced 
by a majority of the UK adult population at some point in their life. A recent systematic 
analysis of the global burden of disease highlighted LBP as the leading cause 
contributing the most to the overall years lived with disability (13). It is difficult to 
estimate the prevalence of LBP as it tends to vary from study to study. However a 
systematic review of studies for LBP prevalence from 1966 to 1998 reported that there 
was 12% - 33% point prevalence, 22% - 65% 1-year prevalence and up to 84% life 
time prevalence (14). LBP is a recurrent problem that fluctuates over time. The 
majority of LBP patients, around 70%, will experience at least one recurrent episode 
within a 12 month period (15, 16). Estimates suggest that every year, around a third of 
the adults in the UK experience acute LBP but the symptoms often resolve quickly. A 
large number of patients do not consult the NHS and instead opt to self-manage their 
LBP. It is estimated that up to 20% approach their general practitioner (GP) about their 
problem (17). This works out to be around 2.6 million additional consultations every 
year (18), of which nearly 75% still have symptoms after a year and around 30% 
develop prolonged recurrent LBP (19, 20).  
 
2.4 Costs 
 
Health care costs are referred to as being direct financial costs whereas production loss 
costs and the cost of insurance as a result of injury are referred to as indirect costs. In 
all developed countries, the direct and indirect financial costs of LBP are considerably 
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large. However, it is not possible to make any direct comparisons of the cost of LBP due 
to varying health and social systems (21).  
 
Based on the most recent UK cost of illness study, the direct healthcare costs to the 
National Health Service (NHS) due to LBP were in the region of £1,632M (3). 
Approximately a third of this (£565M) was from non-NHS based health care costs 
which were primarily due to the use of private sector services (physiotherapists, 
osteopath’s, chiropractors, acupuncturists and others). The indirect cost estimates on 
the other hand vary due to the type of model used but could have been as much as 
£10,668M (3). It is important to remember here that these estimates are based on 
estimates made in 1998. Since then, there has been inflation as well as a dramatic 
change in the economy and therefore it is likely that the current direct and indirect 
financial costs for LBP are higher than those figures published in 1998.  
 
2.5 Available Treatments 
 
There are a wide variety of available treatments for the management of persistent non-
specific LBP that have been recommended in guidelines in the UK (National Institute 
for Health and Care Excellence (NICE) guidelines), Europe (European Guidelines-COST 
B13) and America (American College of Physicians and American Pain Society 
guidelines) (9, 22, 23). When there has been evidence to suggest that an intervention is 
beneficial, it is often not possible to distinguish whether the benefit is because of the 
intervention itself (specific effect) or as a result of the therapist’s delivery of the 
intervention (non-specific effect). For this reason, each of the guidelines clearly clarify 
that any guidance for the management of LBP is based on the assumption that the 
effects are purely down to the intervention package alone.  
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All patients presenting with non-specific LBP should first be given advice and 
information to encourage self-management of their problem (9). This involves 
informing the patient of the characteristics and symptoms of non-specific LBP along 
with advice to remain physically active and to persist in their normal daily activities as 
much as they can. This is standard practice for all patients. Next, all treatment options 
should be clearly communicated by the healthcare professional to the patient. 
Subsequently, a decision is made jointly by the patient and the healthcare professional 
taking into account the patient’s treatment preference and needs when selecting one of 
the following recommended treatments: 
 
- Physical activity 
- Exercise 
- Manual therapy 
- Combined physical and psychological treatment 
 
From the above, the combined physical and psychological treatment option is 
considered a bit later on in the care pathway after the other three simpler treatments 
and before any suggestions of surgery. If the chosen treatment package is not 
successful then another package should be offered. A person should only be referred 
for surgery if they have completed the best possible package that is suited to them and 
their severe LBP still remains. In such an instance, the patient should be referred to a 
service that specializes in spinal surgery.  
 
Drug Treatments 
In the first instance, paracetamol should be offered as initial medication. If paracetamol 
fails to provide effective relief then weak opioids, non-steroidal anti-inflammatory 
drugs (NSAIDs) or both can be offered. It is essential that the potential side-effects, 
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particularly in the elderly population, based on each individual are taken into account. 
This should then be explained to the patient so that the drug can be prescribed based 
on patient preference.  
 
Treatments not recommended 
There are a number of treatments for which there is not enough adequate evidence to 
know whether or not they work for the management of non-specific LBP and are 
therefore not recommended. They include: 
 
- Laser therapy 
- Therapeutic ultrasound 
- Interferential therapy 
- Transcutaneous electrical nerve stimulation (TENS) 
- Lumbar supports 
- Spinal traction 
- Therapeutic matter injected into the back 
- Selective serotonin reuptake inhibitors (SSRI) 
- Intradiscal electrothermal therapy (IDET) 
- Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) 
- Radiofrequency facet joint denervation 
 
The recommended treatments and best practice advice described above are primarily 
from the recommendations of the more recent UK (2009) and American (2007) 
guidelines which are based on more current evidence. The UK and American guidelines 
make rather similar recommendations for the management of non-specific LBP but 
have a few subtle differences when compared to the European guidelines (9, 22, 23). 
For example, the European guidelines do not recommend acupuncture and massage 
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therapy for the management of chronic LBP; whereas NICE and American guidelines 
do. However, these differences are most likely due to the lack of evidence available in 
the literature at the time when forming the European (2004) guidelines. 
 
2.6 Outcome Measures 
 
Many of the earlier trials investigating interventions for non-specific LBP used different 
outcome measures which made between study comparisons rather problematic. It was 
then decided by a group of international investigators that a main set of 5 domains 
should be used in all trials to standardize the outcome measures and to better facilitate 
the comparability amongst studies (24). The five domains are (i) pain symptoms, (ii) 
back related function, (iii) Generic well-being, (iv) Disability and (v) Satisfaction with 
care. A brief description of the most common outcomes used within each of these 
domains is given below: 
 
(i) Pain Symptoms 
 Troublesomeness/Bothersomeness - this is typically a single question asking the 
patient how troublesome or bothersome their LBP is. Patients can answer the 
question by selecting one of the five possible response categories which are Not 
at all, Slightly, Moderately, Very much and Extremely (25, 26). 
 Pain Severity – the severity or intensity of back pain is often measured using 
either a numerical rating scale (NRS) on a scale of 0 (No pain) to 10 (Worst 
possible pain) or a visual analogue scale (VAS) on a scale of 0 (No pain) to 100 
(Worst imaginable pain) (27).  The NRS is a one-dimensional measure that can 
be administered either graphically or verbally. The patient is required to 
indicate a whole number on an 11-point scale from 0 to 10 that best reflects 
their level of pain. The number indicated by the patient is then recorded by the 
person administering the questionnaire. The VAS on the other hand is a 
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continuous one-dimensional scale that can take the form of either a horizontal 
or vertical line that is 100mm (10cm) in length. The VAS is administered to the 
patient for self-completion where the patient is required to draw a line 
perpendicular to the VAS line that best reflects their level of pain. 
 Frequency – this is a single question that enquires about how frequently the 
patient experiences LBP. The most commonly used question requires that the 
patient selects the category that best reflects their frequency of pain. The 
number of available response categories varies but the two extremes are 
usually ‘Never’ and ‘Always’. An alternative measure of frequency might be the 
number of days of pain over a certain duration e.g. over the past 4 weeks. 
 
(ii) Back related function 
 Roland Morris Disability Questionnaire (RMDQ) – the RMDQ questionnaire 
consists of twenty-four items and measures back related disability (28). The 
patient is required to tick any of the twenty-four items that applies to them. The 
final score is computed by simply counting the number of ticked boxes. The 
final score is on a scale of 0-24 where a lower score indicates less severe 
disability. However a problem with this questionnaire is that it has not got any 
‘No’ tick boxes. This makes it impossible to distinguish whether an un-ticked 
box is genuinely un-ticked or has been missed by the patient. 
 Oswestry Disability Index (ODI) – the ODI questionnaire consists of ten 
questions related to everyday activities of daily living, where each question is 
on a scale of 0 (no disability) to 5 (worst disability) (29). The scores for each of 
the questions are then summed and converted to a scale of 0-100% where a 
lower score indicates less disability.  
 Von Korff Scale (VKS) - the modified Von Korff questionnaire measures both 
pain and disability using six questions, with each question having a scale of 0 
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(no pain/disability) to 10 (worst pain/disability). The first three questions are 
used to compute a measure of disability whereas the last three are used to 
measure pain. The scores are then transformed to a 0-100% scale where a 
lower score represents less pain or disability (30). 
 
(iii) Generic well-being 
 SF-12 or SF-36 - the SF-12 or SF-36 are commonly used as a measure of health-
related quality of life. The SF-12 questionnaire consists of 7 questions with 12 
items in total whereas the SF-36 questionnaire consists of 11 questions with 36 
items in total (31, 32). An algorithm is then applied to the item responses to 
create eight subscales that measure functional health and well-being. These 
eight subscales measure physical functioning, role-physical, bodily pain, 
general health, vitality, social functioning, role-emotional and mental health. 
These eight subscales are then used to create two aggregated summary 
measures of physical and mental health. These are measured on a scale of 0-
100 where a lower score indicates poorer physical or mental functioning. 
 EQ-5D – the EQ-5D is an outcome that measures the health-related quality of 
life of a patient. The questionnaire consists of two parts. The first part asks 
questions based on five dimensions (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression), hence why it is also referred to as 
the EQ-5D, where each dimension consists of three possible options (33). An 
algorithm is then applied to the responses to compute a healthy utility score 
that is usually on a scale of 0 (death) to 1 (perfect health state). It is also 
possible to obtain a negative utility score which suggests that a patient’s quality 
of life is worse than death. The second part of the questionnaire consists of a 
visual analogue scale (VAS) that has a scale of 0 (worst imaginable health state)  
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to 100 (best imaginable health state). The patient is required to mark on the scale 
how good or bad their health state is today. 
 
(iv) Disability 
 Days off work – this question simply asks the patient for the number of days off 
from work due to LBP over a certain period of time. The period of time for 
which this information is required varies from study to study e.g. number of 
days off from work during the past 4 weeks? Or number of days off from work 
during the past 3 months? 
 
(v) Satisfaction 
 Participant satisfaction – this is a single item question, as recommended by the 
international low back forum, that enquires about how satisfied the patient is 
with the effectiveness of the treatment they have received (24). There may be 
variations of the response categories available for this outcome measure. 
Typically the categorical responses are on a five point Likert scale ranging 
between the two extremes of ‘Very dissatisfied’ and ‘Very satisfied’. 
 Specific health transition question – this single question asks the patient how 
they feel since they were last assessed. The patient can choose one of several 
categorical responses on a Likert scale that best reflects how they feel. 
Responses include ‘are you much worse’, ‘a bit worse’, ‘the same’, ‘a bit better’ 
or ‘a lot better’.  
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Table 2.1 – Comparison of interventions from high-quality RCTs at short term (3 month) and long term (12 month) follow-up 
 
 
 
 
Mean Difference in RMDQ (95% CI);  SMD 
Study Control Intervention 3 month 12 month 
UK BEAM (2004) GP care Exercise 1.36 (0.63, 2.10); 0.34 0.39 (-0.41, 1.19); 0.10 
 
 Manipulation 1.57 (0.82, 2.32); 0.39 1.01 (0.22, 1.81); 0.25 
   Manipulation plus exercise 1.87 (1.15, 2.60); 0.47 1.30 (0.54, 2.07); 0.33 
     
  
ATEAM (2008) Usual care Massage 1.96 (0.74, 3.18); 0.39 0.58 (0.77, 1.94); 0.12 
 
 Alexander technique (6 sessions) 1.71 (0.47, 2.95); 0.34 1.40 (0.03, 2.77); 0.28 
   Alexander technique (12 sessions) 2.91 (1.66, 4.16); 0.58 3.40 (2.03, 4.76); 0.68 
     
  
BeST (2010) Advice only Cognitive behavioural therapy 1.10 (0.38, 1.71); 0.22 1.30 (0.56, 2.06); 0.27 
 
   
  
York Yoga (2011) Usual care Yoga 2.17 (1.03, 3.31); 0.50 1.57 (0.42, 2.71); 0.36 
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2.7 Effect sizes in positive studies 
 
Due to the severe debilitating effect of LBP and the enormous economic burden 
induced, substantial amounts of time and money have been expended researching 
various interventions since the mid-1990s. There are now several randomized 
controlled trials (RCTs) of different interventions that have proven to be effective with 
some of these also being cost-effective. To give some examples, Table 2.1 details the 
results of some high-quality RCTs, namely the UK BEAM trial, ATEAM, BeST and York 
Yoga trial (34-37). The magnitude of the effect sizes presented in Table 2.1 may be 
important at the population level however such effect sizes are much smaller than the 
general consensus of the minimum important change (MIC) at the individual level (38).  
 
Not all studies use the same outcome measure and so it is rather difficult to compare 
effect sizes amongst studies. To overcome this, effect sizes are typically standardized 
by dividing it by the standard deviation of the outcome measure at baseline to convert 
it to a standard unit of measure. The standardized measure thus reflects how many 
standard deviations the outcome measure changes from baseline up to the follow-up 
time point of interest. Standardized effect sizes, also referred to as standardized mean 
differences (SMD), are commonly described as being small (0.2), moderate (0.5) and 
large (0.8), as described by Cohen (39). In general, the effect sizes for the different 
available interventions in the area of LBP are of a similar magnitude; demonstrating, at 
best, small to moderate standardized mean effect sizes. Nevertheless, there is no clear 
indication of a substantial reduction in the health and social impact of LBP such as time 
lost from work and the burden of disability. This is clearly evident in a recent study of 
the UK global burden of disease which suggests that there was a 12% increase in the 
years lived with disability in the UK between 1990 and 2010 (40). The question then 
remains as to whether or not these treatments are really worthwhile.  
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There are plenty of useful LBP data from different trials to show these approaches 
work relatively well for the general LBP population as a whole. Thus, one approach to 
maximize treatment benefit for the individual would be to utilize these data to identify 
those who most benefit from different treatments. Identifying such subgroups would 
help enable clinicians to target treatment accordingly which in turn would improve 
individual patient care. For this reason, discovering which patients most benefit from 
treatment is highlighted as a key recommendation by the UK National Institute for 
Health and Care Excellence (NICE) LBP guidelines (9). 
 
Typically, LBP RCTs are designed and powered to test a main hypothesis in terms of a 
primary outcome measure. Thus, any secondary subgroup analyses will be 
substantially underpowered to detect the same effect size as that of the primary 
analysis. Notwithstanding this lack of statistical power, secondary subgroup analyses 
still have the potential to identify important patient subgroups, provided that the 
quality of subgroup analyses is of a high standard. Any identified subgroups would 
need to be further investigated in future trials. Numerous papers in the LBP literature 
claim to have performed subgroup analyses however the overall quality of these 
analyses is unknown. If the quality, conduct and reporting of subgroup analyses is 
poor, then it will have false implications on future research and future treatment. For 
example, assuming a paper reports a positive finding for a subgroup analysis that has 
been incorrectly conducted; another investigator may thereafter naively use the 
reported finding to conduct a future piece of research. Not only would this be a waste 
of the investigators time and money, but this would also increase the chances of more 
poor quality findings being reported in the literature. Thus it is very important to 
ensure that the quality of subgroup analyses in the area of LBP is of a good standard by 
following available proposed subgroup analyses guidelines (41-44). 
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2.8 Discussion 
 
This chapter gave an insight to the background of non-specific LBP as well as briefly 
describing the recommended available treatments based on the evidence to date. In 
general, the recommended treatment options available all show small to moderate 
effect sizes in improving non-specific LBP and there is no indication that a particular 
treatment is superior compared to the others. 
 
A number of Cochrane reviews in the area of non-specific LBP have been performed 
either comparing various treatments with each other or compared to usual care (45-
49). Typically, these reviews provide a clear and consistent message that the available 
treatments are only able to demonstrate small to moderate positive change when 
compared to usual care but there is no indication of a single specific treatment being 
superior. Thus the evidence suggests that the available treatments are relatively 
effective in the general LBP population as a whole. However, it may well be that certain 
subgroups of individuals benefit more (or less) from these treatments. As we are 
striving towards more individualized patient care, it is important that secondary 
analyses be performed to identify these subgroups and extract as much information as 
possible. This was one of the key recommendations made in the UK, European and 
American guidelines for future research for the management of non-specific LBP (9, 22, 
23).  
 
Over the years, there have been several studies evaluating different interventions for 
the management of LBP that have also performed secondary subgroup analyses. 
Acknowledging the fact that subgroup analyses are severely underpowered, it is not 
entirely clear what the quality of subgroup analyses is like in the LBP literature as a 
whole. It is therefore of interest to perform a systematic review of the quality, conduct 
and reporting of these secondary subgroup analyses. As most of the positive evidence 
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is for therapist delivered interventions, the systematic review as well as the rest of this 
PhD will be based on therapist delivered interventions and finding subgroups in this 
area.  
 
Prior to reviewing subgroup analyses in the LBP literature, it is important to review the 
statistical aspects and current proposed guidelines or recommendations for 
performing subgroup analyses in RCTs in general. Therefore, the next chapter will 
review current proposed recommendations for performing subgroup analyses in RCTs. 
The subsequent chapter will then describe a systematic review to evaluate subgroup 
analyses performed in RCTs of therapist delivered interventions for non-specific LBP. 
 
 
 
 
 
 
 
 
 
23 
 
 
Chapter 3 
 
Subgroup Analyses in 
Clinical Trials 
 
 
3.1 Introduction 
 
The previous chapter described how low back pain (LBP) is a very common and costly 
problem that affects most adults at some point during their life. It was also highlighted 
that identifying patient subgroups that most benefit from treatment is regarded as a 
high research priority in the LBP community. However, there are many arguments for 
and against performing subgroup analyses in general (41, 50). Some arguments against 
subgroup analyses are from statisticians who warn of the dangers in relation to the 
statistical issues associated with such analyses. On the other hand, clinicians argue that 
applying the overall result of a trial to individuals without considering the factors 
associated with an individual’s response can also be dangerous. Large amounts of 
money are expended in conducting trials with interest in testing primary hypotheses. 
Therefore a simplistic argument would be to fully utilize the data to extract as much 
information as possible by performing secondary analyses instead of performing just 
the primary analyses alone.  
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Despite the arguments against subgroup analyses, many still see the advantages and 
still perform them. In fact, there are statisticians, clinicians and health professionals in 
academia and the pharmaceutical industry that have a genuine interest in subgroup 
analyses. Generally speaking, subgroup analyses that are performed are exploratory in 
nature; i.e. they are not pre-planned and do not aim to prove an effect. Exploratory 
subgroup analyses can be classified into three types. The first type is to evaluate the 
internal consistency of the overall results from a trial. Many areas of research conduct 
trials to test hypotheses regarding the overall mean treatment effect in the population 
of interest. Though there might be an overall effect, one cannot make the assumption 
that this effect is the same across subgroups. Hence conclusions assuming the effects 
are the same in subgroups without investigating the internal consistency might be 
considered a wrong thing to do. The second type of exploratory subgroup analyses are 
post-hoc analyses to identify subgroups with improved treatment effect. Identifying 
such subgroups can help improve individualized patient care by targeting treatment 
accordingly. Finally, the third type is to find positive inference from a trial that failed in 
terms of statistical significance in the primary endpoint. Although the overall mean 
treatment effect was not beneficial to the study population, there may be subgroups 
that do actually benefit from treatment.  
 
From the three types of exploratory analyses described above, it is clear that over and 
above the statistical issues, there are several benefits and uses of performing subgroup 
analyses. The second of the three types is considered a research priority in the area of 
LBP research. Several subgroup analyses have been performed in the LBP literature 
over the years. It is therefore of interest to review the quality, conduct and reporting of 
these secondary analyses. Prior to doing so, it is important to understand the concept 
of subgroup analyses, the associated issues and review what the current proposed 
guidelines or recommendations are for performing subgroup analyses in RCTs in 
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general. Therefore, this chapter will initially describe what subgroup analysis is and the 
associated statistical issues without considering anything in relation to the specific 
clinical aspects. To better deal with the associated issues, a number of subgroup 
analyses guidelines have been proposed. Thus, some of the key recommendations from 
proposed guidelines within the context of RCTs will be described. Some concerns 
regarding the current recommendations will also be discussed thereafter. 
 
3.2 Subgroup analysis concept 
 
A randomized controlled trial (RCT) is considered the most valid way of evaluating the 
effectiveness of a new health care intervention (51-53). Consider a RCT that is designed 
to assess the effectiveness of a new intervention compared to a control arm or an 
existing intervention where we want to test the null hypothesis that both the 
interventions are equally effective in terms of some primary endpoint. Subsequently, 
we want to perform secondary subgroup analyses with the aim of trying to identify 
subgroups of patients for whom the new intervention works differently i.e. is more (or 
less) beneficial. Though this may seem rather easy and straightforward, in reality it is 
not that simple. Subgroup analyses are associated with a number of issues (discussed 
in this chapter) which require due consideration when performing analyses. If these 
issues are ignored and not appropriately acknowledged or addressed, it could lead to 
the over-interpretation of results which in turn might wrongly influence and misguide 
future research (41, 43, 44, 50, 54, 55). The statistical challenges associated with 
performing subgroup analyses are well documented in the literature. These challenges 
will be described and discussed below to familiarize the reader with the problems 
faced when performing subgroup analyses.  
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3.3 What is a subgroup analysis? 
 
A subgroup analysis is defined as the evaluation and comparison of treatment effects in 
subgroups of patients defined by baseline characteristics (44). It is most commonly 
referred to as subgroup analysis but is also, and less commonly, referred to as 
moderator analysis, subset analysis and test for treatment-by-covariate interaction. For 
example, in a low back pain (LBP) trial comparing a new exercise regimen 
(intervention arm) to advice to remain physically active (control arm), the investigator 
may wish to test the null hypothesis that both treatments are equally effective. They 
then might go on to test a secondary null hypothesis, pre-specified in the study 
protocol, that the treatment effect does not differ (is not more or less beneficial) in the 
employed subgroup compared to the unemployed subgroup and subsequently test this 
on completion of the trial. 
 
Any baseline characteristics that show evidence of a significant subgroup effect are also 
referred to as moderators of treatment effect. At this point it is important to distinguish 
between moderators, mediators and predictors. Moderators are baseline 
characteristics, measured before receiving any treatment, that have an interactive 
effect with treatment on outcome. Mediators are potential mechanisms, measured 
during treatment, that have interactive effect with treatment on outcome (56). 
Predictors, as the name suggests, are variables or factors that help predict or forecast 
the value of a future outcome irrespective of treatment. In a statistical model, there is a 
clear distinction between factors that have an overall effect and factors that have a 
differential or moderating effect i.e. an interaction with treatment. In this PhD, the 
focus will be on identifying those factors that that have an interaction effect with 
treatment.  
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3.4 Statistical concepts and issues with subgroup analyses 
 
Testing for subgroup effects 
Let us continue with the same example from above of a trial comparing a new exercise 
regimen (intervention arm) to advice to remain physically active (control arm). 
Assuming the trial reaches completion; there are clearly two possible scenarios that 
can occur. The first scenario is when the overall outcome of the trial fails to provide 
evidence of a statistically significant difference between the two arms. Even though the 
trial failed to detect an overall difference there is still a possibility that particular 
subgroups of patients did benefit from the new intervention e.g. the employed 
subgroup. In the second scenario, the overall result of the trial concludes superiority of 
the intervention arm, in which case the size of the benefit might differ across certain 
subgroups e.g. increased benefit in the employed subgroup compared to unemployed 
subgroup. Observing varying treatment effects across different subgroups is also 
referred to as treatment effect heterogeneity. 
 
When performing subgroup analyses, the investigator may be naturally inclined to test 
within individual subgroups separately. For example, the investigator may test for a 
treatment effect in the employed subgroup and find evidence of a significant treatment 
effect and then they may test for treatment effect in the unemployed subgroup and fail 
to detect a treatment effect. They might then erroneously conclude from this, ignoring 
the uncertainty, that a subgroup effect exists and that employed people do better with 
treatment than unemployed people. However, the uncertainty must never be 
overlooked. Separate tests for treatment effect only assess if the effects are different 
from zero in each particular subgroup; it does not test if the difference in treatment 
effect between both groups is different from zero. Thus, performing tests for treatment 
effect within subgroups separately is an incorrect approach to subgroup analyses for 
two reasons (41, 43, 50, 55, 57, 58). Firstly, applying this kind of an approach does not 
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directly evaluate the treatment effect heterogeneity of the subgroups. The most 
appropriate method of directly evaluating the treatment effect heterogeneity of 
subgroups is by using a statistical test for interaction in the regression model (54, 59, 
60). The second reason is that it inflates the overall type I error rate (probability of a 
false positive result) due to twice as many tests being performed (multiple testing), 
compared to using just the interaction test. The issue of type I error inflation will be 
explained in more detail in section 3.5. 
 
Table 3.1 – Summary table of treatment group by employment status interaction 
 
 
 
 
 
 
Interaction test example 
Let’s consider a simple regression model where 𝑌 is an outcome variable and 𝑇𝑟𝑡 and 
𝑋1 are two independent binary variables. In this example, let’s assume that 𝑇𝑟𝑡 is the 
treatment indicator (control=0, intervention=1) and 𝑋1 is an indicator of membership 
for the subgroup of interest, which in this example is employment status 
(unemployed=0, employed=1). A test for interaction can be performed to estimate the 
interaction effect between 𝑇𝑟𝑡 and 𝑋1 using a regression model and including an 
interaction term: 
 
𝑌 = 𝛽0 + 𝛽1𝑇𝑟𝑡 + 𝛽2𝑋1 + 𝛽3𝑇𝑟𝑡 ∙ 𝑋1 + 𝜀 .                 (3.1) 
 
where 𝜀 is the normally distributed error with mean 0. The interaction term in this 
model to be explored by the investigator is created by simply multiplying 𝑇𝑟𝑡 and 𝑋1. 
  Control (𝑇𝑟𝑡 = 0) Intervention (𝑇𝑟𝑡 = 1) 
Unemployed 
 (𝑋1 = 0) 
𝜇00 = 𝛽0 𝜇01 = 𝛽0 + 𝛽1 
Employed 
(𝑋1 = 1) 
𝜇10 = 𝛽0 + 𝛽2 𝜇11 = 𝛽0 + 𝛽1 + 𝛽2 + 𝛽3 
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The term 𝛽0 is the intercept of the line, and 𝛽1 and 𝛽2 are the coefficients for the 
treatment indicator (𝑇𝑟𝑡) and employment status indicator (𝑋1) respectively. The 
coefficients of the binary variables, 𝑇𝑟𝑡 and 𝑋1, are interpreted as the mean difference 
between the two levels being compared e.g. 𝑇𝑟𝑡 = 1 compared to 𝑇𝑟𝑡 = 0. The 𝛽3 
coefficient is interpreted as the interaction effect estimate i.e. the difference in the 
treatment effect between the employed and unemployed subgroups. To better 
understand the interaction effect, we can draw a 2x2 table of 𝑇𝑟𝑡 and 𝑋1 with the 
expected values (See Table 3.1). The expected values are denoted by 𝜇00 and  𝜇01 for 
the unemployed subgroup (𝑋1 = 0) who are in the control group (𝑇𝑟𝑡 = 0) and 
intervention group (𝑇𝑟𝑡 = 1) respectively. Similarly, the expected values are denoted 
by 𝜇10 and 𝜇11 for the employed subgroup (𝑋1 = 1) who are in the control group and 
intervention group respectively. To investigate if employment status moderates 
treatment effect, we need to see if there is a difference in the within subgroup 
treatment effect between the two subgroups i.e. to see if there is an interaction effect. 
This means, using table 3.1, that we want to evaluate: 
 
(𝜇01 − 𝜇00) − (𝜇11 − 𝜇10) = 𝜇01 − 𝜇00 − 𝜇11 + 𝜇10.          (3.2) 
 
and test to see if it is zero. The interaction effect can be easily shown by using the 
regression model (3.1) to evaluate (3.2). Using (3.1), the treatment effect in the 
unemployed subgroup is: 
 
(𝛽0 + 𝛽1 + 0 + 0) − (𝛽0 + 0 + 0 + 0) =  𝛽0 + 𝛽1 − 𝛽0 = 𝛽1. 
 
Similarly, the treatment effect in the employed subgroup is: 
 
(𝛽0 + 𝛽1 + 𝛽2 + 𝛽3) − (𝛽0 + 𝛽2 + 0 + 0) = 𝛽0 + 𝛽1 + 𝛽2 + 𝛽3 − 𝛽0 + 𝛽2 = 𝛽1 + 𝛽3. 
 
So 𝛽1 is the treatment effect of those who are unemployed (𝑋1 = 0) and the treatment 
effect of those who are employed (𝑋1 = 1) is 𝛽1 + 𝛽3. Thus using (3.2), the difference 
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between the subgroups is (𝛽1 + 𝛽3) − (𝛽1) = 𝛽3. Thus 𝛽3 is the estimate of the 
interaction effect that is to be tested.  
 
The test for interaction effect uses a t-statistic to test the null hypothesis H0: 𝛽3=0, i.e. 
the interaction effect is equal to zero. The alternate hypothesis is therefore H1: 𝛽3≠0. 
The t-statistic is computed by dividing the ?̂?3 interaction effect estimate by its 
estimated standard error. The t-statistic is then used to test the interaction effect by 
computing the associated p-value using a t-distribution and comparing it to a pre-
specified significance level (e.g. 0.05). If the test for the interaction term is significant 
i.e. there is evidence of an interaction effect present, then we cannot interpret 𝑇𝑟𝑡 in 
terms of our dependent variable 𝑌 alone as there is some dependency on the variable 
𝑋1. In other words, the magnitude of the effect of the treatment variable (𝑇𝑟𝑡) on the 
dependent variable 𝑌 is moderated by the subgroup variable (𝑋1). However it is 
important to note that although the interaction term is significant, this does not 
necessarily mean that it is a genuine effect. It might just be a spurious finding due to 
other reasons (discussed later on). 
 
Types of interaction 
All interaction effects can be distinctly classified as being either quantitative or 
qualitative (43, 44, 50). When the intervention arm is superior or inferior to the control 
arm in both subgroups (e.g. employed and unemployed) but varies by different 
degrees, then the interaction is called quantitative (Figure 3.1). On the other hand 
when the intervention arm is superior in one subgroup (e.g. employed) but is found to 
be worse in the other subgroup (e.g. unemployed) then the interaction is said to be 
qualitative (Figure 3.2). It is probably worth noting here that quantitative interactions 
can be removed by a monotonic transformation of the measurement scale whereas 
qualitative interactions cannot. 
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Figure 3.1 – Quantitative Interaction (treatment effect in the same direction) 
 
 
 
 
 
 
 
 
 
Figure 3.2 – Qualitative Interaction (treatment effect in different directions) 
 
 
 
 
 
 
 
 
 
Multiple comparisons 
When an investigator performs a single interaction test to assess treatment 
heterogeneity across subgroups, they must initially specify a significance level. A 
significance level is a fixed probability of finding a false positive result i.e. falsely 
rejecting the null hypothesis of equal treatment efficacy if it is actually true, also called 
the type I error. The significance level is kept limited to reduce the chances of the 
investigator making a false claim with the aim of producing a result that is believable. 
Intervention Control 
Employed Subgroup 
Unemployed Subgroup 
Intervention Control 
Employed Subgroup 
Unemployed Subgroup 
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The most commonly used significance value is α=0.05 which means, in frequentist 
terms, that there is a 5% chance of a significant effect when the null hypothesis is true.  
 
Most of the time there are several subgroups that are of interest either due to some 
clinical reasoning, evidence in previous literature or purely just for exploratory 
purposes. Therefore implementing the interaction test for each of these subgroups 
individually will inflate the overall type I error rate hence increasing the chances of a 
spurious finding. Let α be the significance level, where α =Type I error i.e. the 
probability of finding a false positive result for a single test. Then the probability of 
correctly failing to reject the null hypothesis for a single independent test is simply (1- 
α). If there are m independent tests performed then the combined probability of 
correctly failing to reject any null hypothesis is equal to: 
 
(1 − 𝛼) × (1 − 𝛼) × … .× (1 − 𝛼) = (1 − 𝛼)𝑚 =∏{1 − 𝛼}
𝑚
𝑖=1
  
Therefore the probability that at least one of the m independent null hypotheses is 
falsely rejected is equal to: 
 
   1 − (1 − 𝛼)𝑚 = 𝛼𝑚                              (3.3) 
 
Hence as the number of independent interaction tests (m) increases, the overall type I 
error rate (αm) increases, as illustrated in figure 3.3. For example, when 5 independent 
interaction tests are performed (m=5) using a significance level of α=0.05 then the 
probability, calculated using equation (3.3), of detecting at least one false positive 
result i.e. falsely detecting at least one statistically significant interaction out of the five, 
is approximately 23%. Multiple comparisons may also occur when a significant 
interaction has been found for a categorical variable, which therefore requires multiple 
tests to identify the specific category or categories that are heterogeneous. 
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Figure 3.3 – Probability of falsely detecting at least one significant interaction at the 
5% significance level for independent hypothesis tests 
 
 
 
 
 
 
 
 
 
 
 
 
There are examples of the misuse (multiple testing) and benefits of performing 
subgroup analyses. An overly enthusiastic investigator may inappropriately perform 
several subgroup analyses hence increasing the occurrence of spurious findings. The 
authors of the ISIS-2 study decided to demonstrate the multiplicity issue by 
investigating the star signs of patients in the study. The results suggested that the 
effects of aspirin and streptokinase were significantly different only for patients with 
the star signs Gemini and Libra (61). However, if conducted appropriately, subgroup 
analyses can be of great benefit. For example, subgroup analyses were performed in 
the BARI trial that compared bypass-graft surgery to angioplasty for revascularisation 
of patients with coronary artery disease. They found that there was a significant 
increase in the mortality of patients taking medication for diabetes who underwent 
angioplasty compared to those who underwent bypass-graft surgery (62). There was 
no difference in mortality for the non-diabetic patients. 
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When performing multiple tests, a multiplicity correction can be applied to control for 
the inflated overall type I error (63, 64). A multiplicity correction basically adjusts the 
significance level of each individual test downwards to ensure that the overall 
significance level remains at the same pre-specified level e.g. 0.05. If we assume the 
tests to be independent, we can simply re-arrange equation (3.3) and solve for 𝛼 in 
terms of 𝛼𝑚 to give: 
𝛼 = 1 − (1 − 𝛼𝑚)
1
𝑚 . 
This is often referred to as the Sidak correction which computes the 𝛼 level required 
for each independent test to control 𝛼𝑚. However, the Sidak correction makes the 
assumption of independence whereas in reality there might be some dependency 
between the tests. If the tests are positively correlated then the Sidak correction 
controls the overall type I error rate, but it does not when there is negative correlation. 
An alternative method that can be used and does not assume independence is the 
Bonferroni correction which is formulated using Boole’s inequality. Let 𝐸𝑖  (i=1,..,m) 
denote the event that the i-th test rejects the null hypothesis when it is true i.e. the 
event of a false positive. Boole’s inequality states: 
𝑃(𝐸1 ∪ …∪ 𝐸𝑚) ≤∑𝑃(𝐸𝑖)
𝑚
𝑖=1
. 
If we specify the significance level for each test to be 𝛼, i.e. 𝑃(𝐸𝑖) =  𝛼, then Boole’s 
inequality can be written as: 
𝑃(𝐸1 ∪ …∪ 𝐸𝑚) ≤∑𝑃(𝐸𝑖) =∑𝛼 = 𝑚𝛼.
𝑚
𝑖=1
𝑚
𝑖=1
 
This basically means that the type I error is at most 𝑚𝛼. Therefore, if we want to 
control the overall type I error at a pre-specified 𝛼𝑚 level, we need to adjust the 
significance level (𝛼 ) for each individual test by dividing by the total number of tests 
m. Thus, the Bonferroni correction is given by (
𝛼
𝑚
). When comparing the Bonferroni 
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correction to the Sidak correction, the Bonferroni is more conservative i.e.  (
𝛼
𝑚
)  ≤  1 −
(1 − 𝛼)
1
𝑚  for m>1, as it does not assume independence. 
 
Statistical power 
The significance level and power to detect a desired main effect on a primary endpoint 
is established during the design stages of all trials when estimating the required overall 
sample size. One of the factors thereafter that can negatively influence the power of a 
study to test the null hypothesis is a reduction in sample size. Therefore, performing 
secondary analyses of subsamples will considerably reduce the power to detect an 
effect size of the same magnitude as that of the main treatment effect. Thus, an 
interaction test will only allow substantially larger effect sizes to be detected; however, 
in reality we would probably expect them to be smaller than the main effects. 
 
Consider a two-arm trial with n participants in each arm that is powered to detect a 
main effect  ?̂?1 − ?̂?2. We know that both 𝑣𝑎𝑟(?̂?1) and 𝑣𝑎𝑟(?̂?2) can be computed by 
𝜎2
𝑛
. 
Thus it can be shown assuming independence that the variance of the main effect is 
simply  
 
𝑣𝑎𝑟(?̂?1 − ?̂?2 ) =  
𝜎2
𝑛
+ 
𝜎2
𝑛
= 
2𝜎2
𝑛
 . 
 
Now consider the subgroup example in table 3.1 looking at the difference in treatment 
effect across employment status. This difference is evaluated by use of an interaction 
test (?̂?01 − ?̂?00) − (?̂?11 − ?̂?10). If we assume that the number of participants in each of 
the four subgroups is 
𝑛
2
, then the variance of the interaction effect equates to 
 
𝑣𝑎𝑟((?̂?01 − ?̂?00) − (?̂?11 − ?̂?10)) = 𝑣𝑎𝑟(?̂?01 − ?̂?00) + 𝑣𝑎𝑟(?̂?11 − ?̂?10) 
=
4𝜎2
𝑛
+
4𝜎2
𝑛
=
8𝜎2
𝑛
= 4 × (
2𝜎2
𝑛
). 
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Thus from the above,  in order to observe an interaction effect that is of the same 
magnitude as that of the main effect size i.e. have the same power, the original sample 
size would have to be increased by four-fold and even more if the subgroups are not of 
equal size (58, 59). However, taking such an approach to ensure subgroup analyses are 
powered will have big implications on the trial as a whole. Such a drastic inflation of 
the sample size would prolong the overall duration of the trial, and as a direct 
consequence would incur increased costs to run the trial. Thus such an approach to 
power subgroup analyses is extremely costly, very time consuming and probably not 
worth pursuing.  
 
An alternative and tempting option to increase power when testing interaction effects 
would be to make the significance level less stringent (e.g. α=0.20) making it easier to 
identify subgroup effects. However, a less stringent significance level means that there 
is an increase in the probability of a false positive finding i.e. falsely rejecting the null 
hypothesis when it is true. Moreover, it has been shown that increasing the significance 
level for interaction tests does not always usefully raise the power to a level that is 
considered adequate and is therefore not advised (65, 66). If increasing the significance 
level does not inflate the power to an acceptable level e.g. 80%, then this option is 
probably not worth pursuing as it would just increase the chances of detecting 
spurious findings.  
 
3.5 Subgroup analyses guidance 
 
The key statistical concepts and issues associated with subgroup analyses were 
detailed in section 3.4. These issues are very well recognized in the literature and as a 
result, a number of subgroup analyses guidelines have been proposed (41, 43, 44, 67). 
Although the statistical issues of power and multiplicity remain, complying with these 
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guidelines maximises the credibility of the results. The key recommendations from 
these guidelines will now be described. 
 
Interaction test 
The most appropriate method of directly evaluating the treatment effect heterogeneity 
of subgroups is by using a statistical test for interaction in the regression model (54, 
59, 60).  
 
Pre-planned and post hoc analyses 
Having conducted a trial, it can be extremely tempting to look at the data and perform 
several analyses to test for treatment heterogeneity within subgroups of participants. 
This is considered a misuse of data and is sometimes referred to as data dredging. Such 
an approach is inappropriate as it increases the chances of false positive findings, as 
explained earlier, because the number of such analyses that could be done is very large. 
Therefore an important recommendation to avoid this is to pre-specify the actual 
subgroup analyses to be undertaken, preferably in the study protocol i.e. specified 
without looking at the data, for them to be classed as a priori analyses. However, it 
might well be that an investigator genuinely didn’t think about looking for subgroups 
effects until after (post-hoc) the study. Alternatively, they may have pre-specified a few 
subgroups of interest but then felt the urge to explore other subgroups post-hoc as 
well. Whatever the true scenario is, it is recommended that a clear distinction be made 
between pre-specified analyses and post-hoc analyses. Pre-specified analyses are for 
testing hypothesis (confirmatory analyses) whereas post-hoc analyses (exploratory 
analyses) are for generating hypotheses to be tested in future studies (68-70).  
 
It is important to note here that pre-specifying subgroup analyses to be undertaken 
does not resolve the issue of multiple testing and the inflated type I error rate. For this 
38 
 
reason, it is advised that the number of pre-specified analyses be kept to a minimum 
and that the results be interpreted with caution. When pre-specifying a limited number 
of subgroup analyses, it is recommended that the following information be provided: 
 
 Specification of a limited number of baseline characteristics to be investigated. 
 Specification of the cut point to be used for any continuous baseline variables, 
including some justification of the chosen cut point based on previous 
literature. If no specific cut point is documented in the literature, it is suggested 
that the median is used. 
 A clear explanation as to what is guiding the subgroup analyses with reference 
to relevant literature and findings from previous studies. 
 The end point of interest should be clearly specified. 
 The statistical method to be used to test for subgroup effects (interaction test) 
should be specified. 
 A statement, with some justification, to indicate the expected subgroup effect 
size and direction. 
 
There is a possibility that during the course of the trial and before any data are 
analyzed, some new information may emerge in the literature that was not readily 
available during the design stages of the study. In such instances an amendment to the 
study protocol will suffice.  
 
Multiplicity adjustment 
Subgroup analyses guidelines recommend that an appropriate multiplicity correction 
(e.g. Bonferroni or Sidak) should only be applied when testing a small number of pre-
specified hypotheses i.e. performing confirmatory analyses (41). Multiplicity 
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corrections are not required when performing post-hoc exploratory analyses since the 
aim is to simply generate hypotheses rather than test them (41).  
 
Reporting 
All subgroup analyses that are conducted should be reported. It is recommended that 
the interaction effect estimate, 95% confidence interval and p-value are presented 
when reporting subgroup analyses. Due to the issue of multiple testing as described 
above, it is strongly recommended that the results of any subgroup analyses be 
interpreted with caution (43, 59).  
 
3.6 Issues with current recommendations 
 
The concepts, issues and current recommendations in proposed guidelines for 
performing subgroup analyses have thus far been explained in this chapter. However 
there are a number of issues with these recommendations. One issue that arises is the 
selection of subgroups to be investigated. It is recommended that a limited number of 
subgroups be pre-specified a-priori, preferably in the study protocol, with clear 
justification. This depends on findings from previous relevant literature or clinical 
justification and can thus be a very subjective process. Although some subgroups may 
be identified during this process, it is possible that important subgroup effects in other 
baseline covariates that have not been pre-specified may go unnoticed. This could be 
due to two reasons; either because they have not been previously investigated or that 
the investigator failed to report particular results as the treatment showed signs of 
being more harmful than good. Therefore, one could argue that since conventional 
subgroup analyses are exploratory in nature, all possible baseline covariates should be 
investigated to ensure no important subgroup effects are missed instead of just 
investigating pre-specified subgroups only. Moreover, it is recommended that the cut-
point selection for continuous baseline covariates be pre-specified based on cut-points 
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used in previous literature, if available. This again is a subjective process that could 
miss important subgroup effects of subgroups defined using another cut-point. Hence, 
one could argue that either numerous cut-points or all possible cut-points should be 
investigated when performing subgroup analyses.  
 
Another issue with conventional subgroup analyses is that the selected subgroups are 
assessed independently using separate interaction tests. Testing for subgroup effects 
separately might not be the best way to identify subgroups as we know that each 
individual can be described by several baseline characteristics. Moreover, one may be 
easily inclined to incorrectly interpret the results of separate interaction tests using a 
statement combining the subgroups. For example, let’s say that a subgroup analysis 
using separate interaction tests finds both age and sex to have significant interaction 
effects; more precisely that younger participants benefit more from treatment and 
females benefit more from treatment. These are two separate subgroups that have 
been identified and so should be interpreted separately; however, one may falsely 
interpret this by saying younger females benefit more from treatment i.e. combining 
them into one subgroup. This statement might not necessarily be true since the single 
particular subgroup defined by the two characteristics (age and sex) was not tested. In 
reality, it is highly likely that there are several patient characteristics that are involved 
in determining a subgroup effect and not individual characteristics. This therefore 
suggests that alternative statistical methods need to be sought to perform subgroup 
analyses to incorporate multiple baseline characteristics. More specifically, the method 
should have some systematic way of performing interaction tests to identify subgroups 
whilst simultaneously forming a subgroup defined by several characteristics.  
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3.7 Discussion 
 
The major issues involved with performing subgroup analyses are well recognised and 
documented in the literature. There is some debate surrounding the use and worth of 
subgroup analyses in studies, most of which is subjective. Despite the issues involved, 
the general consensus is that it is highly beneficial to perform subgroup analyses to 
generate important hypotheses that can be tested in future research and provide 
additional information for clinical guidelines. Clearly the ISIS-2 and BARI studies 
exemplify two extremes of the outcomes from subgroup analyses. It is therefore 
essential that the planning, analyses, reporting and interpretation of subgroup analyses 
conducted using interaction tests be performed in a rigorous methodological 
framework as proposed by a number of guidelines (41, 44). Despite the analyses 
lacking power, following recommendations will at least ensure that they are of a good 
credible standard, thus strengthening the implications for future research.  
 
While it has been recommended that treatment effect heterogeneity may be formally 
assessed using a statistical test for interaction, there are key issues that still remain, as 
described in this chapter. The key issues are a lack of power to detect genuine 
treatment-covariate interactions and also the issue of multiplicity. One method of 
overcoming the lack of power is to power the study to incorporate subgroup analyses. 
However, this would require an extremely large study that would be very costly and 
time consuming. An alternative option would be to collect a repository of individual 
patient data from several trials of similar interventions that have already been 
conducted and then perform subgroup analyses of the pooled dataset. While this may 
improve the lack of power issue, the issue of multiplicity still remains due to the 
parametric nature of the statistical methods used and it also introduces other 
challenges. 
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Although following current proposed guidelines ensures the credibility of subgroup 
analyses, the issues of power, multiplicity, failure to investigate other potentially 
important subgroups and incorporating multiple patient characteristics still remains. 
Meta-analyses or individual patient data meta-analyses can be used to improve the 
issue of power. Of the two, individual patient data meta-analysis has the advantage of 
allowing patient-level covariates to be fully explored for subgroup effects (71). While 
the issue of power can be substantially improved by using individual patient data from 
several similar trials, the issue of multiplicity still exists if current parametric statistical 
methods for subgroup analyses are applied. This therefore highlights the need for the 
development of a non-parametric or data driven approach to performing subgroup 
analyses in an individual patient data meta-analyses context focusing on subgroup 
identification using several patient baseline characteristics.  
 
This chapter reviewed the recommendations of current proposed guidelines for 
performing subgroup analyses in trials in general. In non-specific LBP trials, several 
papers have performed and published their findings from subgroup analyses. 
Therefore, it is of interest to evaluate the quality, conduct and reporting of subgroup 
analyses performed in the LBP literature in accordance with current guidelines. Even 
though a number of issues with current recommendations were highlighted in this 
chapter, it is still important to review the LBP literature in line with the current 
guidelines. Thus, the following chapter will describe a systematic review of subgroup 
analyses performed in trials of therapist delivered interventions for the management of 
non-specific LBP. The subsequent chapter (Chapter 5) will then go on to describe 
alternative statistical approaches for performing subgroup analyses in order to address 
the issues highlighted with regard to the current guidelines. 
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Chapter 4 
 
Systematic review of 
subgroup analyses in 
non-specific low back 
pain trials 
 
 
4.1 Introduction 
 
The previous chapter provided a detailed description of the statistical concepts and 
issues associated with subgroup analyses. To better control for these issues, several 
proposed guidelines have been published to ensure, if used, that subgroup analyses are 
of a good standard. Thus the previous chapter also presented the key 
recommendations from proposed guidelines for performing subgroup analyses. A 
discussion regarding several issues with these guidelines and conventional subgroup 
analyses was presented thereafter. Despite these issues, it is still important to review 
the current LBP subgroup analyses literature in line with current guidelines. As 
mentioned in chapter 2, the overall quality of subgroup analyses in the area of LBP is 
unknown. Therefore, this chapter will report a systematic review of the quality, 
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conduct and reporting of subgroup analyses performed in the area of LBP to allow 
interpretation of their findings. The content of this systematic review has been 
published in the Spine Journal (see appendix A) (1).  
 
Objective 
The objective of this systematic review is to identify RCTs of therapist delivered 
interventions for non-specific LBP that have performed secondary analyses in the form 
of subgroup analyses and then evaluate the quality of these analyses. Furthermore, the 
conduct and reporting of subgroup analyses will also be assessed.  
 
4.2 Methods 
 
Search Strategy 
We searched MEDLINE (1948 to July 2013), Ovid MEDLINE(R) In-process & Other Non-
Indexed Citations, Embase (1974 to July 2013), Web of Science and Citation Index and 
Cochrane Controlled Trials Register (CENTRAL). We sought to identify all papers 
reporting RCTs of therapist delivered interventions for non-specific LBP that 
performed subgroup analyses. For that reason, we initially searched for ‘low back pain’ 
terms, ‘RCT’ terms and key subgroup analyses terms such as ‘subgroup’, ‘effect 
modifier’ and  ‘moderator’. These search terms only identified papers that had 
subgroup analyses terms in the title or abstract and therefore missed out publications 
that had these terms in the main text only. We therefore re-ran our searches to identify 
all RCTs of therapist delivered interventions in the area of non-specific LBP using only 
the keywords for ‘low back pain’ and ‘RCTs’. A full list of the search terms used can be 
found in appendix B.  
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Selection of papers 
We scanned all of the titles and abstracts from the search results retrieved to identify 
all papers potentially reporting a subgroup analysis of an RCT testing a therapist 
delivered intervention for LBP. Here we define a therapist as a person trained in 
administering any of the available recommended treatments, excluding drug 
interventions and surgical interventions, for the management of LBP. We then 
examined the full text of every paper to see if they performed some form of subgroup 
analyses and then using specific inclusion and exclusion criteria we decided which 
papers to include in the final review (Table 4.1). Papers testing a clinical prediction 
rule were excluded because they only test to see if a pre-defined rule works rather than 
performing tests to identify subgroup characteristics that modify treatment effect. 
Papers interested in treatment effect modification over time were also excluded 
because typically the primary analysis in a LBP study evaluates the effect at a specific 
time-point e.g. at 12 months, and not over time. Although studies do report outcomes 
at multiple time-points, it is the primary analysis endpoint that is of interest. 
 
Table 4.1 – Inclusion and exclusion criteria used to select papers 
Inclusion criteria: 
 Randomized controlled trials 
 Published in English-language  
 Participants aged 18 years or more with history of non-specific LBP (including 
sciatica) 
 Therapist delivered interventions for non-specific LBP (including psychological 
interventions and intensive rehabilitation programmes) 
 Primary or secondary analysis of RCTs reporting that a subgroup analysis had 
been conducted 
Exclusion criteria: 
 LBP with known likely cause (fracture, infection, malignancy specific cause, 
ankylosing spondylitis and other inflammatory disorders) 
 Studies investigating disorders additional to non-specific LBP e.g. non-specific 
LBP and neck pain 
 Outcome not a valid clinical measure of non-specific LBP e.g. number of day’s sick 
leave  
 Testing a clinical prediction rule 
 Treatment effect modification over time i.e. treatment x moderator x time 
 Pooled datasets of similar trials 
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Quality of subgroup analysis 
Papers included in the final review were assessed for the quality of subgroup analyses 
using the following criteria as proposed by Pincus et al (72).  
 
1) Was the subgroup analysis specified a priori? 
2) Was the selection of subgroup factors for analysis theory/evidence driven? 
3) Were subgroup factors measured prior to randomization? 
4) Was measurement of subgroup factors measured by adequate (reliable and 
valid) measurements, appropriate for the target population? 
5) Does the analysis contain an explicit test of the interaction between moderator 
and treatment? 
 
 
The quality assessment classifies papers as either providing confirmatory findings or 
exploratory findings. Confirmatory findings support hypotheses about moderators 
(hypothesis testing) whereas exploratory findings inform future research (hypothesis 
generating). If a paper satisfies all five criteria then its findings are regarded as being 
confirmatory. Papers satisfying criteria three, four and five only are regarded as having 
exploratory findings. All other remaining papers are regarded as having insufficient 
findings. The quality of subgroup analyses in all of the identified papers was also 
assessed separately by two independent reviewers; Dr Shilpa Patel and Dr Siew Wan 
Hee. Any discrepancies at the end of the process were resolved through discussion. 
 
Assessment of Conduct and Reporting 
There are a number of proposed guidelines that exist for the conduct and reporting of 
subgroup analyses to ensure that the conclusions drawn are plausible (41, 43). These 
guidelines were used to help evaluate the conduct and reporting in the papers 
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identified from the literature search. In particular, three areas were assessed; 1) design 
and methods, 2) reporting of results and 3) interpretation and discussion.  
 
The design and methods was assessed for all papers whereas the reporting of results 
and the interpretation and discussion were only assessed for those papers that used 
interaction tests for subgroup analyses. The conduct and reporting of all papers was 
examined to see if they conformed to the following four key recommendations in the 
area of subgroup analyses (41, 43). 
 
• Exact subgroup definitions should be given beforehand for continuous and 
categorical variables along with some justification to avoid post-hoc data dependent 
definitions of subgroups. 
• Subgroup analyses should be performed on the primary outcome in the study. 
This is simply because trials are designed to detect differences in the primary outcome 
only; therefore performing subgroup analyses on any other outcome measure will 
substantially reduce the power. 
• A differential subgroup effect should be formally evaluated using a statistical 
test for interaction and the interaction effect reported. Performing tests within 
individual subgroups and then comparing the results is an incorrect approach to 
performing subgroup analyses as it does not directly evaluate the subgroup effect. 
• The number of subgroup analyses to be performed should be kept to a 
minimum. This is to avoid the issue of false-positive discovery (type-I error inflation) 
due to multiple testing; a well-known issue if there are several subgroups of interest. 
Any concerns regarding multiplicity should be acknowledged and addressed 
appropriately e.g. applying a Bonferroni correction. 
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4.3 Results 
 
 Selection of papers 
We identified 4,933 papers from the screening of titles and abstracts of which 4,873 
papers were excluded. The full texts for the remaining 60 papers were examined and a 
further 21 papers were excluded based on the inclusion and exclusion criteria. The 
remaining 39 papers were included in the final review (see Figure 4.1, Tables 4.2 and 
4.3). 
 
Most of the included papers were of studies conducted in the Netherlands 8(21%), UK 
8(21%) or the USA 8(21%). The median study size of the included papers was 223, 
range 100 to 3093. Twenty-nine papers (74%) performed subgroup analyses on a total 
study size of around 300 or fewer; the remaining 10 (26%) papers had more than 400 
patients.  
 
Quality of subgroup analyses 
Of the 39 papers; three (8%) papers met all five criteria and therefore provided 
confirmatory findings (73-75), 18(46%) papers provided exploratory findings, i.e. they 
met criteria three, four and five, and 18(46%) papers provided insufficient findings 
(Table 4.2).   
 
Assessment of conduct and reporting: Design and methods 
Only one trial was designed to have adequate power to detect important treatment-
covariate interactions; however no specific subgroups of interest were specified a 
priori (76). The majority of the papers, 31(79%), did not pre-specify which subgroups 
were to be investigated in the analyses. Eight papers pre-specified subgroups for 
confirmatory analyses (73-75, 77-81). Six of these additionally performed exploratory 
analyses; however this distinction was not always made clear at the outset. Baseline 
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characteristics that were pre-specified for subgroup analyses included age, sex, 
baseline Roland and Morris Disability Questionnaire (RMDQ) score, psychological 
distress, work load, history of back pain, radiculopathy, patient preference, 
catastrophizing, coping, pain self-efficacy (PSE), anxiety, depression, stress, 
troublesomeness, fear-avoidance, patient expectation, pain changes with position or 
movement, presence of leg pain, pain worse with flexion and duration (73-75, 77-81). 
 
Figure 4.1 – Flow diagram 
Total number of citation 
identified from search 
strategy: N = 4,933 
Excluded on the basis of titles 
and abstract: (n) = 4,873 
 
Full text papers retrieved 
and reviewed (n) = 60 
Final papers included in 
review (n) = 39 
Reason for exclusion: (N) = 21 
Included patients aged less than 18 years 
(n) = 3 
Intervention not delivered by therapist 
(n) = 3 
Looked at effect modification over time 
(n) = 2 
Looked at an additional disorder (n) = 2 
Outcome in subgroup analysis not a 
clinical outcome (n) = 6 
Pooled datasets of similar trials (n) = 1 
Testing a clinical prediction rule (n) = 2 
HTA report. Secondary subgroup 
analyses paper published elsewhere and 
used instead (n) = 2 
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Four of the papers did not mention in the methods section that subgroup analyses 
would be performed and just included the analyses in the results section of the paper 
(82-85). All 39 papers, regardless of whether they performed a formal test for 
interaction, did measure the subgroups of interest before randomization. The majority 
of these subgroup factors, 33(85%), were measured using adequate (reliable and valid) 
measurements. The commonest subgroup factor that was not measured adequately 
was patient expectation.  
    
Only one (3%) paper gave any indication as to the size and direction of the subgroup 
effect they were expecting prior to performing the analyses (73). Three (8%) of the 
papers only provided a prediction for the direction of the subgroup effect and around a 
third of the papers provided some justification regarding the choice of subgroups to be 
analysed.  
 
Thirteen of the papers were able to provide exact definitions of subgroups although 
only five (13%) provided clear justification for the cut-points used to define subgroups. 
All 39 papers performed subgroup analyses on the primary outcome of which four 
(10%) also performed subgroup analyses using secondary outcomes.  
 
Two papers in particular reported around sixty interaction tests in addition to the 
primary analyses; implying a substantial inflation of the overall type-I error rate, thus 
increasing the chance of detecting spurious findings (12, 74). Of the three papers that 
provided confirmatory findings, only one of them acknowledged and dealt with the 
issue of multiple testing. They did this by including a multiplicity correction 
(Bonferroni correction) for the confirmatory subgroup analyses they performed (75).    
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Twelve (31%) of the papers did not use a statistical test for interaction to assess for 
treatment effect modification. Two of these papers did not give any indication as to 
what statistical method they used for this (82, 86). Two papers looked at correlations 
between individual subgroups and outcomes within each treatment arm separately 
(87, 88). Two papers used t-tests between treatment groups within individual 
subgroups (77, 84). Five papers used either multiple linear regression or multiple 
logistic regression for each individual subgroup (89-93). Finally, one paper compared 
the medians across three trial arms within individual subgroups using Kruskal-Wallis 
tests (78). 
 
Assessment of conduct and reporting: Reporting of results 
There is some confusion in the papers between investigating ‘subgroup effects’ and 
investigating ‘differential subgroup effects’ where the former investigates a specific 
subset or subpopulation of the entire sample for a main effect and the latter 
investigates treatment effect heterogeneity using an interaction test between 
subgroups defined by factors measured prior to treatment (50). Twenty-seven (69%) 
of the papers used a statistical test for interaction to perform subgroup analyses. Four 
of these reported subgroup analyses within individual subgroups (94-97), ten papers 
reported results from interaction tests (12, 73-75, 80, 81, 98-101) and the remaining 
13 papers either did not report any results at all or just reported the p-value for the 
interaction term (37, 76, 78, 79, 83, 85, 102-108). Six papers reported both the 
interaction effect sizes with confidence intervals and the corresponding p-values (12, 
81, 98-101), four papers reported only the interaction effect sizes with confidence 
intervals (73-75, 80), eight papers reported the p-values only (37, 76, 85, 95, 97, 104, 
105, 107) and nine papers did not report either the interaction effect sizes and 
confidence intervals or p-values (78, 79, 83, 94, 96, 102, 103, 106, 108). 
 
52 
 
Assessment of conduct and reporting: Interpretation and discussion 
Four out of 27 papers that performed interaction tests reported subgroup analyses 
within individual subgroups and thus based the interpretations and discussion on this 
as well. Around a third of the papers provided supporting or contradictory findings 
from other relevant studies. Twelve of the twenty-seven papers that used an 
interaction test reported significant findings, of which only two suggested the 
identified subgroups for investigation in future studies. Twelve papers acknowledged 
the limitations of performing subgroup analyses in the discussion section of the paper.  
 
4.4 Discussion 
 
The objective of this systematic review was to assess the quality, conduct and reporting 
of subgroup analyses performed in RCTs of therapist delivered interventions for the 
management of non-specific LBP. This quite possibly is the first study of the overall 
quality, conduct and reporting of subgroup analyses in the area of low back pain.  
 
Reporting quality 
Many authors have performed subgroup analyses or have attempted some form of 
subgroup analyses. There is some clear confusion between investigating ‘subgroup 
effects’ and investigating ‘differential subgroup effects’ (50). The results of the quality 
assessment suggest that only three of the papers are able to provide confirmatory 
findings and that the majority of the papers provide exploratory or insufficient 
findings. These results are solely based on the outcomes from the quality assessment; 
the results of an apparently high quality subgroup analysis need to be interpreted in 
light of the quality of the main study. The general content and reporting of these papers 
in relation to subgroup analyses i.e. in terms of design and methods, results, 
interpretation and discussion, is quite poor. These papers can be seen as missed 
opportunities. Several of these subgroup analysis papers could have either used more 
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appropriate methodology i.e. statistical test for interaction, improved the standard of 
reporting or both. Had this been done, they would have been able to contribute 
valuable information to the existing pool of subgroup related literature in the area of 
low back pain. That nearly half of the identified papers provided insufficient findings 
raises concerns that the already published subgroup literature be misinterpreted when 
considering future subgroups research or making treatment choice. Although most 
subgroup analyses lack power and are of an exploratory nature, a well conducted and 
reported subgroup analysis will ensure credibility of findings that can be tested in 
future studies.  
 
Sample size 
All but one of the papers that were reviewed had inadequate sample size and were thus 
substantially underpowered to detect any meaningful interaction effects in the primary 
outcome. The one trial designed and powered to detect important treatment-covariate 
interactions did not, however, pre-specify subgroups of interest (76). Some subgroups 
were found to significantly moderate treatment effect in this trial; however it was quite 
disappointing to see only p-values reported. As part of the systematic review for the 
main funded project, we did contact the author to provide us with more information 
but they were unable to do so.  
 
Lack of power is a well-known issue associated with subgroup analyses. A simple 
model proposed by Lachenbruch, assuming equal group sizes, suggests that a total 
sample size of approximately 503 participants provides 80% power to detect a 
moderate standardized effect size of 0.5 in the interaction effect at a two-sided 5% 
significance level between two arms where the outcome is continuous and normally 
distributed (109). To date, we are only aware of four trials with subgroup analyses that 
have this sample size (n≥500) (34, 36, 76, 103). These were high-quality RCTs that 
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were designed and powered to detect a standardized mean difference of around 0.4 in 
the main effect. However inspection of the main effect sizes suggest that the 
standardized effects were much lower and only ranged from 0.12 to 0.23 (37). If the 
larger trials are failing to pick up a moderate standardized main effect size, it is highly 
unlikely that any plausible and clinically meaningful interaction effects will be detected 
in any subgroup analyses unless the interaction effect is considerably larger than the 
main effect. In a simple model, with equal numbers in each subgroup such a large 
interaction effect with a small main effect of treatment would consequentially mean 
that there is a large benefit in one sub-group and a smaller harm in the other subgroup. 
 
A trial to identify a differential subgroup effect needs to be approximately four times 
larger than a trial powered to detect a main effect of the same magnitude only (59). 
Any such trial would only be able to test a moderator of treatment effect for one 
subgroup. Unless there is an overwhelming a priori hypothesis that needs testing in 
such a study, this is unlikely to be a worthwhile expenditure of academic effort and 
funders’ resources. We are not aware of any such overwhelming a priori hypothesis. 
Furthermore, our existing pool of baseline predictors only explain about a third of the 
variance in outcome making it unlikely that we can identify a single strong moderator 
of treatment effect to underpin such a strong a priori hypothesis (110). Even if such a 
study was designed it would, if it was to inform clinical practice, need to ensure that 
whatever moderators were proposed could easily be applied in clinical practice.  
Therefore, it is clear that different approaches are needed.  
 
One possible alternative approach, as mentioned in the previous chapter, would be to 
collect individual patient data from several similar trials. Although collecting individual 
patient data would improve the issue of insufficient power, the issue of multiple testing 
and hence the inflation of the family-wise type I error rate (probability of a false 
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positive result) still remains. This therefore highlights the need to identify or develop 
alternative statistical approaches for performing subgroup analyses. Moreover, as 
highlighted in the previous chapter, conventional subgroup analyses typically use 
interaction tests to investigate patient characteristics one at a time. However, it is quite 
obvious that patients have multiple characteristics that also need to be investigated 
either simultaneously or in some stepwise fashion. Thus this further highlights the 
requirement of novel statistical approaches to allow for the identification of multiple 
patient characteristics or clusters of moderators that would identify who is most (or 
least) likely to benefit. 
 
In conclusion, finding moderators of treatment effect has been identified as a high 
research priority internationally for the management of non-specific LBP in a step 
towards better individualized patient care. The findings of this review suggest that the 
majority of subgroup analyses performed in low back pain trials to date are only able 
to provide exploratory or insufficient findings. Papers with insufficient findings are not 
very credible and could potentially provide false implications for guiding future 
research. Moreover, the general content and reporting of subgroup analyses is rather 
poor. It is thus recommended that authors use available guidelines when performing 
subgroup analyses to ensure that they are reliable and of a good standard (41, 44, 67). 
We do, however, have serious concerns that current approaches are inadequate for the 
task at hand. There is a need to find and develop alternative statistical methods for 
performing subgroup analyses to overcome or better deal with the existing issues 
associated with current methodology. The following chapter will therefore review the 
generic statistical methodology currently used to perform subgroup analyses.  
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Table 4.2 – Summary of included papers ordered by subgroup quality assessment 
Subgroup 
Quality 
Assessment Author Published Country 
Study 
Size 
Interventions 
compared 
Outcome measure 
and follow-up 
Subgroups 
Identified 
(Interaction 
test only) 
Confirmatory 
Findings 
Sheets 2012 Australia 148 
First-line care group 
vs McKenzie group 
Pain measured at 1 
week and 3 weeks. 
Global perceived effect 
at 3 weeks. None 
Smeets 2009 
Australia & 
New Zealand 259 
Exercise and advice vs 
Exercise and sham 
advice vs Sham 
exercise and advice vs 
Sham exercise and 
sham advice 
Pain intensity (11 point 
scale) and Patient-
specific function scale 
(0-10 scale) measured 
at baseline 6 weeks and 
52 weeks  None 
Underwood 2011 UK 701 
Advice plus Cognitive 
behavioural 
intervention vs Advice 
only 
RMDQ and MVK 
measured at baseline, 3 
months, 6 months and 
12 months 
Age & 
Employment 
Exploratory 
Findings 
Becker 2008 Germany 1378 
Multifaceted guideline 
implementation (GI) 
vs GI plus motivational 
counselling (MC) vs 
Postal dissemination 
of guideline (Control) 
Hannover Functional 
Ability Questionnaire 
measured at baseline 
and 6 months None 
Cecchi 2012 Italy 210 
Back school vs 
Individual 
physiotherapy vs 
Spinal manipulation 
RMDQ measured at 
baseline, 3 months, 6 
months and 12 months None 
Cherkin 1998 USA 321 Physical therapy vs Bothersomeness of Mental Health 
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Chiropractic 
manipulation vs 
Educational booklet 
symptoms and RMDQ 
measured at baseline, 4 
weeks and 12 weeks 
Cherkin 2001 USA 262 
Chinese acupuncture 
vs Therapeutic 
Massage vs Self-care 
education 
Bothersomeness of 
symptoms and RMDQ 
measured at baseline, 4 
weeks, 10 weeks and 1 
year None 
Cherkin 2009 USA 638 
Individualised 
acupuncture vs 
Standardized 
acupuncture vs 
Simulated 
acupuncture vs Usual 
care 
Bothersomeness of 
symptoms and RMDQ 
measured at baseline, 8 
weeks, 26 weeks and 1 
year None 
Hansen 1993 Denmark 180 
Intensive dynamic 
back-muscle exercise 
vs Conventional 
physiotherapy vs 
Placebo control 
semihot packs and 
light traction) 
Pain level (10 point 
scale) measured at 
baseline, 4 weeks, 6 
weeks and 1 year None 
Hay 2005 UK 402 
Brief pain 
management vs 
Manual physiotherapy 
RMDQ measured at 
baseline, 3 months and 
12 months None 
Juni 2009 Switzerland 104 
Standard care alone vs 
Standard care plus 
Spinal Manipulative 
Therapy (SMT) 
Pain intensity (11 point 
scale) and analgesic use 
measured at baseline, 
days 1 to 14 and 6 
months None 
Karjalainen 2004 Finland 170 Mini-intervention Pain intensity (11 point Perceived risk 
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group vs Worksite 
visit group vs Usual 
care group 
scale) measured at 
baseline, 3 months, 6 
months, 1 year and 2 
years 
for not 
recovering & 
type of 
occupation 
(comparing 
mini-
intervention vs 
usual care and 
worksite visit 
vs usual care) 
Kole-
Snijders 1999 Netherlands 159 
Operant behavioural 
treatment with 
cognitive coping skills 
training (OPCO) vs 
Operant behavioural 
treatment with group 
discussion (OPDI) vs 
Waiting list control 
(WLC) 
Main outcome unclear. 
Outcomes measured at  
post-treatment, 6 
months and 1 year None 
Roche 2007 France 132 
Active individual 
therapy (AIP) vs 
Functional restoration 
program (FRP) 
Main outcome unclear. 
Outcomes measured at 
baseline and 5 weeks Sorenson score 
Sherman 2009 USA 638 
Individualised 
acupuncture vs 
Standardized 
acupuncture vs 
Simulated 
acupuncture vs Usual 
care 
Bothersomeness of 
symptoms and RMDQ 
measured at baseline, 8 
weeks, 26 weeks and 1 
year Baseline RMQ 
Smeets 2006 Netherlands 223 Active physical RMDQ measured at Baseline RMQ 
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treatment (ATP) vs 
Cognitive behavioural 
treatment (CBT) vs 
Combined APT and 
CBT (CT) vs Waiting 
list (WL) 
baseline, 10 weeks, 6 
months and 12 months 
Smeets 2008 Netherlands 223 
Active physical 
treatment (ATP) vs 
Graded activity with 
problem solving 
training (GAP) vs 
Combination 
treatment (CT) vs 
Waiting list (WL) 
RMDQ measured at 
baseline, 10 weeks, 6 
months and 12 months None 
Tilbrook 2011 UK 313 Yoga vs Usual care 
RMDQ measured at 
baseline, 3 months, 6 
months and 12 months None 
Underwood 2007 UK 1334 
Control (Best care in 
General Practice) vs 
Exercise programme 
vs Spinal manipulation 
vs Combined 
treatment 
(manipulation and 
exercise) 
RMDQ measured at 
baseline, 3 months and 
1 year Expectation 
van der 
Hulst 2008 Netherlands 163 
Roessingh Back 
Rehabilitation (RRP) 
vs Usual care 
RMDQ measured at 
baseline, 1 week after 
treatment and 4 
months after treatment 
Pain intensity 
& Depression 
Witt 2006 Germany 3093 
Acupuncture vs 
Control (delayed 
Hannover Functional 
Ability Questionnaire 
Initial back 
pain, age & 
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acupuncture 
treatment 3 months 
later) 
(0-100 scale) measured 
at baseline, 3 months 
and 6 months 
years of 
schooling 
Insufficient 
Findings 
Bendix 1998 Denmark 816 
Functional restoration 
(FR) program vs 
Outpatients program 
(Control) 
Main outcome unclear. 
Outcomes measured at 
baseline and 1 year   
Beurskens 1995 Netherlands 151 
Traction vs Sham 
traction 
GPE and severity 
measured on visual 
analogue scale (VAS) at 
baseline and 5 weeks   
Bishop 2011 USA 112 
Supine thrust 
technique vs Side-lying 
thrust vs Non-thrust 
technique 
ODQ measured at 1 
week, 4 weeks and 6 
months None 
Carr 2005 UK 237 
Group exercise 
programme vs 
Individual 
physiotherapy 
RMDQ measured at 
baseline, 3 months and 
6 months   
Ferreira 2009 Australia 191 
General exercise vs 
Motor control exercise 
vs Spinal manipulative 
therapy 
GPE (11 point scale), 
Patient specific 
functional status, 
RMDQ, Pain intensity 
(10 point scale) and 
spinal stiffness 
measured at baseline 
and 8 weeks None 
Glasov 2010 Australia 100 
Laser acupuncture vs 
Sham acupuncture 
(control) 
Pain (VAS) measured at 
baseline, immediately 
after treatment, 6 
weeks and 6 months   
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Gudavalli 2006 USA 235 
Flexion distraction 
(FD) vs Active trunk 
exercise protocol 
(ATEP) 
Perceived pain (VAS), 
RMDQ and SF-36 
measured at baseline, 4 
weeks, 3 months, 6 
months and 1 year   
Hsieh 2004 China 146 
Acupressure vs 
Physical therapy 
Short-form pain 
questionnaire 
measured at baseline, 4 
weeks and 6 months   
Jellema 2005 Netherlands 314 
Minimal intervention 
strategy (MIS) vs Usual 
care 
RMDQ, perceived 
recovery (7 point scale) 
and sick leave 
measured at baseline, 6 
weeks, 13 weeks, 26 
weeks and 1 year   
Johnson 2007 UK 234 
Group exercise and 
education using a 
cognitive behavioural 
approach vs Usual care 
Pain (VAS) and RMDQ 
measured at baseline, 3 
month, 9 month and 15 
months 
Patient 
preference 
Kalauokalani 2001 USA 166 
Acupuncture vs 
Massage (Subanalysis 
of Cherkin 2001 
paper) 
RMDQ measured at 
baseline, 4 weeks, 10 
weeks and 1 year 
Patient 
expectations 
Mellin 1989 Finland 456 
Inpatient treatment vs 
Outpatient treatment 
vs Control (Advice) 
Low back pain 
disability index (scale 
0-45) measured at 
baseline and 3 months   
Moffett 2004 UK 187 Exercise vs Usual care 
RMDQ measured at 
baseline, 6 weeks, 6 
months and 1 year   
Myers 2008 USA 444 Usual care vs Usual RMDQ measured at None 
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care plus patient 
choice of 
accupuncture, 
chiropractic or 
massage 
baseline, 5 weeks and 
12 weeks 
Seferlis 1998 Sweden 180 
Manual therapy 
program (MTP) vs 
Intensive training 
program (ITP) vs 
General practitioner 
program (GPP) 
Main outcome unclear. 
Outcomes measured at 
baseline, 1 month, 3 
months and 12 months   
Thomas 2006 UK 241 
Traditional 
acupuncture vs Usual 
care 
Bodily pain dimension 
of the SF-36 (0-100 
scale) measured at 
baseline, 3 months, 12 
months and 24 months Expectation 
van der Roer 2008 Netherlands 114 
Intensive group 
training protocol vs 
Guideline group 
RMDQ measured at 
baseline, 6 weeks, 13 
weeks, 26 weeks and 
52 weeks   
Vollenbroek-
Hutten 2004 Netherlands 163 
Roessing Back 
Rehabilitation (RRP) 
vs Usual care 
RMDQ measured at 
baseline, 1 week after 
treatment and 4 
months after treatment   
*RMDQ - Rolland and Morris Disability Questionnaire; MVK - Modified Von Korff (pain and disability); GPE - Global perceived effect; ODQ - Oswestry Disability 
Questionnaire; 
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Table 4.3 – Summary of excluded papers 
Paper Reason for exclusion 
Childs JD, Flynn TW, Fritz JM. A perspective for considering the 
risks and benefits of spinal manipulation in patients with low back 
pain. Manual Therapy 2006;11:316-20 
Testing a clinical prediction rule (in an 
uncontrolled study) 
Costa LO, Maher CG, Latimer J, Hodges PW, Herbert RD, Refshauge 
KM et al. Motor control exercise for chronic low back pain: a 
randomized placebo-controlled trial. Physical Therapy 
2009;89:1275-86. 
Look at effect modification over time 
Faas A, Chavannes AW, van Eijk JT, Gubbels JW. A randomized, 
placebo-controlled trial of exercise therapy in patients with acute 
low back pain. Spine 1993;18:1388-95. 
Included patients aged less than 18 years 
Faas A, van Eijk JT, Chavannes AW, Gubbels JW. A randomized trial 
of exercise therapy in patients with acute low back pain. Efficacy on 
sickness absence. Spine 1995;20:941-7. 
Included patients aged less than 18 years and 
outcome in subgroup analyses not a clinical 
measure of low back pain (sickness absence) 
George SZ, Fritz JM, Childs JD, Brennan GP. Sex differences in 
predictors of outcome in selected physical therapy interventions for 
acute low back pain. Journal of Orthopaedic & Sports Physical 
Therapy 2006;36:354-63. 
Pooled datasets of similar trials 
George SZ, Zeppieri G, Jr., Cere AL, Cere MR, Borut MS, Hodges MJ et 
al. A randomized trial of behavioral physical therapy interventions 
for acute and sub-acute low back pain (NCT00373867). Pain 
2008;140:145-57. 
Included patients aged less than 18 years and 
also looked at effect modification over time 
Haas M, Groupp E, Muench J, Kraemer D, Brummel-Smith K, Sharma 
R et al. Chronic disease self-management program for low back pain 
in the elderly. Journal of Manipulative & Physiological Therapeutics 
2005;28:228-37. 
Intervention not delivered by therapist 
Hagen EM, Svensen E, Eriksen HR. Predictors and modifiers of 
treatment effect influencing sick leave in subacute low back pain 
patients. Spine 2005;30:2717-23. 
Outcome in subgroup analyses not a clinical 
measure of low back pain (return to work) 
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Hancock MJ, Maher CG, Latimer J, Herbert RD, McAuley JH. 
Independent evaluation of a clinical prediction rule for spinal 
manipulative therapy: a randomised controlled trial. European 
Spine Journal 2008;17:936-43. 
Testing a clinical prediction rule 
Jellema P, van der Windt DA, van der Horst HE, Twisk JW, Stalman 
WA, Bouter LM. Should treatment of (sub)acute low back pain be 
aimed at psychosocial prognostic factors? Cluster randomised 
clinical trial in general practice. BMJ 2005;331:84. 
Look at effect modification over time 
Jellema P, van der Roer N, van der Windt DA, van Tulder MW, van 
der Horst HE, Stalman WA et al. Low back pain in general practice: 
cost-effectiveness of a minimal psychosocial intervention versus 
usual care. European Spine Journal 2007;16:1812-21. 
Outcome in subgroup analyses not a clinical 
measure of low back pain (cost-effectiveness) 
Kool JP, Oesch PR, Bachmann S, Knuesel O, Dierkes JG, Russo M et al. 
Increasing days at work using function-centered rehabilitation in 
nonacute nonspecific low back pain: a randomized controlled trial. 
Archives of Physical Medicine & Rehabilitation  2005;86:857-64. 
Outcome in subgroup analyses not a clinical 
measure of low back pain (days worked over 3 
months) 
Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V et 
al. A multicentred randomised controlled trial of a primary care-
based cognitive behavioural programme for low back pain. The 
Back Skills Training (BeST) trial. Health Technology Assessment 
(Winchester, England) /20;14:1-253. 
HTA report. Secondary subgroups analyses 
paper published elsewhere and used instead 
(Underwood 2011) 
Scheel IB, Hagen KB, Herrin J, Oxman AD. A randomized controlled 
trial of two strategies to implement active sick leave for patients 
with low back pain. Spine 2002;27:561-6. 
Outcome in subgroup analyses not a clinical 
measure of low back pain (active sick leave) 
Skargren EI, Carlsson PG, Oberg BE. One-year follow-up comparison 
of the cost and effectiveness of chiropractic and physiotherapy as 
primary management for back pain. Subgroup analysis, recurrence, 
and additional health care utilization. Spine 1998;23:1875-83. 
Looked at an addition disorder (neck pain) 
Skargren EI, Oberg BE, Carlsson PG, Gade M. Cost and effectiveness 
analysis of chiropractic and physiotherapy treatment for low back 
and neck pain. Six-month follow-up. Spine 1997;22:2167-77. 
Looked at an addition disorder (neck pain) 
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Staal JB, Hlobil H, Koke AJ, Twisk JW, Smid T, van MW. Graded 
activity for workers with low back pain: who benefits most and how 
does it work? Arthritis & Rheumatism 2008;59:642-9. 
Outcome in subgroup analyses not a clinical 
measure of low back pain (return to work) 
Steenstra IA, Knol DL, Bongers PM, Anema JR, van MW, de Vet HC. 
What works best for whom? An exploratory, subgroup analysis in a 
randomized, controlled trial on the effectiveness of a workplace 
intervention in low back pain patients on return to work. Spine 
2009;34:1243-9. 
Outcome in subgroup analyses not a clinical 
measure of low back pain (return to work) 
Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J, Campbell 
M et al. Longer term clinical and economic benefits of offering 
acupuncture care to patients with chronic low back pain. Health 
Technology Assessment (Winchester, England) /1/10;9:iii-iiv. 
HTA report. Secondary subgroups analyses 
paper published elsewhere and used instead 
(Thomas 2006) 
Toda Y. Impact of waist/hip ratio on the therapeutic efficacy of 
lumbosacral corsets for chronic muscular low back pain. Journal of 
Orthopaedic Science 2002;7:644-9. 
Intervention not delivered by therapist (Corsets 
given to patients) 
van Poppel MN, Koes BW, van der Ploeg T, Smid T, Bouter LM. 
Lumbar supports and education for the prevention of low back pain 
in industry: a randomized controlled trial. JAMA 1998;279:1789-94. 
Intervention not delivered by therapist 
(Lumbar supports given to patients) 
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Statistical Methodology 
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Chapter 5 
 
Review of subgroup 
methodology 
 
 
5.1 Introduction 
 
The previous chapter presented findings from a systematic review of the quality, 
conduct and reporting of subgroup analyses performed in randomized controlled trials 
(RCTs) of therapist delivered interventions for the management of non-specific low 
back pain (LBP). The review found that the majority of subgroup analyses performed in 
the area of non-specific LBP are only able to provide exploratory or insufficient 
findings. Moreover, the general content and reporting of subgroup analyses is rather 
poor. The review concluded that more novel statistical approaches need to be sought to 
better deal with the existing issues associated with the conventional approach. 
 
Alternative methods for performing subgroup analyses or subgroup identification may 
exist elsewhere in other fields of research. The term subgroup analysis has different 
meanings for different people. Some regard it as the analyses of a defined subset or 
subpopulation of the entire data e.g. analysis of elderly individuals only. Some may 
consider it an approach to identify prognostic subgroups i.e. subgroups with high or 
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low outcome, whereas some understand it to be the identification of subgroups defined 
by baseline characteristics that moderate treatment effect. In this thesis, the latter is of 
interest however it is important to describe these other approaches to better 
understand the distinction. Though methods for identifying prognostic subgroups are 
not the primary goal, it is important to set the scene and also to review methods here 
that might be useful for finding moderators. This chapter will therefore present a 
review of statistical methods for conducting subgroup analyses or subgroup 
identification in general for a single trial based setting. Firstly the identification of 
prognostic subgroups will be described and discussed, followed by a description of 
methods for subgroup analyses to identify moderators of treatment effect. As 
highlighted in the previous chapter, one option to improve the power issue is to 
perform subgroup analyses on individual patient data (IPD) collected from several 
similar trials measuring similar outcomes. Therefore, this chapter will also briefly look 
at current methods used for performing subgroup analyses in IPD meta-analyses.  
 
5.2 Methods to identify subgroups with high or low outcome 
 
Regression modelling 
In many fields of research, a ‘subgroup analysis’ refers to the identification of 
subgroups with high or low outcome i.e. prognostic subgroups. Such analyses are 
performed in different kinds of study designs such as RCTs, prospective cohort studies 
and retrospective studies. The identification of prognostic factors provides clinicians 
with valuable information to aid decision making and to help them better predict 
outcome. Depending on the outcome of interest associated with the field of research, an 
appropriate multivariate regression modelling approach is taken to identify and 
evaluate prognostic factors. For example, linear regression modelling is used when the 
outcome is continuous and normally distributed. There is no ideal approach to 
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identifying and modelling prognostic factors. However, two standard strategies are to 
either fit a full model that includes all potential prognostic factors or to use backward 
elimination (111). Inferences can then be made by observing the parameter estimates 
of the final fitted model as to whether any of the included factors are predictive of 
outcome. For example, imagine the final model was of the form 
 
𝐸(𝑦) = 1.3 + 3.4 ∗ 𝐺𝑒𝑛𝑑𝑒𝑟(𝐹𝑒𝑚𝑎𝑙𝑒) 
 
where 𝑦 is a continuous and normally distributed outcome, which here might, for 
example be a pain score on a scale from 0-100, where a higher score indicates worse 
pain. Also, suppose gender was found to be statistically significant in the model output, 
hence suggesting it is a prognostic factor. Then the regression coefficient for gender 
would suggest that females, on average, experience more pain than males i.e. the 
gender of an individual helps predict whether the response will be high or low. 
 
Non-parametric methods 
When the predictor is continuous, one may encounter situations where there is a non-
linear association between the potential prognostic factor and the dependent variable 
i.e. the linearity assumption does not hold. In such a situation, one might consider using 
generalized additive models (GAMs) to model the non-linearity (112). Typically 
regression models such as linear and logistic regression work by modelling the 𝑋𝑖  (𝑖 =
1,… ,𝑚) potential variables (including interaction variables) as a linear predictor of the 
form 𝐸(𝑌) = 𝛽0 + ∑𝛽𝑖𝑋𝑖 . GAMs work by replacing the linear predictor by an additive 
predictor of the form 𝐸(𝑌) = 𝛽0 + ∑𝑓𝑖(𝑋𝑖) with a monotonic link function to link 𝛽0 +
∑𝑓𝑖(𝑋𝑖) to the expectation of Y. Here,  𝑓𝑖 (𝑖 = 1,… ,𝑚) are non-parametric smooth 
functions that are estimated from the data. This approach is relevant when a 
continuous covariate is of interest e.g. age. A general linear model can thus be 
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considered a special case of a GAM, where the link function is simply the identity 
function. The flexible nature of GAMs allows the assumption of linearity to be relaxed 
however extra caution must be taken not to over-fit the data (112).   
 
Cluster analysis 
An alternative approach is cluster analysis; an approach used in the field of data mining 
and machine learning for identifying subgroups or clusters of patients that are most 
similar in terms of outcome only, i.e. ignoring the predictors (113-115). Cluster 
analysis is based on mathematical formulation, whereby each individual is assigned to 
only one subgroup based on the Euclidean distance from an initial starting value or 
centroid. This method works by taking a large heterogeneous population and breaking 
it down into subgroups that maximize the between subgroup heterogeneity whilst 
minimizing the within subgroup heterogeneity. The number of subgroups to be formed 
has to be specified before running the analyses; however the choice of how many is a 
difficult task. Moreover, a starting point or centroid for each of the pre-determined 
subgroups also has to be specified. The following example illustrates how the cluster 
analysis algorithm works. Consider a sample of patients that have reported a pain 
score (0-100; higher score is worse). Assuming we pre-specify that we are interested in 
forming two subgroups. We therefore have to specify a starting point for each 
subgroup. Based on the pain score, let’s give one of the subgroups a low starting point, 
say 10, and the other subgroup a high starting point, say 80. The method works by 
computing the distance of the outcome of each patient from the two subgroup starting 
points and then assigning each patient to the subgroup it is closest to. A natural 
measure of the distance for each patient in this example would be the squared error. 
Thus, in the first iteration, all patients will be assigned to one of two subgroups. The 
mean pain score in each of the subgroups is then computed and used as the starting 
point for the next iteration. The iterations continue until the starting points no longer 
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change. Once the subgroups have been formed, the outcome measure can be 
summarized within each subgroup and then labelled accordingly to best describe the 
subgroup e.g. good response and poor response. The final clusters can then be 
compared in terms of the characteristics of the patients within each cluster or 
subgroup. Any differences found in the characteristics of the two groups can aid in 
predicting outcome of new patients. For example, the cluster classified as having a 
good response may be on average younger than the cluster classified as having poor 
response. Thus, age would be a predictor of outcome for a new patient. A common and 
well documented problem associated with cluster analysis is that different solutions 
are often produced when different starting points or centroids are used. Thus there is 
no justification as to which solution is the correct or final solution.  
 
Data mining methods 
In the field of data mining, a number of data driven approaches exist that are an 
attractive alternative for performing subgroup analyses with the aim of identifying 
main effects i.e. subgroups that are predictors of outcome. Many of these are 
sophisticated data mining methods, such as support vector machines (SVM), neural 
networks, Bayesian networks and K-nearest neighbour classifiers, which specialize in 
discovering patterns and relationships between covariates and outcome within large 
datasets using algorithms. An initial concern with many of these complex methods is 
that there are numerous algorithms available for each of these methods. The majority 
of the data mining methods identified from the literature search do not look for 
treatment effect heterogeneity or interaction effects. Instead, they simply look for 
subgroups or subsets of the entire dataset with heterogeneous outcome. However, 
there are some data mining methods that do exist that aim to identify interactions. 
These methods will be described later on in section 5.3.2. 
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As mentioned earlier, the approaches in this section of the chapter aim to identify 
subgroups that differ in terms of a final outcome i.e. identifying prognostic subgroups. 
Though these methods are a form of subgroup analysis, they do not identify subgroups 
that have high or low treatment effects, which is the focus of this thesis. The next 
section will therefore describe several methods that can be used to identify and 
evaluate subgroups with high or low treatment effects i.e. differential subgroups 
effects. 
 
5.3 Methods to identify subgroups with high or low treatment effects  
 
5.3.1 Single factors 
 
In general across many fields of research, it is of particular interest to perform 
subgroup analyses to investigate how the effect of one variable on an outcome variable 
of interest is moderated by the value of a third variable (moderator variable). In a 
clinical trial setting when comparing two treatments, the aim of subgroup analyses is to 
determine whether or not there is treatment effect heterogeneity in terms of an 
outcome between subgroups of patients. These subgroups are defined by the patient’s 
individual baseline characteristics collected prior to randomization (56). Commonly, 
the baseline characteristics are investigated one at a time i.e. single factors. A number 
of statistical methods for evaluating single baseline factors will now be described.  
 
Statistical test for interaction 
Interaction tests as described in Chapter 3 are the most common approach for 
conducting subgroup analyses. There have been a number of different interaction tests 
proposed over the years for performing subgroup analyses, in particular, detecting 
treatment effect heterogeneity (116-118). However, in essence, subgroup analyses are 
performed by selecting an appropriate regression model depending on the outcome 
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variable and then subsequently adding an interaction term to the model. When the 
outcome is continuous and normally distributed then a linear regression model is used 
and when the outcome is binary then a logistic regression model is used. The baseline 
variable used to form the interaction term can either be categorical or continuous. 
When the baseline variable is continuous, it will require categorization that is clinically 
justified and sensible to allow for easier interpretation of the subgroup analyses 
results.  
 
Qualitative interaction test 
As mentioned in Chapter 3, interactions can be classified as being either quantitative or 
qualitative (43, 44). Just to recap, an interaction is said to be quantitative when the 
treatment effect is in the same direction (i.e. superior or inferior) within each subgroup 
but differs in terms of size. On the other hand, an interaction is said to be qualitative 
when the treatment effect in one subgroup is in the opposite direction compared to the 
other subgroup. Clinically, both types of interaction are of interest. Of the two, 
quantitative interactions are expected to occur whereas qualitative interactions are 
more difficult to find but are really important as they indicate which patients are 
harmed. Numerous qualitative interaction tests have been developed and proposed. 
Assuming there are two trial arms being investigated, these tests evaluate whether or 
not qualitative interactions exist across two or more disjoint subgroups. Gail and 
Simon initially proposed a likelihood ratio test (119) which was then compared in 
terms of power to a range test proposed by Piantadosi and Gail (120). The power 
comparison of both methods found that the likelihood ratio test had more power when 
the treatment was found to be harmful in several subgroups, whereas the range test 
had more power when the treatment was harmful in only a small number of subgroups 
(120).  An extension of the range test was later developed by Li and Chan that 
outperformed the original range test and had greater power than the likelihood ratio 
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test when one treatment was found to be superior than the other in most subgroups 
(121). However, a limitation with qualitative interaction tests is that the disjoint 
subgroups must be pre-defined and formed prior to the analyses. For example, a 
continuous covariate such as age will have to be dichotomized or categorized prior to 
the analysis. 
 
Non-parametric methods 
When the distributional assumptions of a regression model do not hold or if there is 
some indication that they will be violated, then one may be inclined to utilize a non-
parametric approach for performing subgroup analyses. Crump et al. developed and 
proposed two non-parametric tests for testing treatment effect heterogeneity. The null 
hypothesis for the first test is that the mean treatment effect for all subgroups defined 
by covariates is zero, whereas the null hypothesis for the second test is that the mean 
treatment effect conditional on the covariates is the same for all subgroups (122). 
Kraemer et al also proposed a non-parametric approach for performing subgroup 
analyses to test binary moderators by using area under the receiver operating curve 
(AUC) (123).  
 
Graphical methods 
Some statisticians argue that variables measured on a continuous scale should not be 
dichotomized as it reduces the power to detect any difference between the 
dichotomized variable and the outcome (124, 125). To avoid this issue and maintain as 
much power as possible, a number of graphical methods have been proposed that 
individually evaluate continuous variables. Royston and Sauerbrei introduced the 
multivariable fractional polynomials interaction (MFPI) method (126). The MFPI 
method involves using fractional polynomials to model the best fit of a continuous by 
binary interaction. A graphical representation of the continuous treatment effect 
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function would then be used to interpret any significant interactions found. Although 
the variable is kept continuous, ultimately a cut-point selection is still required having 
observed the graph to best define the subgroups. A similar method was also introduced 
by Bonnetti and Gelber called the subpopulation treatment effect pattern plot (STEPP) 
that investigates one or more subgroup variables of interest (127). It investigates 
interactions by using a graphical approach looking at overlapping subpopulations of 
patients and assessing the treatment effects across the subpopulations. However issues 
with this approach, as acknowledged by the authors, are multiplicity when considering 
other subgroups and also how to define groups when two or more overlapping 
subgroups show conflicting subgroups effects (127). 
 
Bayesian approach 
There are several concerns with the classical approach of hypothesis testing to perform 
subgroup analyses such as multiple testing and lack of power. Alternative Bayesian 
approaches have therefore been proposed that use shrinkage estimation techniques to 
perform subgroup analyses and identify differential subgroups. Despite the proposition 
of alternative Bayesian approaches, the classical approach to subgroup analyses and 
identification are still preferred and utilized. One of the reasons for this is that it can be 
quite challenging to specify an appropriate prior distribution when using a Bayesian 
approach. Bayesian methods for performing subgroup analysis are relatively new and 
are currently an ongoing area of research, including the extension of Bayesian 
subgroup analyses using shrinkage estimation in a meta-analysis framework (128).  
 
5.3.2 Multiple factors 
 
A particular limitation with the aforementioned differential subgroup analysis methods 
(section 5.3.1) is that they are typically employed to investigate patient characteristics 
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one at a time, whereas it is quite obvious that each patient has multiple characteristics. 
It is possible for some of the aforementioned methods e.g. regression based 
approaches, to consider multiple patient characteristics by investigating all possible 
treatment-covariate interactions in some sort of a stepwise manner. However, such an 
approach may not be sensible as it would drastically exacerbate the multiplicity issue 
due to the increased number of hypotheses being tested. For this reason, alternative 
approaches that incorporate multiple patient characteristics have been proposed in the 
literature. One approach is a risk-stratified analysis to create subgroups that can then 
be investigated for heterogeneity. This approach is described in more detail below. 
Furthermore, there are methods that exist in the field of data mining that can also be 
considered for performing subgroup analyses or subgroup identification. These 
methods do not make any distributional assumptions and as the name suggests, they 
mine the data with the aim of unearthing patterns or structures inherent within the 
data. These alternative candidate approaches, namely multivariable risk-stratified 
analysis and tree based methods, for subgroup analyses or subgroup identification that 
take into account multiple patient characteristics will now be described in more detail.  
 
Multivariable risk-stratified analysis 
To incorporate multiple patient characteristics when investigating treatment effect 
heterogeneity, Hayward et al suggested using a multivariable risk-stratified analysis. 
This method uses an adequate externally developed and pre-validated risk prediction 
tool that is readily available to form risk-stratified subgroups that are then tested for 
treatment effect heterogeneity (129). Although this approach is commendable, an issue 
with it however is that a pre-developed risk prediction tool is required but may not be 
available in the field of research where it is to be applied. Moreover, if a risk prediction 
tool is utilized and no treatment heterogeneity is found, then one possible reason for 
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this could be that the wrong subgroups are being investigated. This therefore might not 
be a suitable approach to pursue. 
 
Tree based methods 
Considering the multidisciplinary nature of the research areas in which subgroup 
analyses are applied, it is important that the methodology used is understandable, 
applicable and interpretable by clinicians and not overly complex. There is one such 
data mining approach in particular, tree based modelling, which is quite popular and 
commonly used in data mining as well as many other fields of research. Tree based 
methods are exploratory in nature and employ a rather intuitive technique referred to 
as recursive partitioning. Moreover, they do not require as many complex tuning 
parameters to be specified compared to many other data mining methods. 
Furthermore, the basic principles behind this approach can be easily understood and 
the output easily interpreted. 
 
Tree based methods allow us to explore the entire covariate space for relevant simple 
and complex interactions as opposed to conventional subgroup analyses which only 
explore covariates of interest one at a time. The method uses recursive partitioning, a 
non-parametric technique, that makes no assumptions about the functional form 
relating covariates to outcome. This therefore makes the method more robust to any 
violation of the assumptions made by the conventional regression approach to 
subgroup analyses (130). In brief, these methods rely on a splitting criterion to 
recursively form binary splits of the entire covariate space to identify homogenous 
subgroups that when compared are heterogeneous in terms of some outcome measure. 
A more detailed explanation as to how tree methods work will be provided in Chapter 
6. The results are then displayed as a hierarchical tree structure that is easily 
interpretable to all. Classification and Regression Trees (CART) is probably the most 
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popular tree based method that is used today (131). Although the original tree based 
approach searches for heterogeneity in the outcome measure, there are now several 
advanced variants that have been recently proposed to identify subgroups of 
heterogeneous treatment effect (132-136). While this approach is completely 
exploratory in nature, it is a subgroup identification method that investigates 
subgroups defined by multiple characteristics that may have gone unnoticed using the 
conventional regression based approach. 
 
5.4 Subgroup analysis methods for IPD from trials 
 
Ordinary meta-analyses that synthesize aggregated data from several similar studies 
are a popular form of analyses. The methodology has been used for many years and 
hence is very well established. Individual patient data (IPD) meta-analyses on the other 
hand, regarded as the gold standard for meta-analyses, use the original individual 
patient data from each of the studies, which makes the analyses rather different. IPD 
meta-analyses have greater power and are particularly more useful compared to 
individual trials and ordinary meta-analyses methods when patient-level covariates 
are of interest rather than or in addition to just the mean effects. Though it is the ideal 
approach for performing meta-analyses, like any method, there are a number of 
challenges faced mainly to do with the approach being resource intensive (71). 
Performing IPD meta-analyses has only recently gained much popularity and therefore 
its methods are not as well established as ordinary meta-analyses methods. 
 
When performing IPD meta-analyses, in particular subgroup analyses, the existing 
methodology requires that one takes either a two-step approach or a one-step 
approach. In the two-step approach, the subgroup analyses are carried out in each 
individual dataset separately to obtain subgroup effect estimates along with their 
respective variance estimates. These estimates are then synthesized in a similar 
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manner to when performing ordinary meta-analysis using existing techniques. 
However, a problem with this approach is that often a simple fixed-effect pooling is 
used that does not incorporate the heterogeneity among the studies (137). This issue is 
overcome by using a one-step approach, a more flexible approach, which fits a single 
and simple hierarchical model with the inclusion of an interaction term (similar to the 
linear/logistic regression models) and also includes random effects to account for the 
between study heterogeneity. 
 
Despite IPD meta-analyses having greater power when wanting to identify moderators 
of treatment effect, the current methodology used may not be ideal. The problem is 
that we only know how to extend the simpler models to the IPD meta-analyses setting. 
To be more precise, when either a one stage or a two stage approach is used for 
subgroup analyses, interaction tests are performed testing one patient characteristic at 
a time; they do not consider the multiple characteristics of patients. This is the exact 
same issue highlighted earlier with the methods used in single trials. Therefore, 
although IPD meta-analyses provide an ideal framework for subgroup analyses, there 
is a need for methodological development to incorporate multiple patient 
characteristics when performing subgroup analyses. 
 
5.5 Discussion 
 
The term subgroup analysis is interpreted differently by different people. The 
distinction between prognostic subgroups and differential subgroups was made at the 
start of this chapter where the latter is of interest in this thesis. Differential subgroup 
analyses are most commonly performed using a regression based approach with the 
inclusion of a treatment-covariate interaction to test for treatment effect moderation. 
This chapter performed a broad literature review to explore the wider literature for 
other proposed methods of performing subgroup analyses. The review process found a 
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number of methods that have been proposed to date for investigating subgroup effects 
and subgroup identification using individual patient characteristics and also using 
multiple characteristics as well. Moreover, IPD meta-analysis methods were briefly 
described since an IPD framework is ideal for performing subgroup analyses. However, 
it became apparent from this review that there is a need for methodological 
development in both the single trial case and IPD meta-analysis case to incorporate 
multiple patient characteristics when identifying subgroups because in general only 
the simpler regression type models with a single interaction effect are used.  
 
Having reviewed the literature and identified various methods, it would not be possible 
to explore and evaluate every single method. Therefore, it is probably worthwhile at 
this stage to contrast what is written in current proposed guidelines for performing 
subgroup analyses to the findings from the systematic review of subgroup analyses in 
the area of low back pain presented in Chapter 4. One of the key recommendations in 
current proposed guidelines is that a clear distinction be made between pre-specified 
and post-hoc analyses where the former is for hypothesis testing (confirmatory 
analyses) and the latter for hypothesis generating (exploratory analyses). A limited 
number of pre-specified subgroups for investigation must be chosen using either a 
clear clinical justification or it must be based on findings from previous studies. As 
highlighted in chapter 3, if clinical justification is used then this could be quite 
subjective and it may be that important subgroups may go unnoticed. On the other 
hand if one were to base their choice of subgroups on findings from previous studies, 
then this may not be very wise if the quality, conduct and reporting of subgroup 
analyses in that particular field is poor; as was found in the systematic review in 
Chapter 4. For these reasons, it often makes sense to keep the subgroup analyses 
entirely exploratory in nature and use a method that investigates the entire covariate 
space such that no important subgroup effects go unnoticed. Any subgroups that are 
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identified from the exploratory analyses can then be tested in a future trial. Tree based 
methods, as described in this review, are one such method that can accommodate this. 
Furthermore, recent development of this methodology makes this a promising 
approach for subgroup identification in the context of clinical trials. The rest of this 
thesis will therefore focus on the evaluation, development and application of tree based 
methodology for identifying subgroups when using individual patient data from 
several similar trials.  
 
A key constituent of tree based approaches is the utilization of a technique referred to 
as recursive partitioning. Therefore the following chapter will introduce the recursive 
partitioning methodology, followed by a description of the several advanced tree based 
method variants that have been proposed in the literature to date for performing 
differential subgroup analyses. A simulation study will be performed thereafter to 
assess the performance of these variant methods in detecting interactions in a single 
trial setting and the results presented. 
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Chapter 6 
 
Introduction to 
Recursive Partitioning 
 
 
6.1 Introduction 
 
The previous chapter provided a broad review of the available methods for conducting 
subgroup analysis or subgroup identification in a single trial based setting as well as 
methods typically used for individual patient data (IPD) subgroup meta-analyses. Of 
the methods described in the review, it was identified that tree based methods are an 
attractive possibility for performing subgroup analyses using multiple patient 
characteristics. Whilst the application of tree based methodology is evident elsewhere 
as a valuable tool for identifying subgroups, its use in IPD meta-analyses and clinical 
trials of musculoskeletal disorders research is un-explored. 
 
Tree based methods are a data driven approach from the field of data mining that use a 
simple intuitive technique called recursive partitioning. It is important to initially fully 
understand the underlying recursive partitioning methodology of the tree based 
methods before looking at advanced variants of this methodology and considering 
possible extensions to an IPD meta-analyses setting. This chapter will therefore start 
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by describing the recursive partitioning methodology along with its relevant steps. 
Since outcome measures in the area of low back pain research are mainly of the 
continuous type, the explanation of the recursive partitioning procedure in this chapter 
will be for the continuous outcome case (regression trees). It is important to note here 
that the recursive partitioning methodology described in this chapter will first focus on 
identifying subgroups of patients that differ in terms of outcome, thereafter recursive 
partitioning methods to find moderators of treatment effect will be considered. 
However in traditional subgroup analyses, the aim is to identify subgroups that differ 
in terms of treatment effect i.e. treatment effect heterogeneity. Therefore the sole 
purpose of section 6.2 is for the reader to gain a good understanding of the concepts 
and basic methodology of recursive partitioning for tree based methods. The advanced 
variants of this methodology that have been proposed in the literature to date to 
identify treatment effect heterogeneity will be explained thereafter in section 6.3. 
 
6.2 Tree Based Methods 
 
As highlighted in previous chapters, there are several limitations to the conventional 
approach to subgroup analyses. These issues include a lack of power, multiplicity, 
subgroup selection for analyses and consideration of multiple patient characteristics. 
Selection of subgroups to be investigated in conventional analyses is rather subjective. 
Also, the selected subgroups are investigated independently despite the fact that 
patients have multiple characteristics. Tree based methods resolve these issues by 
searching the entire covariate space to identify subgroups using multiple patient 
characteristics. 
 
The earliest evidence of the application of recursive partitioning to create regression 
trees was in 1963 by Morgan and Sonquist at the University of Michigan, who proposed 
a method then referred to as the Automatic Interaction Detection method (AID)(138). 
84 
 
This method was primarily developed to analyse multiple covariates in terms of a 
single continuous response variable to detect interactions effects. However, this 
approach was very rarely implemented due to a serious problem, as highlighted by 
Breiman et al., of over-fitting and the results being unstable (131). In 1984, Breiman et 
al. then went on to extend the AID methodology to overcome these problems and 
proposed a method that is most commonly referred to today as the Classification And 
Regression Tree (CART) method (131). As the name suggests, the method is applicable 
to situations where the outcome is either categorical (classification trees) or 
continuous (regression trees). Since the proposal of CART, several other variants based 
on the CART methodology and application have been proposed. A limitation of the 
CART method is that there is no formal way of making statistical inference. Therefore 
some of the more recent advancements combine multiple regression analysis with 
regression trees to accommodate a formal way of making statistical inference. Some of 
these include methods for estimating regression models consisting of both main effects 
and interaction effects. These methods include multivariate adaptive regression splines 
MARS) proposed by Friedman in 1991, the M5 algorithm proposed by Quinlan in 1992 
and generalised unbiased interaction detection and estimation (GUIDE) proposed by 
Loh in 2002 (139-141). There are also methods that have been specifically developed 
or have the ability to detect treatment-effect heterogeneity. For example the 
Regression Trunk Approach (RTA) proposed in 2004 by Dusseldorp et al and the 
Simultaneous Threshold Interaction Modelling Algorithm (STIMA) proposed in 2010 
by the same authors (132, 133). It is thus evident that recursive partitioning 
methodology has developed over the years and an excellent detailed review is 
provided by Zhang and Singer (2010) on modern recursive partitioning and its 
applications (130).  
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Initially, it is essential to understand the underlying methodology of recursive 
partitioning as it is a key component of tree based methods. This consists of three key 
steps: 
1) Growing the initial fully grown tree 
2) Pruning the fully grown initial tree to identify potential optimal sub-trees 
3) Select the optimal sized sub-tree 
 
These steps will now be described in the following sections.  
 
6.2.1 Growing an Initial Fully Grown Tree 
 
Tree based methods involve the use of a technique referred to as recursive 
partitioning; a non-parametric technique. Recursive partitioning is a process that, as 
the name suggests, recursively forms binary splits of the covariate space 𝑋𝑗, where 𝑗 
denotes the 𝑗th covariate, with each new split forming two homogenous subgroups of 
individuals that when compared are most heterogeneous in terms of some response 
variable, say Y, where Y is either categorical or continuous (130).  
 
The process initially starts at a unique root node, denoted by 𝜏, that consists of the 
entire dataset i.e. all 𝑁 individuals. A binary split of the root node is then created to 
form two new child nodes by choosing an optimal split point, say 𝑠, of a covariate 𝑋𝑗  
that is either continuous or categorical. How to find the optimal split point will be 
explained later on. If 𝑋𝑗 is continuous then individuals with a value less than or equal to 
the optimal split point 𝑠 are assigned to the left child node 𝜏𝐿 = {𝑖|𝑖 ∈ 𝜏, 𝑋𝑖,𝑗 ≤ 𝑠} and 
the remaining individuals with a value greater than the optimal split point 𝑠 are 
assigned to the right child node 𝜏𝑅 = {𝑖|𝑖 ∈ 𝜏, 𝑋𝑖,𝑗 > 𝑠}, where 𝑋𝑖,𝑗  is the value of the jth 
covariate for the ith individual. If 𝑋𝑗 is categorical then the split point 𝑠 will form two 
disjoint subsets, say 𝐴 and 𝐵, such that individuals contained in subset 𝐴 are assigned 
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to the left child node 𝜏𝐿 = {𝑖|𝑖 ∈ 𝜏, 𝑋𝑖,𝑗 ⊂ 𝐴} and those contained in subset 𝐵 are 
assigned to the right child node 𝜏𝑅 = {𝑖|𝑖 ∈ 𝜏, 𝑋𝑖,𝑗 ⊂ 𝐵}. These newly formed child 
nodes are also referred to as internal nodes. The same binary splitting process at an 
optimal split point 𝑠 of a covariate 𝑋𝑗 is then applied to each of the newly formed 
internal nodes. This process of recursively creating binary splits of the internal nodes 
continues until either a formal stopping rule criterion is met or when no more splits 
can be made on the most recently created internal nodes, hence resulting in a fully 
grown initial tree. Choosing which split is best and when to stop growing a tree is 
described later on in section 6.2.3. Internal nodes that cannot be split any further are 
referred to as terminal nodes, where each terminal node is simply a homogenous 
subgroup in terms of the outcome and also a subset of the root node.  
 
6.2.2 Tree growing example 
 
A simple hypothetical example of the initial stages of a tree growing process with a 
continuous outcome (regression tree) has been illustrated in figure 6.1. This example 
assumes we have some data from a non-specific LBP RCT where the outcome is the 
change from baseline to 12 months in the Rolland and Morris Disability Questionnaire 
(RMDQ) and the aim is to identify predictors rather than moderators (28). The 
regression tree consists of three layers; the first layer contains just node 1 i.e. the root 
node 𝜏, the second layer contains one terminal node (node 2) and one internal node 
(node 3) and finally the third layer contains two internal nodes (node 4 and node 5). In 
the first layer, the root node is split using the baseline RMDQ score at 𝑠=4 to form left 
(node 2) and right (node 3) child nodes,  𝜏𝐿 and 𝜏𝑅 respectively. The newly formed 
child nodes are then split in the same manner as the root node. Let’s assume node 2 
cannot be split any further due to some stopping criterion. Node 2 therefore becomes a 
terminal node; represented by a square box. This therefore suggests that the subgroup 
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of patients with baseline RMDQ≤4 would expect to see a mean change from baseline to 
12 months of 0.33 in the RMDQ score. Node 3 can be split further using the binary 
covariate employment status (unemployed and employed) as it is the best split for this 
node out of all possible splits (optimal split). This split creates a new set of left and 
right child nodes (node 4 and node 5). What this means is that the subgroup of patients 
with baseline RMDQ>4 and who are also employed would expect to see a mean change 
from baseline to 12 months of around 3.60 in the RMDQ score. Whereas the subgroup 
of patients with baseline RMDQ>4 but who are also unemployed would expect to see a 
mean change from baseline to 12 months of 1.79 in the RMDQ score. Nodes 4 and 5 
then become internal nodes, represented by circles, which then need to be searched to 
see if they can be split further. The binary splitting process continues in this way until 
all internal nodes cannot be split any further resulting in all the end nodes becoming 
terminal nodes. 
 
Figure 6.1 – Example of a regression tree 
 
 
 
 
 
 
 
 
6.2.3 Node splitting  
 
Number of splits 
Having explained the basic concepts behind growing an initial fully grown tree, there 
are two questions that need to be addressed: 
Employed 
≤4 
Employment status 
Baseline RMDQ 
 
>4 
Unemployed 
 1: 𝜏  
 3: 
  
5: 
3.60 
4: 
1.79 
2: 0.33 
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1) How to choose which covariate out of all covariates to split and at what 
optimal split point 𝑠 to split at?  
2) How to decide when not to split an internal node (i.e. when to decide that an 
internal node is a terminal node)?  
 
Before answering the first question, it is important to note here that the total number 
of potential split points varies at each stage of the tree growing process depending on 
whether the covariates are continuous or categorical. For a continuous covariate or 
discrete ordered covariate, the number of possible split points is simply one minus the 
total number of its distinct values. For example a continuous variable with 100 distinct 
values will have 100-1=99 possible split points. If a covariate is categorical, with 𝑀 
categories, then there are 2𝑀−1 − 1 potential split points. For example, assume 
ethnicity is a categorical covariate with three categories; white, black and asian. Thus, it 
has three possible split points; white vs black and asian, white and black vs asian and 
finally white and asian vs black. The overall number of possible splits when initially 
splitting the root node is simply the summation of all possible splits from all covariates. 
Therefore to answer the first question, all potential splits for all variables are evaluated 
using a goodness-of-split criterion to decide which covariate to split and at what 
optimal split point 𝑠 to split at.  
 
Splitting criterion 
The goodness-of-split criterion is typically an impurity function that measures the 
reduction in the heterogeneity of an outcome 𝑌 between two newly formed child nodes 
created when splitting an internal node. An impurity function is basically a function 
that quantifies how impure or heterogeneous two child nodes are having formed a 
split. In an ideal case, we would want an optimal split 𝑠 to form two subgroups of 
individuals that are completely homogenous (pure) in terms of an outcome  𝑌, 
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however, we know this will be highly unlikely and that the child nodes will be ‘partially 
homogenous’ or ‘impure’. Moreover, the amount of node impurity will vary for all 
possible splits over all 𝑋𝑗 covariates. Therefore an impurity function is evaluated for all 
possible splits to find the optimal split that maximises the reduction in impurity i.e. 
produces the most “pure” subgroups. The type of node impurity measure used depends 
on whether the response variable is continuous or categorical. In the case where the 
response is continuous, a natural option for a node impurity measure is the within-
node sum of squares: 
 
𝑖(𝜏) = ∑ (𝑌𝑖 − ?̅?𝜏)
2
𝑖∈𝜏        (6.1) 
 
 
where 𝑖 ∈ 𝜏 are the individuals in node 𝜏 and ?̅?𝜏 is the mean of the response for those 
individuals in node 𝜏. The goodness-of-split (impurity function) can therefore be 
calculated for a split 𝑠 of an internal node 𝜏 to form left and right child nodes, 𝜏𝐿 and 𝜏𝑅 
respectively, as follows: 
 
𝜑(𝑠, 𝜏) = ∆𝑖(𝑠, 𝜏) = 𝑖(𝜏) − 𝑖(𝜏𝐿) − 𝑖(𝜏𝑅)    (6.2) 
 
 
Here the impurity function simply subtracts the impurity of the two child nodes from 
the impurity of its parent node. As mentioned earlier, the impurity function is 
evaluated over all possible splits to find the optimal split 𝑠 for each covariate 𝑋𝑗 . 
Subsequently the covariate that maximises 𝜑(𝑠, 𝜏) i.e. the split that leads to the biggest 
difference between the means of the two groups, is chosen to form the new split. This 
procedure is recursively applied to the newly formed internal nodes at each stage to 
continue the tree growing process. 
 
Stopping criteria 
The second question is how to determine when to stop growing a tree. One possible 
solution, although not the best, is to implement some sort of stopping rule also referred 
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to as pre-pruning. For example you could set a minimum size for the number of 
individuals in a child node e.g. n=10 or 2% of the original sample size, such that it 
becomes a terminal node (i.e. stops splitting) if it goes below that number. However 
implementing such a stopping rule can be problematic resulting in the tree growing 
process either stopping too early (under-fitting) or too late (over-fitting) (131). 
Breiman suggested that no stopping rules be put in place and that an initial fully grown 
saturated tree 𝑇0 is formed such that the nodes cannot be split any further i.e. all 
individuals in the node are identical. Such a tree is very well fitted to the available data 
but is rather unstable and relatively poor when predicting future data. Instead, simpler 
subtrees nested in 𝑇0 may fit the data well enough but prove to be better predictors of 
future data hence making predictions more generalizable; however going through all 
possible subtrees could be a daunting task. Thus to overcome the problem of under or 
over fitting, improve model stability, improve the predictability of future data and to 
limit the choices of optimal subtrees, Breiman introduced the concept of post-pruning; 
a process analogous to backward stepwise regression that simply removes nodes that 
minimally contribute to the predictive accuracy of the tree (130). The next section will 
describe the post-pruning process which will be referred to as just “pruning” from now 
onward. 
 
6.2.4 Pruning  
 
The pruning process initially starts with a fully grown tree. The procedure then 
iteratively removes branches that least contribute to the predictive accuracy of the tree 
to form a sequence of potentially optimal nested subtrees from which the best optimal 
subtree 𝑇∗ is selected. The best optimal subtree is the subtree that minimises the 
overall predictive error; explained in more detail in 6.2.5. This concept in the area of 
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tree based methods is referred to as cost-complexity pruning. For a fully grown tree, 𝑇, 
the total tree cost-complexity is defined as: 
 
𝑅𝛼(𝑇) = 𝑅(𝑇) + 𝛼|?̃?|                                                                 (6.3) 
 
where 𝑅(𝑇) is a measure of the quality of a tree or the tree cost, 𝛼(≥0) is the complexity 
parameter (the cost of an additional single terminal node), and |?̃?| is the number of 
terminal nodes in the fully grown tree. Here the cost of the total tree 𝑅(𝑇), measured 
by the quality of its terminal nodes, is penalized further with respect to the complexity 
of the tree where the complexity is measured simply by the size of the tree i.e. the 
number of terminal nodes |?̃?|. The complexity parameter 𝛼 is a positive continuous real 
number where each value of 𝛼 may lead to a different subtree that minimizes the cost-
complexity. Breiman et al were able to show that every value of 𝛼 has a unique subtree 
of the fully grown tree that minimizes the cost-complexity, thus there are a finite 
number of subtrees corresponding to a infinite number of complexity parameter values 
(142). Therefore, instead of searching through every possible subtree for each value of 
𝛼 to find the subtree with minimal cost-complexity using (6.3), Breiman and colleagues 
proposed an algorithm that created a sequence of complexity parameter values. This 
algorithm utilises a function 𝛼(𝜏) to estimate the complexity parameter 
 
𝛼(𝜏) =
𝑅𝒔(𝜏) − 𝑅𝒔(?̃?𝜏)
|?̃?𝜏| − 1
                                                                (6.4) 
 
where ?̃? is the set of all terminal nodes and ?̃?𝜏 is the set of offspring terminal nodes of 
the internal node 𝜏, 𝑅𝒔(𝜏) is the resubstitution cost of the internal node 𝜏 and 𝑅𝒔(?̃?𝜏) is 
the resubstitution cost of the offspring terminal nodes ?̃?𝜏. Breiman et al. used the 
resubstitution cost to help prune back a tree. It is called the resubstitution cost because 
the same data used to build the tree are again used to estimate the cost of a tree. The 
function numerator 𝑅𝒔(𝜏) − 𝑅𝒔(?̃?𝜏) in (6.4) basically compares the cost of a node 𝜏 to 
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the total cost of the terminal nodes in the branch connected to 𝜏, denoted by ?̃?𝜏. Since 
we are describing regression trees here, i.e. the response is continuous; the pruning 
algorithm uses the sum of squared errors (SSE) as a measure of the resubstitution cost 
to prune back a tree (𝑅𝒔(𝜏) = ∑ (𝑌𝑖 − ?̅?𝜏)
2
𝑖∈𝜏 ). Note that the SSE was also used as the 
impurity function in the tree growing process described in the previous section.  
 
Now that the components of the complexity parameter estimating function 𝛼(𝜏) have 
been described, the steps of the pruning algorithm for determining the first subtree can 
now be explained. The algorithm consists of the following steps: 
 
1) Let 𝑇0 be a fully grown tree. Compute the estimate of the complexity 
parameter 𝛼 using the function 𝛼(𝜏) (see (6.4)) for all internal nodes 
(i.e.∀𝜏 ∉ ?̃?) of the initial fully grown tree 𝑇0 
2) Find the internal node with the smallest value of 𝛼(𝜏) and remove (prune) 
all subsequent branches connected to this node. This internal node 
therefore becomes a terminal node. The resulting tree thus forms the first 
subtree 𝑇1 corresponding to the complexity parameter estimate 𝛼1, as 
estimated by 𝛼(𝜏). 
3) Repeat steps 1) and 2) using 𝑇1 as the initial tree. 
 
Steps 1) and 2) from the above algorithm are continuously repeated using the 
previously formed subtree as the initial tree of the next iteration. The value 𝛼(𝜏) 
computed for each internal node (step 1) reflects how much additional predictive 
accuracy the branch connected to node 𝜏 contributes to the tree. Hence, larger values of 
𝛼(𝜏) indicate greater contribution. Therefore, each iteration of the pruning procedure 
removes the branch that least contributes to the trees predictive accuracy thus forming 
an increasing sequence of complexity parameter estimates 𝛼0 < 𝛼1 < 𝛼2 < ⋯ < 𝛼𝑚, 
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where 𝛼0 = 0 for the fully grown tree i.e. there is no additional cost for extra terminal 
nodes hence a fully grown tree is the best predictor. Furthermore, the complexity 
parameter sequence 𝛼𝑚 (𝑚 = 0,1,… ,𝑚) corresponds to a sequence of nested optimal 
subtrees 𝑇0 ⊃ 𝑇1 ⊃ 𝑇2 ⊃ ⋯ ⊃ 𝑇𝑚, where each subsequent subtree in the sequence is a 
subtree of the previous tree i.e. 𝑇𝑚−1 ⊃ 𝑇𝑚. The algorithm continues until the final 
subtree 𝑇𝑚 in the sequence is just the root node. The optimal subtree 𝑇
∗ is then 
selected from the sequence of nested optimal subtrees. How to select the optimal 
subtree is described in the next section. This pruning procedure is quite often referred 
to as weakest-link pruning. 
 
6.2.5 Selecting the optimal sub-tree 
 
The previous sections of this chapter have described in detail the tree growing process. 
It was shown how to initially form a fully grown saturated tree that over-fits the data 
followed by a pruning procedure to remove unwanted branches that minimally 
contribute towards the predictive accuracy of the tree, thus forming a sequence of 
nested optimal subtrees of which one final optimal subtree 𝑇∗ is to be selected. In order 
to select an optimal subtree, the predictive accuracy of each of the nested subtrees 
needs to be evaluated. This is done by initially computing the resubstitution SSE cost 
(continuous response) for each subtree and then selecting the optimal subtree that has 
the smallest cost. When no test data are available the original data used to generate the 
tree can be used to evaluate the predictive accuracy. This is referred to as the 
resubstitution estimate as the same data are being re-substituted. However, an 
identified problem with the resubstitution SSE cost estimates for the subtrees is that 
they tend to be biased downwards. This bias occurs because the same data are used to 
estimate the SSE cost hence the cost is lower due to better fitting subtrees, thus 
resulting in the final chosen optimal subtree 𝑇∗ being larger than optimal (130). To 
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overcome this problem, the predictive accuracy of each of the subtrees needs to be 
estimated by applying it to an independent test dataset, if it is available. The 
individuals in the test dataset are sent down each of the subtrees and the cost of each 
subtree estimated from which the optimal subtree with minimal cost is selected.  
 
Usually an independent test set is not available and so to overcome this, an intuitive 
resampling method can be used, namely, V-fold cross-validation. This method works by 
firstly separating the entire dataset into V equal pieces; typically V is set to 5, 10 or 25. 
If the dataset was split into 5 pieces (i.e. V=5) for example, then it would be referred to 
as 5-fold cross-validation. The next step is to hold out one of the pieces, say piece v, 
v=1,…,V, to form a test sample and use the remaining pieces as a training sample. So 
first of all, v=1 will be held out as the test sample and v=2,...,V will be combined 
together to form the training sample. A fully grown tree is then formed using the 
training sample and then subsequently pruned using each of the complexity 
parameters from the sequence obtained when pruning the original fully grown tree 
using the entire dataset. This forms a sequence of nested subtrees that are then each 
applied to the test sample (v=1) to form unbiased estimates of the SSE cost, thus 
completing the first iteration. Similarly, the next iteration works by holding out v=2 as 
the test sample and using v=1,3,...,V as the training sample. In the same way, the 
iteration continues until each individual piece v=1,...,V has been held out so that 
ultimately there are V sequences of nested subtrees with their corresponding SSE 
costs. Finally, an estimate of the SSE cost is then calculated by averaging the cost over 
all V folds for each complexity parameter 𝛼𝑚 in the sequence. Now that these costs 
have been estimated, all that remains is to select the final optimal subtree 𝑇∗.  
 
There are two ways in which this can be done. The first way is to choose the complexity 
parameter corresponding to the smallest average SSE cost as the optimal complexity 
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parameter value 𝛼∗. Therefore the subtree from the sequence of optimal subtrees that 
corresponds to this particular optimal complexity parameter value 𝛼∗ is chosen as the 
optimal tree 𝑇∗. However, the final optimal subtree selected in this way can still be 
unstable. The second approach avoids this issue by using a method known as the 1-SE 
rule; an alternative method proposed by Breiman et al. that takes into consideration 
the standard errors of the SSE costs estimated from cross-validation. Not only does this 
reduce instability but it also selects the simplest subtree whose predictive accuracy is 
similar (within 1 standard error) to that of the tree selected from the cross-validation 
procedure. Let 𝑅𝑐𝑣(𝑇𝑚) denote the cross-validation estimates of the SSE cost given by 
 
𝑅𝑐𝑣(𝑇𝑚) =  
1
𝑉
∑  𝑅𝒔(𝑇𝑚,𝑣)                                                         (6.5)
𝑉
𝑣=1
 
 
where 𝑇𝑚 is the 𝑚th subtree corresponding to the complexity parameter estimate 𝛼𝑚, 
𝑣 = 1,… , 𝑉 denotes the index of the fold used as the test set in the cross-validation and 
thus 𝑅𝒔(𝑇𝑚,𝑣) is the SSE cost of the 𝑚th subtree obtained using the vth fold from the 
cross-validation corresponding to the complexity parameter estimate 𝛼𝑚. Then the 
variance for the SSE cost estimate of the 𝑚th tree can be computed as follows: 
 
𝑉𝑎𝑟(𝑅𝑐𝑣(𝑇𝑚)) =
1
𝑁
∑[(𝑌𝑖 − ?̂?𝑖,𝑣)
2
− 𝑅𝑐𝑣(𝑇𝑚)]
2
𝑁
𝑖=1
                                        (6.6) 
 
where 𝑌𝑖  and ?̂?𝑖,𝑣 are the observed and predicted value for the 𝑖th individual in the 𝑣th 
test set respectively. The predicted value ?̂?𝑖,𝑣 for an individual is simply the mean 
outcome in the terminal node they are assigned to having sent them down the tree. 
Having computed the variance, we can go on to compute the standard error: 
 
𝑆𝐸(𝑅𝑐𝑣(𝑇𝑚)) = √
𝑉𝑎𝑟(𝑅𝑐𝑣(𝑇𝑚))
𝑁
                                                        (6.7) 
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It is important to note here that this is a heuristic approximation of the standard error 
estimate since it incorrectly assumes that the predicted values for all 𝑖 individuals are 
independent. Having computed the SE, all that remains is to select the optimal tree 
using the 1-SE rule. This is done by firstly summing the smallest SSE cost estimate 
(computed using V-fold cross-validation) with the smallest SE estimate. The smallest 
subtree whose SSE cost estimate is no larger than this summation is chosen as the final 
optimal tree 𝑇∗. The selection of 𝑇∗ using the 1-SE rule has been empirically shown in 
most cases to be of better quality compared to choosing the tree with minimum cross-
validated SSE cost (referred to as the 0-SE rule) (130). 
 
6.2.6 Interpretation of the optimal tree  𝑻∗ 
 
Once a final optimal tree 𝑇∗ has been determined, we can easily make inferences about 
any subgroups inherent within the data by simply summarising the terminal nodes. 
When the response is continuous, subgroups identified using a regression tree are 
summarised by simply averaging the response for the individuals within each of the 
terminal nodes, thus creating a piecewise constant prediction function.  
 
6.3 Advancements of recursive partitioning methodology to detect moderators of 
treatment effect 
 
Since the formulation of the CART approach as proposed by Breiman, there have been 
several advanced variants of the CART type routine proposed in the literature. The 
majority of these variants focus on finding marginal effects rather than differential 
treatment effects; where the latter is of interest in this thesis. There are a handful of 
methods that are either designed specifically, or are capable of detecting differential 
subgroup effects. In particular, these methods are the Interaction Tree (IT), Regression 
Trunk Approach (RTA), Simultaneous Threshold Interaction Modelling Algorithm 
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(STIMA) and Subgroup Identification based on a Differential Effect Search (SIDES) 
(132, 133, 135, 136). 
 
The IT method was proposed by Su et al to specifically detect treatment-covariate 
interactions i.e. moderators of treatment (136). The IT approach is similar to the CART 
approach but uses a different splitting criterion that specifically looks for maximal 
interaction effects. The RTA and STIMA approaches were both proposed by Dusseldorp 
et al with the aim of estimating a linear regression model as well as searching for 
interactions. The RTA approach, proposed in 2004, uses a three phase procedure for 
specifically detecting treatment-covariate interactions in addition to estimating a linear 
regression model. The authors then proposed the STIMA approach in 2010 as an 
improved version of the RTA method. The STIMA method is a more generalised method 
compared to RTA as it detects all interactions and not just treatment-covariate 
interactions. Moreover, it simultaneously estimates a linear regression model and a 
tree model whereas the RTA method uses three phases to do this. For STIMA to detect 
treatment-covariate interactions only, it requires the user to force the first split on 
treatment when growing the tree. As STIMA is an improved version of RTA, only the 
STIMA method will be considered further in this thesis.  
 
The objective of the IT and STIMA procedures is to identify subgroups that most differ 
in terms of treatment effectiveness; hence aiming to find subgroups with a large 
treatment-covariate interaction. Moreover, both of these approaches follow a similar 
procedure to CART in that they initially grow a tree, prune the tree and finally select 
the optimal tree from the set of pruned subtrees. The trees produced by IT and STIMA 
tell us how many and what types of interactions are inherent within the entire dataset. 
Moreover, all of the data are sent down the tree and are contained within the terminal 
nodes. Therefore, inferences can be made about the entire dataset by observing the 
98 
 
terminal nodes. The terminal nodes can tell us which subgroups benefit the most, 
which subgroups benefit less and also which subgroups, if any, are harmed. The SIDES 
procedure on the other hand is rather different to IT and STIMA. At each level of the 
tree, SIDES also searches for subgroups with the largest treatment-covariate 
interaction. However, each time an interaction is found, the subgroup with the larger 
treatment effect is retained and the remainder or the data disregarded. Hence, the aim 
of SIDES is to identify subgroups in which the treatment arm outperforms the 
comparator arm. Furthermore, the SIDES procedure does not follow the typical CART 
type procedure, as will be explained later on, but does use recursive partitioning 
methodology. The difference between SIDES compared to IT and STIMA becomes 
clearer when considering the final tree obtained. Each of the terminal nodes of the 
SIDES tree defines a different candidate subgroup with enhanced treatment effect. It is 
quite likely that individuals in one candidate subgroup may also be contained in 
another candidate subgroup. Thus these subgroups are subsamples (possibly 
overlapping subsamples) of the entire dataset therefore inferences can only be made 
about subsets of the entire data. Moreover, unlike the IT and STIMA trees, the 
subgroups identified by SIDES can only conclude benefit. Although the aim of SIDES is 
different to the aims of IT and STIMA, from a clinical perspective, both of these aims are 
quite important. These methods will now be described in more detail. 
 
6.3.1 IT method 
 
Splitting criterion 
The IT method works in a similar way to the CART procedure but instead uses a 
splitting criterion that detects treatment-covariate interaction. Suppose we split a node 
𝜏 at some split point s to form two child nodes; 𝜏𝐿 and 𝜏𝑅 respectively. Also assume that 
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we have a continuous response Y and a treatment indicator, say Trt (control=0 and 
intervention=1). We can display this split as follows 
 
 𝝉𝑳 𝝉𝑹 
Trt=0 ?̅?0
𝐿  𝑠1
2  𝑛1 ?̅?0
𝑅  𝑠2
2  𝑛2 
Trt=1 ?̅?1
𝐿  𝑠3
2  𝑛3 ?̅?1
𝑅  𝑠4
2  𝑛4 
 
The terms in the first quadrant above (?̅?0
𝐿   𝑠1
2  𝑛1) represent the sample mean, sample 
variance and sample size respectively in the left child node 𝜏𝐿 for when Trt=0. The 
other quadrants are interpreted in the same manner. Now that two nodes have been 
formed, all that is required is to determine the treatment effect heterogeneity between 
both nodes. This requires that we compare the treatment effect in the left node (?̅?1
𝐿 −
?̅?0
𝐿) with the effect in the right node (?̅?1
𝑅 − ?̅?0
𝑅). In other words, we are interested in the 
treatment-covariate interaction. The authors therefore proposed a splitting criterion 
for evaluating the interaction effect for each potential split in the tree growing process. 
The proposed splitting criterion is given by 
 
𝐺(𝑠) =
(
 
(?̅?1
𝐿 − ?̅?0
𝐿) − (?̅?1
𝑅 − ?̅?0
𝑅)
?̂? ∙ √
1
𝑛1
+
1
𝑛2
+
1
𝑛3
+
1
𝑛4)
 
2
                                                  (6.8) 
 
where  ?̂?2 = ∑ 𝑤𝑖
4
𝑖=1 𝑠𝑖
2  is a pooled estimator of the constant variance and where 𝑤𝑖 =
(𝑛𝑖−1)
∑ (𝑛𝑗−1)
4
𝑗=1
 (136). Thus when growing the tree, the splitting criterion G(s) is evaluated 
for every single potential split and the split with the maximum G(s) is chosen as the 
best split. In other words, the split that gives the largest interaction effect is chosen as 
the best split.  
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Growing a tree – parameter specifications 
A fully grown tree, say 𝑇0, is grown using the aforementioned split function until either 
some stopping criterion is met or the tree cannot split nodes any further. The code for 
the IT approach was very kindly provided by the author Dr Xiaogang Su. When 
applying the IT procedure, it requires a couple of user-defined parameters to be 
specified to aid the tree growing process. These include the minimum node size i.e. the 
minimum number of individuals in any given node, and the maximum depth of a tree 
i.e. how many levels the tree has (the complexity of a tree). 
 
Pruning 
The IT method uses weakest link pruning, similar to CART (see equation 6.4), to 
determine the complexity parameter values and the associated subtrees of the fully 
grown tree 𝑇0. Thus the function 
 
𝛼(𝜏) =
∑ 𝐺(𝜏)𝜏∈𝜏−?̃?
|𝜏 − ?̃?|
 
 
is evaluated for every internal node 𝜏 where the numerator  ∑ 𝐺(𝜏)𝜏∈𝜏−?̃?  is the overall 
amount of interaction of the internal nodes in the branch connected to the internal 
node 𝜏 and the denominator |𝜏 − ?̃?| is the number of internal nodes in the branch 
connected to 𝜏. The internal node with the smallest value of 𝛼(𝜏) is pruned i.e. the 
branch connected to the internal node is removed and the internal node itself becomes 
a terminal node to form the first subtree 𝑇1. In the same way as CART, this process 
continues to form a sequence of subtrees until we are left with just the root node.  
 
Selecting the best tree 
The quality or performance of an interaction tree, say T,  is assessed using an 
interaction complexity measure; similar to the CART procedure (see equation (6.3)). 
The interaction- complexity measure is given by 
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𝐺𝛼(𝑇) = 𝐺(𝑇) − 𝛼 ∙ |𝑇 − ?̃?| 
 
where 𝐺(𝑇) = ∑ 𝐺(𝜏)𝜏∈𝜏−?̃?  is the sum of the interaction in the internal nodes of the tree 
T and |𝑇 − ?̃?| is the number of internal nodes in tree T. The above interaction-
complexity measure can be evaluated for every subtree and the one with the maximum 
value is chosen as the best tree. What remains is the selection of the complexity 
parameter value 𝛼, i.e. the penalty for additional splits. This can be done using V-fold 
cross-validation as described in section 6.2.5, using the 1-SE rule to determine the best 
tree size and thus the complexity parameter value. The authors also recommend a 
bootstrapping method, used by LeBlanc et al, as an alternative option for validating the 
trees (136, 143). 
 
Interpretation of the final tree 
Once a final tree has been selected, the interpretation is rather straightforward. The 
outcome of interest, which in this case is the treatment effect, is computed for each of 
the terminal nodes of the final selected tree. The conclusions are then based on the 
comparison of the terminal nodes summaries. For example, say that a single one-way 
interaction effect exists in a dataset, then the final chosen interaction tree should 
consist of a single split of the root node i.e. two terminal nodes. Thus, the difference in 
the treatment effect between the two terminal nodes should be equivalent to the size of 
the interaction effect.  
 
6.3.2 STIMA method 
 
Splitting criterion 
The STIMA method simultaneously estimates a linear regression model whilst 
searching for interaction effects by growing a tree. As mentioned before, the STIMA 
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method is more generalised compared to the previously proposed RTA method 
because it searches for all types of interaction. Therefore, in order for the method to 
search specifically for treatment-covariate interactions, the user has to force the first 
split on the treatment variable. It may be difficult to see how forcing the first split 
allows the tree to search for treatment-covariate interactions; however this will be 
explained later on. 
 
The first step in the algorithm requires a linear regression model to be fitted using all 
covariates in the root node. Thereafter, all possible split points, say s, for all covariates 
are searched to identify the split that generates the largest effect size when comparing 
the model that was fit before split s to the model after adding split s as an indicator 
variable. The effect size is determined using 
 
𝑓𝑠
2 =
(𝜌𝑠
2 − 𝜌𝑠−1
2 )
(1 − 𝜌𝑠
2)
                                                                 (6.9) 
 
where 𝜌𝑠−1
2 =
∑ (?̂?𝑖(𝑠−1)−?̅?)
2
𝑖
∑ (𝑌𝑖−?̅?)2𝑖
 is the squared multiple correlation coefficient of the model 
before split s i.e. s-1, thus 𝜌𝑠
2 =
∑ (?̂?𝑖𝑠−?̅?)
2
𝑖
∑ (𝑌𝑖−?̅?)2𝑖
 is the squared multiple correlation coefficient 
of the model having split the node on s (133). This effect size essentially measures the 
increase in the variance-accounted-for (VAF) from the model without split s i.e. s-1, to 
the model with split s. The split point s that induces the largest relative increase in VAF 
is chosen as the next best split. 
 
Growing a tree – parameter specifications 
The aforementioned splitting criterion for STIMA is used to grow a full tree, which the 
authors also refer to as a regression trunk. Each iteration of the tree growing process 
evaluates the effect size for every single split of every single variable within every 
single node choosing only a single best split at the end of the iteration. This is different 
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to the IT approach which searches each node separately and creates a split for each 
node if it is permissible, whereas STIMA searches all nodes and forms just the one split. 
If a best split is found, it is added to the linear regression model as an indicator variable 
and then the model is re-estimated. This process is continuously repeated until either a 
stopping criterion is met or if the tree cannot find any more effective splits. 
 
The code for the STIMA approach is readily available on the author’s webpage (Elise 
Dusseldorp - http://www.elisedusseldorp.nl/). When applying the STIMA procedure, it 
requires a number of user-defined parameters to be specified to aid the tree growing 
process. These include the minimum node size, the maximum number of splits, the 
column index of the variable in the dataset on which to force the first split of the tree (if 
required) and finally the specification of the value V for the V-fold cross-validation 
procedure. The authors recommend using either 5-fold or 10-fold for the cross-
validation procedure. 
 
Forced first split on treatment 
In order to detect treatment-covariate interactions, the first split must be forced on the 
treatment variable. To better understand this, consider an example of a single one-way 
interaction between a binary treatment variable, say Trt, and a binary baseline 
covariate, say Grp, with a Trt*Grp interaction effect. We can display the interaction by 
   
 Trt=0 Trt=1 
Grp=0 a b 
Grp=1 c d 
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where a, b, c and d are the cell means. The interaction effect using the above is 
computed by (a-b)-(c-d) = a-b-c+d. After forcing the first split on treatment, 
represented by the bold dashed line, the method then goes onto search all splits for 
every covariate within all nodes to identify the next best single split. In this example, it 
can only split on Grp within both treatments. If the Trt=0 node is further split by Grp, 
then the means in the two newly formed child nodes will be a and c respectively. Hence 
the difference in means between the two child nodes is a-c. Similarly, if the Trt=1 node 
is further split by Grp, then the means in the two newly formed child nodes will be b 
and d respectively. Hence the difference in means between the two child nodes is b-d. 
Since the STIMA method makes just a single split per iteration, of the two splits, the 
method will select the split with the largest difference in cell means and then add it to 
the linear regression model as an indicator variable and the model re-estimated. If the 
next best split in this example is in the Trt=0 node, then one might assume that the 
same split is mirrored in the Trt=1 node in the next iteration, however this is not 
required since the model has been updated and re-estimated to incorporate the 
detected Trt*Grp interaction effect; thus only one split is made. Figure 6.2 better 
illustrates the STIMA tree for the above example of a single Trt*Grp interaction where 
the best split is made using node Trt=0. 
 
Figure 6.2 – Example of STIMA tree for one-way interaction 
 
 
 
 
 
 
 
 
Grp>0 
 
Grp≤0 
     
 Trt=0 
Mean=a Mean=c 
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Selecting the best tree 
Once a full tree has been grown, STIMA then applies V-fold cross validation to select 
the best tree size i.e. the best choice of s; the number of splits in the tree. Although 
CART and IT methods require a pruning procedure i.e. weakest link pruning, to obtain 
a sequence of subtrees, such a procedure is not required by STIMA. The reason for this 
is because STIMA is essentially a set of nested models that are defined by the number 
of splits s it has. Therefore, these nested models can be thought of as the sequence of 
subtrees obtained by the CART and IT pruning procedures. For example, a tree with 
four splits means that there are five candidate nested models to choose from; four 
models with interaction terms and the null model. Thus, the selection of the best size 
model determined by the number of splits s is done by using V-fold cross-validation in 
the same way as CART. To briefly explain, if a fully grown tree on the full dataset has 
three splits (s=3), then the cross-validation procedure will specify that the maximum 
number of splits formed when growing a tree on the training data is also three. This 
will result in four models being fitted, including the null model. The test sample is then 
used to obtain the predictive error of each model. The process is repeated V times in 
order to complete the V-fold cross-validation. In order to obtain stable estimates for 
the averaged predictive error for each tree from the cross-validation, the authors 
suggest repeating the cross-validation procedure several times and then averaging the 
results from which the best tree size is determined. For CART and IT, the best tree size 
is determined using the 1-SE rule, as described in 6.2.5. However the authors of STIMA 
suggest using a rule that depends on the sample size to improve the performance of 
STIMA. They suggest a 0.80-SE rule be used for sample sizes of less than 300 and a 
0.50-SE rule used otherwise.  
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Interpretation of the final tree 
Once the STIMA procedure has selected a final tree from the cross-validation 
procedure, the final tree can then be interpreted. This can be done either by observing 
the model output to see what the estimated interaction effects are for the interactions 
detected by the procedure. Furthermore, a plot of the STIMA tree (or regression trunk) 
can be observed to ease the understanding and interpretation of the subgroups 
identified.  
 
6.3.3 SIDES method 
 
Splitting criterion 
The goal of the SIDES approach is different to that of IT and STIMA in that it aims to 
detect subgroups of patients with enhanced treatment effect. The IT and STIMA 
methods grow trees that represent interactions or differential treatment effects that 
have been detected. The SIDES method also searches for large differential treatment 
effects however once an optimal split is identified, it retains the subgroup with the 
enhanced treatment effect and disregards the rest of the sample. The SIDES procedure 
evaluates all possible splits for every covariate using a splitting criterion that computes 
the differential effect between the two subgroups formed by a split. The splitting 
criterion computes a p-value for all searched splits and is of the form 
 
𝑝 = 2 ∙ [1 − Φ(
|𝑍𝐸1 − 𝑍𝐸2|
√2
)],                                           (6.10) 
 
where 𝑍𝐸1 and 𝑍𝐸2 are the one-sided hypothesis test statistics computed for the two 
subgroups respectively and Φ(
|𝑍𝐸1−𝑍𝐸2|
√2
) is the cumulative distribution function of the 
standard normal distribution (135). The one sided test statistics are obtained from a 
simple linear regression model with just the treatment variable as the covariate where 
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the test statistics are computed by dividing the treatment effect estimate by its 
standard error (t-statistic).   
 
Multiplicity adjustment 
Like all recursive partitioning methods, the SIDES algorithm requires all splits to be 
searched for every covariate at each iteration. A well-known issue with this is that the 
procedure has a greater probability of selecting a covariate with a larger number of 
levels. This issue is referred to as variable selection bias (144, 145). Thus to adjust for 
this, the authors introduced a Sidak-based multiplicity adjustment given by 1 −
(1 − 𝑝𝑖)
𝐺∗ , where 𝑝𝑖  is the unadjusted p-value obtained using the splitting criterion 
(equation 6.10) for the i-th split and 𝐺∗ is the effective number of splits (135). The 
effective number of splits basically incorporates the correlation between the p-values 
for any single covariate and is estimated by 𝐺∗ = 𝐺1−?̅?, where 𝐺 is the number of splits 
for a given covariate and ?̅? is the mean correlation of the p-values computed using the 
splitting criterion having evaluated all splits. Thus for a given covariate, the associated 
p-values for all potential splits are adjusted to reduce the variable selection bias.  
 
Complexity control 
The complexity of a tree simply refers to the size of a tree usually defined by the 
number of terminal nodes it has. Both the IT and STIMA approaches use pruning and 
cross-validation to control for the complexity of a tree and thus select the best tree size 
respectively. The SIDES approach on the other hand controls the complexity of a tree 
during the tree growing process by using a relative improvement parameter at each 
level of the tree. The relative improvement parameter determines whether or not a 
child node with a large positive treatment effect should become a parent node for the 
next iteration of the algorithm. A child node only becomes a parent node if there is 
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some improvement in the p-value of the child node compared to the p-value of the 
parent node from which it came from. The split is made if  
 
𝑝𝑐 ≤ 𝛾 ∙ 𝑝𝑝,                                                                     (6.11)   
 
where 𝑝𝑐  is the p-value of the child node, 𝑝𝑝 is the p-value of the parent node and 𝛾 is 
the relative improvement parameter which ranges from 0 to 1. A small value of 𝛾 
makes the procedure much more selective; only selecting subgroups with a very small 
p-value. Conversely, a value of 1 for 𝛾 is less restrictive and thus allows the procedure 
to search a wider covariate space i.e. build a bigger tree. 
 
Each level of the SIDES tree has an associated relative improvement parameter. For 
example, if some restriction was only required for the first three levels of the tree, then 
one would need to specify 𝛾𝑖  for stage i. The relative improvement parameters can be 
user specified. If none are specified, they can be determined using 5-fold cross-
validation to try and find the optimal combination. The cross-validation procedure is 
implemented in the same way as described in section 6.2.5. This requires the user to 
define the grid space that needs to be searched for the optimal combination of the 𝛾 
parameters. For example, say we want to define a subgroup using three covariates only 
i.e. a tree with three levels, then we need to specify the values for 𝛾1, 𝛾2 and 𝛾3 to define 
the grid that needs to be searched. Let’s say we specify that  𝛾1 goes from 0.1 to 1.0 in 
increments of 0.1 and both 𝛾2 and 𝛾3 go from 0 to 1 in increments of 0.1, then the grid 
is formed using all combinations of  𝛾1, 𝛾2 and 𝛾3. Thus in this example, the first 
combination would be 𝛾 = (0.1,0,0)  and the last combination would be 𝛾 = (1,1,1). 
Therefore, the 5-fold cross-validation works by applying the SIDES procedure to the 
training sample for each combination of 𝛾 in the grid. The best subgroup with the 
smallest treatment effect p-value is then identified and the same subgroup evaluated in 
the test sample and the corresponding p-value recorded. This is then repeated five 
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times for each fold in the cross-validation. Finally, the p-values are averaged across the 
5-folds for each combination in the grid and the combination with the smallest average 
p-value is chosen as the optimal combination to be used by SIDES. Though this 
approach is good for finding the optimal combination, it can be rather time consuming 
if there are a large number of levels for which a relative improvement parameter is 
required. Therefore, the authors recommend only searching for the optimal 
combination for the first three levels of the tree.  
 
Growing a tree – parameter specifications 
Now that the splitting criterion, multiplicity adjustment and complexity control have 
been defined, the algorithm for growing a SIDES tree will now be described. The 
authors very kindly provided me with the coding for the SIDES method written in R 
software. When applying the SIDES procedure, it is required that a number of 
parameters be specified to aid the tree growing process. Like the IT and STIMA 
methods, SIDES also requires that the minimum node size and maximum number of 
levels of a tree be pre-specified. Specifying the number of levels of a tree helps restrain 
the complexity of the subgroups. The number of levels is equivalent to the number of 
covariates that can define a subgroup. For example, if the maximum number of levels is 
set to 3, then a subgroup can, at most, be defined by 3 covariates. However, in addition, 
SIDES also requires the pre-specification of the best number of splits, say M, to be 
considered for each parent node at each level. For example, if M=3, then for any node, 
all splits will be evaluated for each covariate retaining only the single best split for each 
covariate. The best splits are then ordered from smallest to largest and the best three 
covariate splits are chosen to split on. The SIDES procedure also requires the user to 
either specify the relative improvement parameters to be used, or specify the grid 
space to be searched for the optimal relative improvement parameter combination 
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using cross-validation as described earlier. Once the aforementioned parameters have 
been pre-specified, the SIDES procedure algorithm can be applied as follows 
 
 Initialise: Start at the root node (level 0) consisting of the entire dataset  
 Iteration: 
o Step 1 - Evaluate the splitting criterion for all splits of every covariate 
(exclude covariates already used to define the parent node) retaining 
only the best split for each covariate. Order the covariates from smallest 
adjusted p-value to largest adjusted p-value where the adjusted p-
values are computed using the Sidak-based multiplicity adjustment. 
Ordering the adjusted p-values ensures that covariates with a larger 
number of splits are not favoured i.e. not placed higher up in the 
ordering due to multiplicity.  
o Step 2 - Select the best M covariates from the ordered best splits. For 
each of the M splits, form the split creating two child nodes and retain 
the child node with the larger positive treatment effect, provided it 
satisfies the relative improvement parameter condition (see equation 
6.11). The retained nodes now become parent nodes for the next 
iteration. 
o Step 3 – Repeat steps 1 and 2 for the newly formed parent nodes 
o Step 4 – Continue the above three steps until either the maximum 
number of levels is reached or if no more splits can be formed i.e. 
relative improvement parameter condition not satisfied. In both cases, 
the previously formed parent nodes become terminal nodes.  
 
The above algorithm is implemented until a SIDES tree has been grown. The resultant 
tree is a collection of candidate subgroups that all have an enhanced treatment effect 
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where each subgroup is defined by up to M covariates. However, many of the candidate 
subgroups might be spurious findings due to inflated type I error rates. Thus to control 
for this and to remove possibly spurious subgroups, the authors propose a resampling 
based procedure to adjust the p-value for each candidate subgroup and control the 
type I error in the weak sense (135). The resampling procedure firstly randomly 
permutes the rows of the outcome variable and treatment variable in the dataset to 
form a null dataset. The outcome and treatment variables are kept together and 
permuted then reattached to the covariate values. It is done in this way to ensure the 
overall treatment effect is maintained as well as the correlation structure of the 
covariates. The SIDES procedure is then applied to the null dataset using the same 
parameters used to grow the initial tree i.e. the same complexity parameters, minimum 
node size, etc, and the p-value of the best subgroup recorded. This process is repeated 
many times, e.g. 500 or 1000 times, forming a distribution of p-values. The observed p-
values from each of the candidate subgroups is then adjusted by calculating the 
proportion of p-values in the distribution from the resampling procedure that fall 
below the observed p-value. More precisely, the adjusted p-value for a given candidate 
subgroup is computed by 
 
𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑝 − 𝑣𝑎𝑙𝑢𝑒 =
number of p − values from null less than observed p − value
number of permutations
. 
 
Once the p-values for each of the candidate subgroups have been adjusted using the 
resampling procedure, inferences can be made by observing the adjusted p-values and 
thus the final subgroups chosen. This basically means that the adjusted p-value is a 
comparator for the unadjusted p-value in the sense that it reflects how true the 
subgroup found may be. If the unadjusted p-value is significant and the adjusted p-
value is non-significant, then this suggests that the identified subgroup is quite possibly 
a spurious finding.   
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SIDES algorithm illustration 
A simple example will now be considered to better illustrate how the SIDES procedure 
works; see Figure 6.3. Assuming we have three covariates, say X1, X2 and X3, and that 
we allow SIDES to split up to a maximum of two levels i.e. any candidate subgroups 
found can be defined by up to two covariates. Moreover, assume that we select the best 
two splits (M=2) at each level of the tree. The SIDES procedure initially starts at level 0 
with a single parent node consisting of the entire dataset, illustrated by a black circle. 
From the first iteration, the covariates X1 and X2 contain the best two splits at split 
points S1 and S2 respectively. The treatment effect in subgroup X1≤S1 is substantially 
larger than the effect in X1>S1, thus the sample X1>S1 is disregarded and the sample 
with X1≤S1 is retained thus forming a parent node at level 1. Similarly for the second 
split on X2, the sample X2>S2 is retained and the sample X2≤S2 is disregarded thus the 
sample X2>S2 forms another parent node at level 1. Any disregarded nodes after a split 
has been made have been coloured grey in figure 6.3. Therefore at level 1, there are 
two new parent nodes (two black circles) that can both be searched for the best two 
splits respectively in the next iteration. Note that only those covariates that have not 
already been used to define the parent node are searched for the next split. For 
example, if at level 1 the covariate X1≤S1 is used to define the parent node, then the next 
iteration of SIDES can only search covariates X2 and X3 for the next best two splits. 
Exactly the same process is carried out on the two parent nodes at level 1. The first 
parent node at level 1 can be split by the covariates X2 and X3 at split points S12 and S13 
respectively. From these splits, X2≤S12 and X3≤S13 are retained to form two new parent 
nodes at level 2. Similarly, the second parent node at level 1 can be split by the 
covariates X1 and X3 at split points S21 and S23 respectively. From these splits, X1≤S21 
and X3≤S23 are retained to form two more parent nodes at level 2. Thus there are four 
new parent nodes formed at level 2. If we recall earlier, we specified the maximum 
number of covariates used to define a subgroup as being two i.e. maximum of two 
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levels. Thus, the SIDES procedure stops here and the four parent nodes identified at 
level 2 thus become terminal nodes. Therefore at the end of the procedure, four 
candidate subgroups have been identified; subgroup1 {X1≤S1 and X2≤S12}; subgroup2 
{X1≤S1 and X3≤S13}; subgroup3 {X2>S2 and X1≤S21}; subgroup4 {X2>S2 and X3≤S23}. 
Though this example has been illustrated using Figure 6.3 in the form of a single tree 
(i.e. in the same form illustrated by the authors) it can also be illustrated as two 
separate trees defined by the two branches stemming from the root node. The reason 
we can do this is because each branch stemming from the root node is essentially a 
different way in which we can initiate the tree growing process starting with the entire 
dataset. Thus, if we specify that we want the procedure to consider the best M  splits 
for each node, then this means that we can illustrate the final identified subgroup by up 
to M separate trees with the root node being the entire dataset.  
 
6.4 Discussion 
 
Tree based methods are a promising alternative to performing exploratory subgroup 
analyses in randomised controlled trials. These methods overcome many of the issues 
with existing conventional subgroup analyses as highlighted in previous chapters. 
Moreover, all tree based methods utilise a simple technique referred to as recursive 
partitioning. Therefore, this chapter provided a detailed description of the recursive 
partitioning methodology to better understand the method. The method was described 
in reference to the commonly used and well established CART type procedure simply 
to demonstrate how the method works. The CART method is typically applied to data 
where the goal is to detect interactions that are predictive of outcome; however it does 
not detect treatment effect heterogeneity i.e. treatment-covariate interactions; which is 
the focus of this thesis. However, there are a number of advanced variants based on the 
CART type procedure, namely the IT, STIMA and SIDES methods, which do look for 
treatment effect heterogeneity. These methods were thus described with reference to 
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the recursive partitioning methodology described earlier on in the chapter since the 
steps in the algorithm of these methods are relatively similar. 
 
This chapter highlighted a clear difference in the aims of the IT and STIMA methods 
compared to the SIDES method. The IT and STIMA methods both look to identify 
subgroups with the aim of maximising the treatment-covariate interaction effect 
whereas the SIDES method aims to detect subgroups of individuals who have an 
enhanced treatment effect. Despite there being this difference, from a clinical 
perspective, both aims are very important. 
 
This chapter gave a detailed insight into tree based methods and the underlying 
methodology. Moreover, three recently proposed advanced variants for performing 
subgroup analyses or subgroup identification were also described. Having identified 
and described these methods, it is important to evaluate them in a variety of simulated 
scenarios to assess if they actually do what they aim to do. Therefore, the next chapter 
will describe a simulation study to evaluate these methods with the aim of identifying 
the best method(s) for performing subgroup analyses or subgroup identification. 
 
115 
 
Figure 6.3 – Example of the SIDES procedure with two levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
    
 
   
X1≤s1 X1>s1 X2≤s2 X2>s2 
X2≤s12 X2>s12     X3≤s23 X3>s23 
 
LEVEL 1 
LEVEL 2 
  
LEVEL 0 
X3≤s13 X3>s13 X1≤s21 X1>s21 
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Chapter 7 
 
Simulation study to 
evaluate tree based 
methods 
 
 
7.1 Introduction 
 
The previous chapter introduced the recursive partitioning methodology; a key 
component of tree based approaches. Although there are several variants of the tree 
based method that employ a CART type routine, there are only a few that specifically 
look to identify differential subgroups effects, which is what is of interest in this PhD. 
Moreover, these methods enable us to identify subgroups defined by multiple baseline 
characteristics. The tree based methods that do identify differential subgroup effects 
are interaction trees (IT), Simultaneous Threshold Interaction Modelling Algorithm 
(STIMA) and Subgroup Identification based on a Differential Effect Search (SIDES) 
(133, 135, 136). As highlighted in the previous chapter, there is a clear distinction in 
the aims of both the IT and STIMA methods compared to the SIDES method. The IT and 
STIMA methods aim to identify baseline characteristics that are moderators of 
treatment effect i.e. each split in the tree represents a detected interaction effect, 
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whereas the SIDES method aims to identify subgroups with enhanced treatment effect 
i.e. each split in the tree represents an identified subpopulation with a large treatment 
effect. 
 
Both of the aforementioned aims from a clinical perspective are very important. 
Therefore, all three of these methods stand as good candidate methods that could 
potentially be extended to an IPD subgroup meta-analysis setting to identify subgroups 
defined by multiple characteristics. Before considering ways to extend these methods, 
it is initially important to evaluate how well these methods perform in a single trial 
setting. This chapter will therefore describe the setup of the simulation study in a 
single trial setting along with a description of the simple scenarios to be considered. 
The results of the simulation study will then be presented and assessed to see how well 
the IT, STIMA and SIDES methods perform in a number of simple simulated scenarios. 
 
7.2 Simulation study setup 
 
Simulation study design 
The purpose of this simulation study was to evaluate the performance of the IT and 
STIMA methods in detecting treatment-covariate interactions and to evaluate the 
performance of the SIDES method in detecting subpopulations with enhanced 
treatment effect. In this first instance, we will keep the simulation study relatively 
simple rather than looking at absolutely everything to ease the assessment of these 
methods in a single trial setting. Data were simulated using a single linear regression 
model of the following form, 
 
𝑌 = 𝛽0 + 𝛽1𝑇 + 𝛽2𝑋1 + 𝛽3𝑋2 + 𝛽4𝑋1 ∙ 𝑋2 + 𝛽5𝑇 ∙ 𝑋1 + 𝛽6𝑇 ∙ 𝑋2 + 𝛽7𝑇 ∙ 𝑋1 ∙ 𝑋2 + 𝜀    (7.1) 
 
where 𝑌 is a continuous response variable, 𝑇 is a treatment variable consisting of two 
arms (𝑇1 and 𝑇2), 𝑋1 and 𝑋2 are covariates each with two categories and 𝜀 is the 
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normally distributed error with mean 0 and variance 1. The main effect sizes and 
interaction effect sizes were thus varied in model (7.1) to create scenarios in which to 
evaluate the methods. The main effects in the simulation study were set to a constant 
term, say zero (𝛽1 = 𝛽2 = 𝛽3 = 0), since the methods are not influenced by the main 
effects i.e. they only detect treatment-covariate interaction effects. Moreover, the 
coefficients corresponding to the interaction term not including treatment and the two-
way interaction were also set to zero i.e. 𝛽4 = 0 and 𝛽7 = 0. Using model (7.1), the 
simulation study evaluated how well these methods perform in three simple scenarios: 
 
1) Null model – The null model is just a main effects model with no interaction 
effects present. This corresponds to model (7.1) with all coefficients set to zero 
i.e. 𝛽𝑖 = 0. Evaluating the methods in this scenario will allow for the assessment 
of the type I error rate of these methods. 
2) Single one-way interaction – This model consists of main effects with the 
inclusion of a single one-way treatment-covariate interaction. This corresponds 
to 𝛽5 being specified in the model (7.1). 
3) Two one-way interactions – This model consists of a main effects model with 
the inclusion of two one-way treatment-covariate interactions. This 
corresponds to 𝛽5 and 𝛽6 being specified in the model (7.1). 
 
Three factors were varied in the simulation study; the sample size, the effect size for 
the 𝑇 ∙ 𝑋1 interaction and the effect size for the 𝑇 ∙ 𝑋2 interaction. To make the entire 
simulation study more efficient and to mimic all three scenarios using just one model 
(model (7.1)), a full-factorial design was used. In this full factorial design a set of 
simulations is performed for every single combination of the three varying factors. 
Since the simulation study was based on single trial data, a variety of small to large 
sample sizes were considered; N=200, 400, 500, 600, 1000. Standardized interaction 
effect sizes of 0, 0.2 (small), 0.5 (medium), 0.8 (large) and 1.5 (very large) were 
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considered for both the 𝑇 ∙ 𝑋1 and the 𝑇 ∙ 𝑋2 interactions, which correspond to the 
coefficients 𝛽5 and 𝛽6 respectively in the model. The simulated data were set up such 
that there was an equal proportion of individuals in each category of the treatment 
variable 𝑇, and the two covariates 𝑋1 and 𝑋2. In total, each combination in the full-
factorial design was simulated 1000 times and the results summarized. Altogether 
there were 125 combinations therefore in total 125,000 simulations were performed 
for each of the three methods. The simulations were performed using R software 3.0.1. 
 
Data generation procedure 
The model given by equation (7.1) was used to generate the data to perform the 
simulation. The aim was to set up a data generation function such that the required 
effect sizes can be specified and the data generated. We can represent the model given 
by equation (7.1) by a 2 x 2 x 2 table of the cell means as shown in table 7.1. Within 
table 7.1, the means within cells (X11, X21, T1), (X11, X21, T2),…,(X12, X22, T2) are given by a, 
b, c, d, e, f, g, h respectively. In reality, the number of patients within each of these cells 
will not always be equal and this needs to be accounted for. For this reason, the 
marginal means are based on the proportion of imbalance within each covariate, 
denoted by p, q1, q2 and r (displayed using grey text) in table 7.1 to account for this. The 
marginal means have been displayed in table 7.1 using bold text. This enables a 
generalized data generation framework to be setup. Using the tabulation, we can easily 
formulate general expressions for the marginal mean (𝛽0), the overall treatment effect 
(𝛽1), the overall X1 effect (𝛽2), the overall X2 effect (𝛽3), the interaction between X1 and 
X2 (𝛽4), the interaction between X1 and treatment (𝛽5), the interaction between X2 and 
treatment (𝛽6) and finally the interaction between treatment, X1 and X2 (𝛽7). These 
expressions can be written as follows 
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 𝛽0 = pq1ra + pq1(1-r)b + p(1-q1)rc + p(1-q1)(1-r)d + (1-p)q2re + (1-p)q2(1-r)f + (1-p)(1-q2)rg + 
(1-p)(1-q2)(1-r)h 
 𝛽1 = pq1a – pq1b + p(1-q1)c – p(1-q1)d + (1-p)q2e – (1-p)q2f + (1-p)(1-q2)g – (1-p)(1-q2)h 
 𝛽2 = rq1a + (1-r)q1b + r(1-q1)c + (1-r)(1-q1)d - rq2e - (1-r)q2f - r(1-q2)g - (1-r)(1-q2)h 
 𝛽3 = pra + p(1-r)b – prc – p(1-r)d + (1-p)re + (1-p)(1-r)f – (1-p)rg – (1-p)(1-r)h 
 𝛽4 = ra + (1-r)b – rc – (1-r)d – re – (1-r)f + rg + (1-r)h 
 𝛽5 = q1a – q1b + (1-q1)c – (1-q1)d – q2e + q2f – (1-q2)g + (1-q2)h 
 𝛽6 = pa – pb – pc + pd + (1-p)e – (1-p)f – (1-p)g + (1-p)h 
 𝛽7= a – b – c + d – e + f + g – h   
 
To find the solutions to the above equations, we simply convert them to matrix form 
and then invert the matrix. See Appendix C for the matrix form of the above equations. 
Thus inverting the matrix will provide solutions for computing each of the cell means 
that are in the same form as that of equation (7.1). The solutions are as follows: 
 
a = 𝛽0 + (1 – r) 𝛽1 + (1 – p) 𝛽2+ (1 - q1) 𝛽3+ (pq1 - q1 - p + 1) 𝛽4+ (pr - r - p + 1) 𝛽5+ (q1r - r 
- q1 + 1) 𝛽6+ (pq1 - q1 - r - p + pr + q1r - pq1r + 1) 𝛽7 
b = 𝛽0+ (-r) 𝛽1+ (1 – p) 𝛽2+ (1 - q1) 𝛽3 + (pq1 - q1 - p + 1) 𝛽4 + (pr – r) 𝛽5+ (q1r – r) 𝛽6+ 
(pr - r + q1 r - p q1 r) 𝛽7 
c = 𝛽0+ (1 – r) 𝛽1+ (1 – p) 𝛽2+ (-q1) 𝛽3+ (p q1 - q1) 𝛽4+ (pr - r - p + 1) 𝛽5+ (q1 r - q1) 𝛽6+ (p 
q1 - q1 + q1 r - p q1 r) 𝛽7 
d = 𝛽0+ (-r) 𝛽1+ (1 – p) 𝛽2+ (-q1) 𝛽3+ (p q1 - q1) 𝛽4+ (pr – r) 𝛽5+ (q1 r) 𝛽6+ (q1 r - p q1 r) 𝛽7 
e = 𝛽0+ (1 – r) 𝛽1+ (-p) 𝛽2+ (1 – q2) 𝛽3+ (p q2 – p) 𝛽4+ (pr – p) 𝛽5+ (q2r - r - q2 + 1) 𝛽6+ (p 
q2 - p + pr - p q2r) 𝛽7 
f = 𝛽0+ (-r) 𝛽1+ (-p) 𝛽2+ (1 - q2) 𝛽3+ (p q2 – p) 𝛽4+ (pr) 𝛽5+ (q2r – r) 𝛽6+ (pr - p q2r) 𝛽7 
g = 𝛽0+ (1 – r) 𝛽1+ (-p) 𝛽2+ (-q2) 𝛽3+ (p q2) 𝛽4+ (pr – p) 𝛽5+ (q2r - q2) 𝛽6+ (p q2 - p q2r) 𝛽7 
h = 𝛽0+ (-r) 𝛽1+ (-p) 𝛽2+ (-q2) 𝛽3+ (p q2) 𝛽4+ (pr) 𝛽5+ (q2r) 𝛽6+ (-p q2r) 𝛽7 
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Table 7.1 – 2 x 2 x2 table of within cell means for T, 𝑋1 and 𝑋2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   R (1-r)  
 
  
 
T1 T2 
 
p X11 
X21 
q1 
a b rq1a + (1-r)q1b 
X22 
(1-q1) 
c d r(1-q1)c + (1-r)(1-q1)d 
(1-p) X12 
X21 
q2 
e f rq2e + (1-r)q2f 
X22 
(1-q2) 
g h r(1-q2)g + (1-r)(1-q2)h 
 
 
 pq1a + p(1-q1)c + (1-p)q2e + (1-p)(1-q2)g pq1b + p(1-q1)d + (1-p)q2f + (1-p)(1-q2)h 
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The values for 𝛽0, 𝛽1, 𝛽2, 𝛽3 and the interaction effects (𝛽4, 𝛽5, 𝛽6, 𝛽7), can thus be 
specified as well as any imbalances we want to consider (p, q1, q2 and r) in order to 
compute the values of each of the cell means (a, b, c , d, e, f, g and h). Outcome data (Y) 
are then generated for the n individuals within each of the cells such that the mean is 
equal to the pre-computed cell mean. This is done by simulating the outcome data (Y) 
from a normal distribution using each of the cell means as the mean, a standard 
deviation of 1 and specifying n. However, the value of n may vary for each cell if there is 
imbalance in the proportions. Here we can assume the proportions across treatment 
arms are the same due to randomization i.e. r=0.5. Still, the proportions within the 
treatment arms can vary i.e. depends on the value of p and q. The simulation setup 
however considers the simplest setting assuming equal proportions of individuals 
within each of the cells; thus p, q and r will all be set to 0.5. To consider an example, if 
we want to simulate outcomes for 40 individuals, then the number of individuals 
within each of the cells would simply be 5 (40 divided by 8).  
 
Now that the outcome generation procedure has been determined, all that is required 
is to create a treatment variable, an X1 variable and an X2 variable, each with two 
categories. The values of the categories used when creating these variables e.g. X1=0 or 
1, must have specific values to ensure the coefficients estimated by the model are 
correct. The correct values can be obtained by looking at the term that is multiplied by 
𝛽1, 𝛽2 and 𝛽3 respectively in the solution for each of the cells produced having inverted 
the matrix. For example, those individuals in cell a will have a value of (1-r) for 
treatment, (1-p) for X1 and (1-q1) for X2. Thus, the values for the variables depend on p, 
q and r. Again in this simulation study setup, the proportions are assumed to be equal 
thus the values for the treatment variable, X1 and X2 will be -0.5 or 0.5. In this way, we 
can generate data to suit our requirements for the simulation study. The data can be 
easily checked by fitting the regression model in (7.1) to the newly generated data.  
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Parameter specifications for tree methods 
All of the tree methods require some parameters to be specified prior to applying the 
algorithm to the simulated data. This section will therefore describe the parameter 
specifications required for the tree methods for estimation. The minimum number of 
individuals in any node at any given time was set to 10% of total sample size. The 
maximum number of levels or splits of the fully grown tree produced by the IT and 
STIMA methods was set to three. The maximum number of levels for SIDES was set to 
two since there are only two covariates to consider; thus any identified subgroups are 
only ever defined by up to two covariates. In addition, the number of best splits to 
consider for each node was also set to two for the SIDES procedure. The STIMA method 
was set up such that the first split of the tree was forced on the treatment variable in 
order to detect treatment-covariate interactions. Where the methods require the use of 
V-fold cross-validation, the number of folds to be used was set to five i.e. 5-fold cross-
validation. However for STIMA, as the authors suggest, the 5-fold validation was 
repeated five times to obtain more stable estimates.  
 
7.3 Final trees grown by methods 
 
Prior to conducting the simulation study, it is useful to establish what the final correct 
tree should be for IT, STIMA and SIDES in each of the three scenarios. More specifically, 
the correct tree for each method in each scenario is determined by the size of the final 
tree selected and the covariates used to form the final tree. Thus the correct final trees 
for each method will now be described. 
 
Final trees grown by IT method 
Scenario 1 – In scenario 1 (null model), the final tree selected by the IT procedure 
should consist of just a single node i.e. the root node, that consists of the entire dataset. 
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Scenario 2 – In scenario 2 (single one-way interaction), the final tree selected by the IT 
procedure should be of size 2 i.e. it has two terminal nodes, see figure 7.1. Moreover, 
the covariate used to form the single split should be either X1 or X2 depending on which 
of the two has been set up in the simulation as having an interaction effect with 
treatment.  
 
Figure 7.1 – Final tree produced by the IT method for a single one-way interaction 
 
 
 
 
Scenario 3 – In scenario 3 (two single one-way interactions), the IT procedure should 
select a final tree of size 4 i.e. it has four terminal nodes, see figure 7.2. The final tree 
should select both X1 and X2 as the covariates used to form the two splits in the tree. 
 
Figure 7.2 – Final tree produced by the IT method for two single one-way interactions 
 
 
 
 
 
 
Final trees grown by STIMA method 
Scenario 1 – In scenario 1 (null model), the final tree selected by the STIMA procedure 
should consist of just a single node i.e. the root node, that consists of the entire dataset. 
Moreover, the linear regression model estimated by STIMA should consist of main 
effects only. 
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Scenario 2 – In scenario 2 (single one-way interaction) the final tree produced by the 
STIMA procedure should be of size 3 i.e. consists of three terminal nodes. Recall that 
the first split is forced on treatment; therefore a single one-way interaction will require 
a single split on either one of the two nodes formed from the forced split as displayed 
in figure 7.3. Recall from the previous chapter, when a split is found by STIMA, it is 
added to the model in the form of an indicator variable and the model is re-estimated 
and updated thus incorporating the detected interaction effect. Therefore, of the nodes 
formed from the first forced split on treatment, it doesn’t matter which one of the two 
nodes it splits on afterwards as the model will be updated accordingly.   
 
 
Figure 7.3 – Final tree produced by the STIMA method for a single one-way interaction 
 
 
 
 
 
 
 
Scenario 3 – In scenario 3, the final tree produced by the STIMA procedure should be of 
size 4 i.e. consists of four terminal nodes. The root node is first split by treatment to 
form two child nodes. Each of the child nodes is then split by one of the covariates X1 or 
X2 to form the final tree, see figure 7.4. Again with each iteration, the STIMA method 
updates the model to include the detected interaction.  
 
 
 
a) b) 
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Figure 7.4 – Final tree produced by the STIMA method for two single one-way 
interactions 
 
 
 
 
 
 
Final trees grown by SIDES method 
Scenario 1 – In scenario 1 (null model), the final tree selected by the SIDES procedure 
should consist of just a single node i.e. the root node, that consists of the entire dataset. 
 
Scenario 2 – In scenario 2 (single one-way interaction), the SIDES procedure identifies 
a single candidate subgroup defined by a single covariate, either X1 or X2, depending on 
which covariate the simulation has set up to have an interaction with treatment. Recall 
that having identified a best split, the SIDES procedure retains the node or subgroup 
with the larger positive treatment effect. Essentially, this is exactly the same as the tree 
produced by the IT procedure in figure 7.1, but then the node with the smaller 
treatment effect is removed; thus identifying a subgroup or subpopulation with an 
enhanced treatment effect. The final tree produced by SIDES in this scenario is 
displayed in figure 7.5 where the removed node has been shaded grey.   
 
 
Figure 7.5 – Final tree produced by the SIDES method for a single one-way interaction 
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Scenario 3 – In scenario 3 (two single one-way interactions), the SIDES procedure 
produces two candidate subgroups of enhanced treatment effect; however the 
structure of the tree for the two candidate subgroups can vary. The first way SIDES can 
identify the two regions with large positive treatment effect is by identifying two 
candidate subgroups at level 1 where one subgroup is defined by splitting on X1 and 
the other subgroup is defined by splitting on X2, as shown in final tree (A) in figure 7.6. 
As mentioned in the previous chapter, the tree in figure 7.6 can also be illustrated as 
two separate trees as shown in figure 7.7. 
 
Figure 7.6 – Final tree (A) produced by the SIDES method for two single one-way 
interactions; illustrated using a single tree. 
 
 
 
 
 
Figure 7.7 – Final tree (A) produced by the SIDES method for two single one-way 
interactions; illustrated using two separate trees. 
 
 
 
 
Another way SIDES can identify the two regions is by further splitting the candidate 
subgroups retained at level 1 using the covariate that has not already been used to 
define that particular subgroup, as shown in final tree (B) in figure 7.8. For example, if 
a candidate subgroup has been split using X1 at level 1, then at level 2 the procedure 
will go on to form a split using X2, and vice versa. Figure 7.8 shows only one of the 
nodes at level 1 being split further to form a subgroup at level 2. However, it is also 
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possible for the other subgroup at level 1 to be split further to form a subgroup at level 
two as well. Again, the tree illustrated in figure 7.8 can also be illustrated using two 
separate trees as shown in figure 7.9.  
 
Figure 7.8 – Final tree (B) produced by the SIDES method for two single one-way 
interactions; illustrated using a single tree. 
 
 
 
 
 
 
 
Figure 7.9 – Final tree (B) produced by the SIDES method for two single one-way 
interactions; illustrated using two separate trees. 
 
 
 
 
 
 
7.4 Simulation Results 
 
IT method results 
The results from the IT procedure simulation are displayed in table 7.2. The results 
from scenario 1 (the null model) are reflective of the type I error rate for the IT 
procedure. More than 90% of the time, the IT procedure correctly selects a tree of size 
1, i.e. the root node only, when there are no interaction effects present. When only a 
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single one-way interaction is present (scenario 2), the IT procedure does not perform 
well when the standardized interaction effect size is small. It performs reasonably well, 
with over 70% correct trees grown, when detecting a medium interaction effect size 
provided the total sample size is ≥600. The method performs quite well and detects the 
correct tree the majority of the time when the sample size is ≥400 when detecting a 
large interaction effect size and for all sample sizes ≥200 when detecting a very large 
interaction effect size. In scenario 3 where there are two one-way interactions, it is 
apparent that the performance of the IT method is affected in the presence of more 
than a single one-way interaction effect. If one of the two one-way interactions has 
either a small or medium effect size, then the method does not perform well. A closer 
inspection of the results from individual simulations suggests that when one of the 
interaction effects is either small or medium and the other interaction effect is greater 
i.e. large or very large, then the IT method seems to only detect the larger effect. When 
one of the interaction effects is large and the second interaction effect is either large or 
very large then the method detects the correct tree the majority of the time provided 
that total sample size is ≥600. The method works very well when both interaction 
effects are very large for all sample sizes ≥200.  
 
STIMA method results 
The simulation results from applying the STIMA procedure are displayed in table 7.3. 
In scenario 1 where no interaction effects are present, the STIMA approach always 
identifies the correct tree consisting of a single root node. In other words, outcome is 
best predicted using a linear combination of the main effects only. When a single one-
way interaction is present, the method detects the correct tree the majority of the time 
if the effect size is large and the sample size is 1000, or for all sample sizes ≥200 when 
the effect size is very large. In scenario 3 where two one-way interactions are present, 
the STIMA method does not perform well for small and medium effect sizes. The 
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method detects the interactions a majority of the time when the sample size is 1000 
and either both interactions are large or when one is large and the other is very large. 
The method also performs well when both the interactions are very large and the 
sample size is ≥200. A closer inspection of the results indicates that interactions are 
hardly ever detected when both the interaction effects are small. Moreover, when the 
interaction effect sizes differ, the STIMA method detects the larger interaction effect 
the majority of the time. When observing all of the results for STIMA, there seems to be 
something rather peculiar happening; the performance consistently deteriorates when 
considering a sample size of 500. This will be reviewed later on in the discussion 
section.   
 
SIDES method results 
The simulation results from applying the SIDES procedure are displayed in table 7.4. In 
scenario 1 where no subgroups with enhanced treatment effect are present i.e. no 
interaction effects, the SIDES procedure correctly identifies no candidate subgroups 
approximately 90% of the time. In scenario 2 where there is a single subgroup with 
enhanced treatment effect (a single one-way interaction), the SIDES method does not 
perform so well when the effect size is small. When there is a medium sized interaction 
effect, the method detects the correct subgroup around 80% of the time provided the 
total sample size is about 1000. When the effect size is large, the method detects the 
correct subgroup a majority of the time if the total sample size is >400. For very large 
effect sizes it detects the correct subgroup a majority of the time for all sample sizes 
≥200. In scenario 3 where there are two regions with enhanced treatment effect i.e. 
two one-way interactions present, the SIDES procedure does not perform very well if 
one of the two interaction effects is small. A closer inspection of the individual 
simulation results suggests that when one effect size is small and the other effect size is 
greater, then the SIDES procedure only detects the larger effect size; thus identifying 
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just one candidate subgroup each time. When both the interactions have a medium 
effect size, or if one has a medium effect and one has a large effect then the method 
detects the correct subgroups a majority of the time for a sample size of 1000. If the 
two interactions are large and very large respectively, then the method performs well 
provided the sample size is ≥400. When both interaction effects are very large, the 
method seems to work very well in detecting both candidate subgroups with large 
treatment effects.  
 
7.5 Discussion 
 
A simple simulation study was performed in this chapter to evaluate the performance 
of the IT and STIMA procedures in detecting interaction effects and to evaluate the 
SIDES procedure in detecting subpopulations with enhanced treatment effect. The IT 
and STIMA procedures both have the same objective of detecting subgroups that 
maximize the interaction effect. Comparison of the results suggests that overall, the IT 
method performs much better than the STIMA method. In particular, it performs well 
when detecting large or very large interaction effects. In addition, the SIDES procedure 
performs quite well in detecting subgroups with large treatment effects. 
 
As highlighted in the results section, there was some peculiarity observed in the STIMA 
results. In the presence of two one-way interactions, one would expect the 
performance of STIMA to improve as the sample size increased from 200 to 1000; 
however, this was not the case. When the sample size is 500, the performance seems to 
worsen. A component of the STIMA method that might influence this result is the 0.50-
SE rule and 0.80-SE rule suggested by the authors for selecting the final tree. The 
simulations were repeated using the typical CART 1-SE rule however this made no 
difference to the results. To investigate the performance further, the STIMA simulation  
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Table 7.2 – Simulation results for the IT method. Results display % of correctly identified final trees. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 200 92.15 6.75 30.80 64.40 89.80 
 
400 93.10 10.90 55.00 86.20 90.60 
 
500 93.85 13.35 63.70 87.15 90.90 
 
600 93.10 16.00 72.05 90.70 90.60 
 
1000 93.70 22.50 85.65 90.75 91.20 
Small=0.2 200 6.40 0.10 0.45 1.10 1.30 
 
400 10.70 0.40 1.30 1.50 1.85 
 
500 13.25 0.25 1.70 2.70 2.55 
 
600 14.45 0.50 2.55 3.35 2.65 
 
1000 23.65 1.25 5.55 5.30 5.20 
Medium=0.5 200 28.80 0.25 1.80 4.65 7.45 
 
400 54.75 0.95 8.95 21.50 21.85 
 
500 63.60 1.95 14.85 27.85 31.10 
 
600 70.40 2.30 21.20 39.20 39.95 
 
1000 86.00 4.85 52.00 68.45 67.90 
Large=0.8 200 66.60 0.60 4.80 15.35 33.65 
 
400 85.05 1.75 19.85 54.45 68.80 
 
500 88.10 2.55 30.40 70.90 79.10 
 
600 88.95 3.15 38.65 81.50 88.70 
 
1000 90.90 5.55 66.85 97.80 98.95 
V. Large=1.5 200 89.60 1.30 8.10 30.60 89.70 
 
400 91.05 2.05 23.15 69.55 99.95 
 
500 91.55 1.85 31.75 81.80 100.00 
 
600 90.75 2.90 37.05 90.00 100.00 
 
1000 92.45 6.05 67.60 98.80 100.00 
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Table 7.3 – Simulation results for the STIMA method. Results display % of correctly identified final trees. 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 200 100.00 0.10 0.50 8.10 99.90 
  400 100.00 0.10 7.00 49.60 100.00 
  500 100.00 0.20 6.90 57.70 100.00 
  600 100.00 0.00 8.60 69.20 100.00 
  1000 100.00 0.00 16.10 90.10 100.00 
Small=0.2 200 0.00 0.00 0.00 0.10 0.10 
  400 0.20 0.00 0.30 0.10 0.00 
  500 0.00 0.00 0.00 0.00 0.00 
  600 0.10 0.00 0.10 0.30 0.00 
  1000 0.00 0.00 0.40 0.30 0.00 
Medium=0.5 200 0.60 0.10 0.40 1.20 1.60 
  400 7.50 0.40 6.70 11.90 4.90 
  500 6.30 0.10 2.90 7.20 0.20 
  600 8.80 0.50 8.20 15.70 7.70 
  1000 16.40 0.20 14.50 22.20 15.20 
Large=0.8 200 7.20 0.20 2.00 6.70 12.30 
  400 48.30 0.60 12.20 45.20 43.90 
  500 56.00 0.10 7.90 35.90 18.10 
  600 69.20 0.30 16.50 61.80 65.20 
  1000 91.50 0.20 20.50 86.40 89.90 
V. Large=1.5 200 84.30 0.20 1.60 11.80 78.10 
  400 100.00 0.20 5.80 42.70 99.80 
  500 100.00 0.00 0.90 19.10 98.70 
  600 100.00 0.00 7.10 64.50 100.00 
  1000 100.00 0.00 14.50 89.00 100.00 
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Table 7.4 – Simulation results for the SIDES method. Results display % of correctly identified candidate subgroups. 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 200 88.50 8.10 26.50 54.20 92.70 
  400 87.80 11.70 47.60 81.00 97.30 
  500 89.80 13.80 51.70 85.30 99.20 
  600 89.00 13.80 64.40 92.10 98.60 
  1000 89.40 20.10 80.50 95.40 98.30 
Small=0.2 200 8.80 3.60 8.40 12.00 7.60 
  400 12.90 5.80 15.20 18.20 7.90 
  500 12.60 8.00 20.30 17.30 8.80 
  600 15.70 10.50 21.00 18.50 9.70 
  1000 23.40 16.90 30.60 23.70 17.90 
Medium=0.5 200 27.20 7.00 18.80 34.20 30.10 
  400 48.20 12.00 45.60 57.80 45.50 
  500 55.80 15.30 52.50 65.00 52.70 
  600 62.50 20.50 66.70 75.40 64.90 
  1000 82.50 28.20 87.60 89.10 83.80 
Large=0.8 200 54.80 10.50 30.90 57.00 63.80 
  400 84.90 15.20 56.00 87.10 89.00 
  500 89.90 15.00 63.60 93.90 93.00 
  600 95.40 17.30 72.80 97.60 96.50 
  1000 97.30 20.30 91.30 99.90 99.80 
V. Large=1.5 200 95.40 7.20 23.70 60.30 97.90 
  400 98.00 6.90 45.80 86.30 100.00 
  500 98.90 7.90 54.70 93.50 100.00 
  600 98.80 8.40 62.50 95.90 100.00 
  1000 98.70 15.70 84.20 99.50 100.00 
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was re-run using a variety of sample sizes within the same range (N=200, 400, 416, 
456, 488, 500, 528, 560, 584, 600, 616, 640, 664, 696, 1000). The results of this 
simulation fluctuated across the sample sizes investigated. For example, table 7.5 
displays the proportions for the different tree sizes grown by the method when one 
interaction effect was very large and the other interaction effect was large for the 
aforementioned sample sizes. In this example, the correct tree identified by the method 
should be of size four i.e. it has four terminal nodes. Here we can see that the effect of 
the sample size is non-monotonic in a complicated way for the method.  
 
Table 7.5 – Simulation results presenting the proportion (%) of the different tree sizes 
obtained for a range of sample sizes to investigate STIMA method when a very large 
and a large interaction effect are present 
 
Tree Size 
N 1 2 3 4 
200 7.0 0.0 81.2 11.8 
400 0.0 0.0 57.3 42.7 
416 0.0 0.0 94.3 5.7 
456 0.0 0.0 94.6 5.4 
488 0.0 0.0 86.5 13.5 
500 0.0 0.0 80.9 19.1 
528 0.0 0.0 62.9 37.1 
560 0.0 0.0 37.6 62.4 
584 0.0 0.0 92.2 7.8 
600 0.0 0.0 35.5 64.5 
616 0.0 0.0 73.0 27.0 
640 0.0 0.0 31.5 68.4 
664 0.0 0.0 81.1 18.9 
696 0.0 0.0 75.5 24.5 
1000 0.0 0.0 11.0 89.0 
 
 
The peculiarities observed in the STIMA results were thoroughly investigated however 
it was extremely difficult to determine why the method performs in the way it does. 
Moreover, Dusseldorp et al recently released the STIMA package in R software in 
November 2013. This code was used to repeat the simulation study and the same 
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issues were observed. Therefore, this method will not be considered going forward in 
this thesis since the results clearly suggest that the IT procedure performs better.  
 
The results from the simulation study suggest that the IT procedure is a good approach 
for detecting large and very large interaction effects in a single trial based setting. In 
addition, the SIDES procedure is a good approach for detecting subgroups with 
enhanced treatment effect. Thus both of these procedures are worth developing and 
extending such that they can be applied to an individual patient data (IPD) subgroup 
meta-analyses framework. The simulation study in this chapter was based on a single 
trial based setting. Thus what is even more promising is that the IPD setting will have 
considerably more data and therefore theoretically this should improve the 
performance of both IT and SIDES in detecting small and medium interaction effects. 
The next chapter will therefore detail the proposed extension of the IT and SIDES 
methods to an IPD subgroup meta-analyses setting. Moreover, a simulation study will 
be performed to evaluate the performance of the proposed method extensions. 
137 
 
 
Chapter 8 
 
Extension of recursive 
partitioning approaches 
to IPD meta-analysis 
 
 
 
8.1 Introduction 
 
The previous chapter described and implemented a simulation study to evaluate the 
performance of the IT, STIMA and SIDES methods in a single trial setting. The results of 
the simulation study suggested that the IT approach was far better than the STIMA 
method in detecting treatment-covariate interactions. Moreover, the SIDES approach 
also performed well in detecting candidate subgroups with enhanced treatment effect. 
Therefore, both the IT and SIDES procedures were highlighted as promising 
approaches that could be extended to an individual patient data (IPD) subgroup meta-
analyses setting.  
 
The implementation and evaluation of subgroup analyses thus far in this thesis has 
been based on a single trial setting. When considering IPD from multiple similar 
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studies, the statistical analyses become rather more complex due to the hierarchical or 
clustered data structure. However there are a couple of approaches, namely the two-
stage and one-stage approach, that are used for IPD meta-analyses to take into account 
the data structure when synthesizing or estimating effects (146). These approaches 
will be worth considering when thinking about the extension of the IT and SIDES 
methods.  
 
A number of extensions of tree based methods for data that have some correlated 
structure have been proposed. However, most of these proposed extensions are all in 
the setting of longitudinal or repeated measures data where responses are collected 
over time at several time points (147-152). Here we are interested in tree methods for 
hierarchical or multilevel data structures using fixed or mixed effects. A mixed-effects 
regression tree has been proposed by Hajjem et al that grows a tree for the fixed 
component of the model (153). However, the aims of the aforementioned extensions 
are all to do with determining the best model for predicting response. None of these 
methods look to specifically identify treatment effect heterogeneity or subgroups with 
enhanced treatment effect. Hence, this chapter presents extensions to the IT and SIDES 
methods as novel statistical approaches to specifically identify subgroups in a 
multilevel or hierarchical data structure setting. 
 
This chapter will initially give a brief introduction to IPD meta-analyses followed by a 
description of the statistical methods currently used to perform subgroup analyses in 
this setting. Thereafter, a proposed extension of the IT and SIDES methods in an IPD 
subgroup meta-analyses framework will then be described. Finally, a simulation study 
will be performed to evaluate the proposed extension in a number of scenarios and the 
results presented.  
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8.2 Introduction to IPD meta-analyses 
 
An IPD meta-analysis uses individual patient data collected from several similar 
studies. There are several advantages of having IPD compared to having aggregated 
data. For example, the IPD can be used to replicate the results from the original study, 
perform analyses adjusting for important covariates and investigate differential 
treatment effects (71). Though there are several advantages, as with any method, there 
are also a number of disadvantages. The main disadvantage is that the entire process 
demands a lot of time, money and effort and is thus resource intensive. In particular, it 
involves several processes such as creating a data sharing agreement document, 
contacting authors of relevant studies, setting up a data transfer protocol using a 
secure link, obtaining the data, cleaning the data, resolving any data queries with data 
provider and finally ensuring the format of the data is consistent across trials. Despite 
these resource related disadvantages, the improvement in the quality of the analyses 
and thus the precision and reliability of the results makes IPD meta-analyses a desired 
approach for evidence synthesis. In particular, especially in relation to the work in this 
thesis, it is an ideal framework for exploring modifiers of treatment effect. However, if 
performing an IPD meta-analysis is beyond ones capacity and resources, then one can 
always employ a meta-analysis approach using aggregate data as an alternative. 
 
A key fact about any meta-analysis study, whether it is using IPD or aggregate data, is 
that the quality of the analyses is totally dependent on the quality of the studies used. If 
the studies used are of a poor design and thus of a poor quality, then the meta-analyses 
will also be of a poor quality. Therefore, it is recommended that a quality assessment is 
made on the original studies considered for inclusion in the IPD meta-analyses (71).   
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8.3  Statistical methods for IPD subgroup meta-analyses 
 
When performing IPD meta-analyses, it is very important to recognize the hierarchical 
structure or clustering and incorporate it into the statistical modelling. In fact, it is well 
recognized that any study with an underlying hierarchical or clustered structure 
should use an appropriate statistical method to account for the clustering (154, 155). 
For example, each individual in an IPD meta-analysis of LBP studies will be associated 
with a particular study in the pooled dataset. Thus in a multi-level model, the 
individuals form the first level in the hierarchy (level 1) and the studies form the 
second level (level 2). This hierarchical structure implies that individuals selected 
randomly from a single particular study will be more similar than individuals randomly 
selected from several studies; thus introducing between-study variation. Simply 
ignoring the clustering of patients within trials during analyses is inappropriate. In a 
standard linear model, the clustering is ignored and it is assumed that the individual 
observations are independent; hence the error values for each observation will also be 
unrelated. As we know, due to clustering at the study level, the outcomes within each 
study will have some degree of correlation. If the outcomes are correlated, the error 
terms will also be correlated thus violating the independence assumption of the linear 
regression model. Therefore, a linear regression model applied to IPD will not be able 
to provide reliable estimates of the coefficient standard errors. The estimated standard 
errors will be underestimated and this could potentially lead to false inferences 
claiming real effects exist when in actual fact they don’t. For that reason it is very 
important, as demonstrated in a recent study, that the clustering of patients within 
studies is accounted for when performing IPD meta-analyses (156). For this reason IPD 
meta-analyses typically use either a two-stage approach or a one-stage approach to 
account for the clustering (146). A two-stage approach conducts the analysis using 
conventional linear regression for each study separately and then synthesizes the 
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results using well established meta-analysis techniques. A one-stage approach on the 
other hand uses a mixed-effect model, also referred to as a multilevel model or 
hierarchical model, to fit a single model to the pooled IPD. It is called a mixed effect 
model because the model consists of fixed effects and random effects; where the 
random effects are used to capture the variation at different levels. A fixed-effects 
model including indicator variables for each study can also be applied for the one-stage 
approach where all the components of the model are fixed. 
 
There are several papers available detailing the application and advantages of using a 
two-stage and a one-stage approach (157-159). However, when considering the 
extension of tree based methods to an IPD setting, it would very difficult and 
computationally intensive to use a two-stage approach. There are two ways in which 
the two-stage approach can be implemented. One approach would be to naively grow a 
tree for each trial separately; however each trial will probably grow a different tree 
thus making it impossible to synthesize the results. Another approach would be to 
evaluate every split for each covariate using the splitting function for each trial 
separately and then synthesize the score across the trials using some weighted average 
(as done in aggregate data meta-analyses). However, a danger with this is that if one of 
the trials does not contain the value of the split being considered, then a score will not 
be computed for that trial and thus the information from that trial will be lost. For 
example, if a tree method was considering a split on gender (males vs. females) in each 
trial separately and if one trial had just females in it, then no score would be computed 
and so the trial would not contribute anything to the estimation of the effect i.e. loss of 
information. Moreover, such a procedure would be computationally intensive. The one-
stage approach on the other hand would not experience the aforementioned difficulties 
associated with the two-stage approach. Hence, a one-stage approach is better suited to 
tree based methods and their application. The main advantage of the two-stage method 
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is simplicity, but as it is lost here, there is no reason to pursue it. Therefore, only the 
one-stage approach will be considered going forward.  
 
In a one-stage approach, the covariates in the mixed effect model can be set-up to have 
fixed effects or random effects to account for the clustering. To account for the 
clustering, one approach would be to use a standard linear regression model and add 
indicator variables to the model for each study (fixed effects) as follows: 
 
𝑌𝑖𝑗 = 𝛽0𝑖 + 𝛽1𝑇𝑖𝑗 + 𝛽2𝑋𝑖𝑗 + 𝛽3𝑇𝑖𝑗 ∙ 𝑋𝑖𝑗 + 𝜀𝑖𝑗                                             (8.1) 
where 𝛽0𝑖 is a vector of indicator variables for each study, the 𝑖𝑗 subscript denotes the 
i-th observation in the j-th study and 𝜀𝑖𝑗  is the normally distributed error term. The 
model therefore allows each study to have a different intercept and is referred to as the 
fixed-effects model. This is basically a general linear model that adjusts for the trial 
effects by including them as indicators in the model. Instead of adding fixed-effects for 
trials as shown in equation (8.1), another option for a one-stage approach would be to 
set the study level covariate as having a random-effect. This basically means that the 
equation is of the same form but the 𝛽0𝑖 term in the model is assumed to be normally 
distributed with mean 𝛽0 and variance 𝜎𝛽0
2 . Thus the fully specified model can be 
written: 
 
𝑌𝑖𝑗 = 𝛽0𝑖 + 𝛽1𝑇𝑖𝑗 + 𝛽2𝑋𝑖𝑗 + 𝛽3𝑇𝑖𝑗 ∙ 𝑋𝑖𝑗 + 𝜀𝑖𝑗                                     (8.2) 
𝛽0𝑖~N(𝛽0, 𝜎𝛽0
2 ) 
The models specified in equations (8.1) and (8.2) are referred to as the fixed-effects 
model and random-effects model respectively. For both of these models, the intercepts 
differ for each study however the slopes remain the same.  
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It is also possible that covariates may differ across studies and so this also needs to be 
accounted for when using either fixed-effects or random-effects models. For example if 
the treatment effect is different across studies, then this could be accounted for in a 
fixed-effect model by including a treatment by study interaction term. In a random-
effects model, random effects can be placed on the treatment variable to give the 
following model 
 
𝑌𝑖𝑗 = 𝛽0𝑖 + 𝛽1𝑖𝑇𝑖𝑗 + 𝛽2𝑋𝑖𝑗 + 𝛽3𝑇𝑖𝑗 ∙ 𝑋𝑖𝑗 + 𝜀𝑖𝑗                                     (8.3) 
𝛽0𝑖~N(𝛽0, 𝜎𝛽0
2 ) 
𝛽1𝑖~N(𝛽1, 𝜎𝛽1
2 ) 
By doing so, the model will have a random intercept and a random treatment effect. In 
this manner, as illustrated by the example models specified thus far, mixed effects 
models can be fitted to best incorporate the correlations inherent within the 
hierarchical data structure to obtain reliable parameter estimates. 
 
Parameter estimation  
This section provides a very brief overview as to how the commonly used REML 
approach is used for parameter estimation in mixed-effects modelling. For a more 
detailed description, one can refer to Pinheiro et al (160). 
 
The one-stage mixed-effect models (equations (8.2) and (8.3)) make use of maximum 
likelihood (ML) or restricted (or residual) maximum likelihood (REML) to obtain 
parameter estimates. Of the two, the REML approach to estimation is preferred as it 
provides unbiased estimates of the variance parameters and performs well when the 
data is unbalanced (160, 161). The REML approach works by maximizing the likelihood 
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for the two components of the mixed model i.e. the fixed effects component and the 
random effects component. We can write the two components of a mixed model in a 
general matrix form as follows 
 
𝑌 = 𝑋𝐵 + 𝑍𝑈 + 𝑒 
 
where Y is a 𝑁 × 1 vector of the reported outcomes, X and Z are the covariate matrices 
for the fixed component and the random component respectively, B and U are both 𝑁 ×
1 vectors containing the fixed effect coefficients and the random effects respectively 
and finally e is vector that consists of the residuals. Typically, both U and e have a 
multivariate normal distribution (MVN) of the form 
 
𝑈~𝑀𝑉𝑁(0,𝐻) 
𝑒~𝑀𝑉𝑁(0, 𝑅) 
  
Initially the covariance components H and R i.e. ?̂? and ?̂?, are estimated using REML so 
that the parameters B and U can be estimated thereafter. As a whole, the model has a 
MVN distribution of the form 𝑌~𝑀𝑉𝑁(𝑋𝐵, 𝑍𝐻𝑍′ + 𝑅) where B is estimated by 
(𝑋′?̂?−1𝑋)−1𝑋′?̂?−1𝑌 where ?̂? = 𝑍?̂?𝑍′ + ?̂?, and the U component is estimated using a 
shrinkage estimate of the form ?̂?𝑍′?̂?−1(𝑌 − 𝑋?̂?) (157, 160). The estimates of the 
covariance H for the random component are referred to as REML estimates as it 
estimates the proportion of the variance explained by the between-study 
heterogeneity.  
 
8.4 Proposed extension of tree methods 
 
To recap, the previous sections in this chapter have so far introduced the IPD meta-
analyses framework and discussed the statistical issues with applying conventional 
analyses in this setting. Moreover, statistical approaches currently used to better deal 
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with the clustering of individuals within studies, in particular the one-stage fixed-
effects and mixed-effects modelling approaches, were introduced. Specifically, a 
number of simple fixed-effect and mixed models were described that can be used to 
perform subgroup analyses; fixed intercept model, random intercept model and the 
random intercept and random slope model. 
 
The objective of this section of the chapter is to propose extensions to the IT and SIDES 
methods such that they can be applied to IPD to perform subgroup analyses. A natural 
approach to consider is to somehow incorporate the currently used fixed-effects and 
mixed-effects models into the tree based procedures to ensure they account for the 
clustering within studies. A recent critical review of statistical methods for detecting 
interactions in IPD meta-analyses by Fisher et al proposed a model that was considered 
to be the most basic yet useful for a one-stage approach. This model includes a vector 
of study indicator variables i.e. 𝛽0𝑖 (fixed effects) with fixed covariate and interaction 
effects i.e. 𝛽2 and 𝛽3 respectively have fixed effects, and with the treatment effect either 
being fixed, as shown in equation (8.1), or random, as shown in equation (8.3) (162). 
The authors also note that any of the components in this basic model can potentially be 
specified as being either fixed or random. Therefore, a number of variations of this 
basic model can be considered i.e. varying the fixed and random effects components, 
when considering possible extensions. At this point, let’s assume that the intercept can 
be either fixed or random and that the treatment, covariate and the interaction are the 
same for all trials i.e. have fixed effects. Hence there are three basic model variations 
(including a null model) that can be considered 
 
 Model A – a null model that ignores the clustering i.e. a general linear model 
that does not include fixed or random trial effects 
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 Model B – a model with fixed trial effect, fixed treatment effect and fixed 
interaction effect (Fixed-effects model) – as shown in equation (8.1) 
 Model C – a model with random trial effect, fixed treatment effect and fixed 
interaction effect (Mixed-effects model) – as shown in equation (8.2) 
 
Having discussed the possible basic models that can be considered, we then need to 
think about how they can be incorporated into extending the tree methods for 
application to IPD subgroup analyses. It is important to note at this stage that the aim 
of the extended IT and SIDES methods are not to obtain some pooled effect size 
estimate e.g. treatment effect or interaction effect, which is typically the aim of most 
IPD meta-analyses. Rather, the aim will be to identify subgroups of individuals defined 
by multiple characteristics that either maximize the differential treatment effect (as 
done by IT) or have enhanced treatment effect (as done by SIDES).  
 
IT method extension (IPD-IT) 
Recall that both IT and SIDES use recursive partitioning which heavily relies on a 
splitting criterion. Therefore, in order for both IT and SIDES to be extended to an IPD 
setting, they require a new splitting criterion to be defined. Let us first consider the 
extension of the IT method. In a single trial setting, the IT procedure used a splitting 
criterion based on the t-test statistic (Chapter 6 – equation (6.8)) to test the null 
hypothesis that the coefficient of the interaction effect is equal to zero. Therefore, a 
natural extension to an IPD meta-analysis setting is to use a splitting criterion based on 
the t-test statistic for the interaction effect when fitting a fixed-effects or mixed-effects 
model. The model would have accounted for the correlation within studies and so the 
estimate of the standard error for the interaction effect would be reliable; hence the 
estimate of the t-test statistic will be reliable. The t-test statistic is computed by  
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𝑡(𝑠) =  
?̂?3
𝜎𝛽3
 
 
where ?̂?3 is the estimated coefficient of the interaction term and 𝜎𝛽3is the associated 
estimated standard error. The computed statistic can either be positive or negative, 
indicating the direction of the interaction. The tree growing procedure aims to 
maximize the interaction effect at each level of the tree regardless of the direction of 
the interaction. For example, it could either be a large positive interaction or a large 
negative interaction. Hence a splitting criterion is required that focuses on maximizing 
the absolute interaction effect. Thus, the splitting criterion can be defined as 
 
𝐺(𝑠) = 𝑡2(𝑠) 
 
which is analogous to the splitting criterion used for the IT procedure in a single trial 
scenario. The criterion 𝐺(𝑠) is essentially the Wald test statistic i.e. 
?̂?3
2
𝜎𝛽3
2  to test the null 
hypothesis that the interaction effect is equal to zero. Therefore, during the tree 
growing process, an optimal split is defined as the split that maximizes 𝐺(𝑠). The 
splitting criterion can be estimated using either a fixed-effects model (model B) or a 
mixed-effects model (model C). Note here that the splitting criterion associated with 
model A is computed in the same way as the original IT method for a single trial. What 
we now require is to choose which out of these three models (A, B and C) provides the 
best estimate of 𝐺(𝑠) having accounted for the hierarchical data structure so that the IT 
method grows the correct size tree. This decision depends on what you believe about 
the distribution of the data. Therefore, it would be good to compare the three models 
as estimators of 𝐺(𝑠) to see how badly the simpler models do when the data really 
come from a more complex model. This will be evaluated in the next section of this 
chapter by performing a simulation study. From now onwards, the extended IT method 
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will be referred to as IPD-IT, which refers to three methods corresponding to models A, 
B, and C above. 
  
SIDES extension (IPD-SIDES) 
A new proposed splitting criterion for the IT method in an IPD meta-analysis setting 
has now been defined (IPD-IT). Let us now consider the extension of the SIDES method 
to an IPD framework. Recall that the SIDES procedure in a single trial setting simply 
computes the one-sided t-test statistic for treatment effect in both the child nodes 
separately. The procedure also stores the associated p-value from the one-sided test 
for inferential purposes should the node be chosen to define a subgroup. Thereafter, 
these two statistics are fed into the splitting criterion (Chapter 6 – equation (6.10)), 
which is essentially a test for interaction, to compute a p-value to test the absolute 
value of treatment effect heterogeneity between the two nodes. Due to asymptotics, the 
t-test statistics are treated as z-statistics and thus the splitting criterion computes a p-
value assuming the test statistics have a standard normal distribution. Hence, one can 
easily extend the SIDES method by computing the p-value in a similar manner using the 
same splitting criterion but substituting in the treatment effect t-test statistic 
 
𝑡(𝑠) =  
?̂?1
𝜎𝛽1
 
 
from either the fixed-effect model (Model B) or the mixed-effect model (Model C), 
where ?̂?1 is the treatment effect estimate and 𝜎𝛽1is the associated standard error. 
Though we can obtain p-values for the one-sided tests for treatment effect in a fixed-
effects model, it is not that simple when using a mixed-effects model. The reason for 
this is that in a hierarchical setting, it becomes difficult to count the degrees of freedom 
which are required to set the distribution for the test statistic. If the variance of the 
fixed-effects component is known then one can easily obtain a p-value. However, the 
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variance is not known and is estimated using REML, hence there will be some degree of 
uncertainty surrounding the variance estimates. As a result, the cumulative 
distribution function of the test statistic will be unknown and thus a p-value cannot be 
calculated (157, 160). A number of approaches have been proposed to better 
approximate the degrees of freedom and thus obtain an approximate p-value (163, 
164). However there is still much debate about how to best approximate the p-values 
and so there is no simple solution. Despite the ongoing debate, if a p-value is required, 
a sensible distributional assumption for the test statistic can be made based on the data 
and thus an approximate p-value obtained. More specifically in the context of IPD, due 
to the large amounts of data, one can treat the t-test statistic from the model as a z-
statistic or z-score. Hence, a p-value from a one-sided test can then be estimated using 
a standard normal distribution which doesn’t require the degrees of freedom to be 
specified. Thereafter, the one-sided z-statistics can be substituted into the splitting 
criterion to estimate the p-value of the interaction effect to aid the SIDES tree growing 
procedure. It is worth highlighting here that the p-values are not estimated to test 
hypotheses; rather they are utilized by the SIDES procedure to aid the exploratory 
search process. This therefore further justifies the distributional assumptions made for 
the test statistics in the fixed component of the mixed model. From now onwards, the 
extended SIDES method will be referred to as IPD-SIDES, which refers to three 
methods corresponding to models A, B and C above. 
  
Now that splitting criteria have been defined for the IPD-IT and IPD-SIDES methods, 
what we now require is to determine which of the splitting criteria associated with 
models A, B and C provides reliable estimates of the splitting criterion score in order to 
detect interaction effects or identify subgroups with large treatment effects. The choice 
of model and thus the associated splitting criterion can be determined by performing a 
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simulation study considering different subgroup scenarios as well as varying degrees 
of between-study heterogeneity. The simulation study setup will now be described.   
  
8.5 Simulation study setup 
 
Data generation procedure 
The simulation setup to evaluate the IPD-IT and IPD-SIDES method required that data 
be generated for several studies thus forming a pooled dataset. The same simulation 
setup described in Chapter 7 (section 7.2) was used to generate data for a single trial. 
Recall from Chapter 7 that the data generation process simply requires the main effects 
and interaction effects to be specified in order to generate the data. The same data 
generation procedure was applied several times to generate multiple single trial data 
that were then combined to form a pooled IPD dataset. However, in addition, this 
required some between-study variation, typically denoted by 𝜏2 in meta-analyses, to be 
introduced to represent the clustering present in the hierarchical data structure. This 
was done by randomly generating an overall mean 𝛽0 for each trial in the pooled 
dataset from a normal distribution 𝛽0~N(0, 𝜏
2) with a mean of zero and a between-
trial variance of 𝜏2, where 𝜏2is to be specified. It is probably worth noting here that the 
ratio of the between-study variation 𝜏2 over the total variation provides another 
measure of heterogeneity commonly used in meta-analyses referred to as the 
intraclass correlation (ICC). Hence, the ICC measures how much of the total variance is 
explained by the clustering within each study. Values of the ICC typically range from 
zero to one where a value of zero suggests that the response values in one study are 
similar to those in other studies and a value of one suggests they are completely 
different. 
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Simulation study design 
A full factorial simulation study design was used where four factors were varied; the 
sample size of each study in the pooled dataset, the interaction effect size for 𝑇 ∙ 𝑋1, the 
interaction effect size for 𝑇 ∙ 𝑋2 and the between-study variance. Each pooled dataset 
consisted of 5 studies with each study having a sample size of 200, 500 and 1000. For 
simplicity, the sample size of each study in the generated pooled dataset remained 
fixed. Furthermore, the simulated data assumed an equal proportion of individuals in 
each category of the treatment variable 𝑇, and the two covariates 𝑋1 and 𝑋2. 
Standardized interaction effect sizes of 0, 0.2 (small), 0.5 (medium), 0.8 (large) and 1.5 
(very large) were considered for both the 𝑇 ∙ 𝑋1 and 𝑇 ∙ 𝑋2 interactions. Between-study 
variances (𝜏2) of 0.1 (small) and 0.9 (large) relative to a residual within study variance 
of 1 were considered as they are within range of the typical between-study 
heterogeneity found in IPD meta-analyses (156, 165). These small and large between-
study variances equate to ICC values of approximately 0.08 and 0.42 respectively in the 
simulated datasets. Varying 𝜏2 will enable us to investigate and contrast how the 
methods perform in varying degrees of between-study heterogeneity. In total, each 
permutation in the full-factorial design was simulated 1000 times and the results 
summarized. The simulations were performed using R software 3.0.1. 
 
8.6 Simulation study results 
 
IPD-IT Simulation Results 
The results for the IPD-IT procedure using models A, B and C when there is small (0.1) 
between-study variation are presented in tables 8.1, 8.2 and 8.3 respectively. In this 
case as there is little between-study variation, we might expect all models to be ok. The 
results of the simulation study suggest that all three models perform similarly in the 
presence of small between-study variance. The small differences that are observed 
when comparing the results are quite likely due to simulation error. All three models 
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detect the correct tree more than 90% of the time when there are no interactions 
present. When only a single one-way interaction is present, all three models detect 
medium, large and very large interactions the majority of the time for all sample sizes 
≥1000 and the models also do well in detecting a small one-way interaction when the 
sample size is 5000. When two one-way interactions are present, all three models 
detect large and very large interactions more than 97% of the time for all sample sizes 
≥1000. When both two-way interactions are of medium size, or when one of them is of 
medium size and the other is either large or very large, then all three models detect the 
correct tree the majority of the time provided the overall sample size is 2500 or more.  
 
The results for the IPD-IT procedure using models A, B, and C when there is large (0.9) 
between-study variation are presented in tables 8.4, 8.5 and 8.6 respectively. All three 
models detect the correct tree a majority of the time when there are no interactions 
present. However, it can be observed that there is a slight decrease in the proportion of 
times the correct tree is detected when either a fixed-effect model (Model B) or mixed-
effect model (Model C) is used i.e. slight increase of false positive rate. When there is a 
single one-way interaction present, the fixed-effect and mixed-models perform better 
than the null model (Model A) when a small interaction effect is present, in particular, 
they detect a small interaction a majority of the time if the sample size is 5000. All 
three models detect medium, large and very large single one-way interactions more 
than 90% of the time where the null model seems to perform a bit better than the 
fixed-effect and mixed-effect models. When there are two one-way interactions 
present, it is most noticeable that the fixed-effect and mixed-effect models in general 
perform far better than the null model. All three models detect the correct tree a 
majority of the time when the two-way interactions are either large or very large for all 
sample sizes ≥1000. Moreover, the method detects the correct tree a majority of the 
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time when one of the interactions is of medium size and the other interaction is either 
medium, large or verge large for sample sizes greater than 2500.  
 
IPD-SIDES Simulation Results 
The results for the IPD-SIDES procedure using models A, B, and C when there is small 
(0.1) between-study variation are presented in tables 8.7, 8.8 and 8.9 respectively. 
Similar to the IPD-IT method, all three models seem to perform rather similarly when 
there is small between-study variation. The method correctly detects the full dataset 
i.e. no subgroups, the majority of the time when no interactions are present. When 
there is a single one-way interaction present i.e. a single region with enhanced 
treatment effect, the IPD-SIDES method detects the correct subgroup more than 95% of 
the time for sample sizes ≥2500 for a medium sized interaction effect, and for all 
sample sizes ≥1000 for a large interaction effect size. When the one-way interaction is 
very large, there seems to be an unusual and rather large drop in the performance of 
the method. For example, it detects the correct subgroup approximately 98% of the 
time when the overall sample size is 1000 however it does not detect any correct 
subgroups at all when the sample size is 5000. This peculiarity will be investigated 
later. When there are two one-way interactions present i.e. two subgroups with 
enhanced treatment effect, the method detects the correct subgroups the majority of 
the time when the interactions are medium, large and very large for all sample sizes 
≥1000. Moreover, the method detects the correct subgroups a majority of the time 
when one of the interactions is small and the other interaction is very large for sample 
sizes ≥2500.  
 
The results for the IPD-SIDES procedure using models A, B and C when there is large 
(0.9) between-study variation are presented in tables 8.10, 8.11 and 8.12 respectively. 
When no interactions are present, all three models detect the full dataset i.e. no 
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subgroups, the majority of the time however it is noticeable that the null model (Model 
A) performs better in this scenario. In general, it is most noticeable that the fixed-effect 
and the mixed-effect models perform far better than the null model when there is large 
between-study variance. For example, when there are two medium sized interactions 
and the sample size is 1000, the null model detects the correct subgroups around 70% 
of the time whereas the fixed-effect and mixed-effect models detect the correct 
subgroups around 85% of the time. Again, there is an unusual drop in performance of 
the method when there is a single very large one-way interaction present. Similar to 
the results of when the between-study variation was small, when there are two one-
way interactions present, the method detects the correct subgroups the majority of the 
time when the interactions are medium, large and very large for all sample sizes ≥1000.   
 
8.7 Discussion 
 
This chapter described the proposed extension of the IT and SIDES procedures to an 
IPD meta-analyses setting. The proposed extensions (IPD-IT and IPD-SIDES) were then 
evaluated using a simulation study to assess which model(s) (Model A - null model, 
Model B - fixed-effect model or Model C - mixed-effect model) provide the best estimate 
of the relevant test statistic to be used in the splitting criterion of both methods. The 
results of the simulation study for both methods suggest that when the between-study 
variation is small, the choice of model to estimate the splitting criterion does not 
matter i.e. it can be treated as a single dataset and the original method applied. On the 
other hand, when there is large between-study variation, both methods perform much 
better when either a fixed-effect or mixed-effect model is used to estimate the splitting 
criterion. The results of the simulation study therefore demonstrate that in the case of 
large between-study variation, the incorrect simpler model without trial effects does 
lead to a real loss in performance. In addition, the simulation results of the IPD-SIDES 
method highlighted an issue associated with detecting subgroups with larger effects. 
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The results of the simulation study are reflective of the approaches currently 
undertaken to analyse data that have a hierarchical structure. Typically, the data are 
firstly assessed for the degree of between-study variation using a measure such as the 
ICC. If the ICC is small and thus negligible, then standard statistical analyses are 
implemented, otherwise, alternative models such as fixed or mixed models are applied 
to account for the clustering. Thus, in the same manner, it is recommended here that 
the between-study variation is assessed beforehand to help determine which model to 
use to estimate the splitting criterion for both the IPD-IT and IPD-SIDES methods when 
applying them to individual patient data.  
 
This chapter has thus developed and evaluated two statistical methods, namely IPD-IT 
and IPD-SIDES, for performing subgroup analyses in an IPD meta-analyses setting. 
Although the IPD-SIDES method performs quite well in most of the scenarios 
considered, the performance of the method somehow deteriorates when detecting 
subgroups with a very large effect. It is therefore worth investigating why this issue 
occurs and possibly find a solution to the problem. The next chapter will therefore 
thoroughly investigate the issue with the IPD-SIDES method with the aim of trying to 
rectify the problem and thus improving the method. 
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Table 8.1 – Simulation results for the IPD-IT method for Model A (Null model) when there is small (0.1) between-study variation. Results display % 
of correctly identified final trees. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 94.50 18.70 86.10 92.80 94.10 
  2500 93.90 51.20 90.70 91.90 93.90 
  5000 93.90 79.30 93.20 93.50 92.70 
Small=0.2 1000 22.70 0.70 4.10 5.10 4.10 
  2500 54.30 9.10 21.40 20.70 20.80 
  5000 80.00 35.90 48.70 51.50 55.70 
Medium=0.5 1000 87.10 3.70 47.90 66.90 65.10 
  2500 91.60 20.80 96.50 98.40 98.40 
  5000 93.00 52.90 100.00 100.00 100.00 
Large=0.8 1000 92.50 4.60 64.60 97.80 98.80 
  2500 93.80 21.10 98.50 100.00 100.00 
  5000 92.00 53.50 100.00 100.00 100.00 
V. Large=1.5 1000 93.20 5.20 64.80 98.70 100.00 
  2500 92.00 19.90 98.20 100.00 100.00 
  5000 93.50 53.60 100.00 100.00 100.00 
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Table 8.2 – Simulation results for the IPD-IT method for Model B (Fixed-effect model) when there is small (0.1) between-study variation. Results 
display % of correctly identified final trees. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 93.90 24.60 86.20 88.70 91.30 
  2500 93.30 54.00 90.80 90.80 92.30 
  5000 92.20 78.40 91.80 92.80 92.00 
Small=0.2 1000 24.00 0.80 6.60 6.50 7.90 
  2500 56.40 8.90 24.50 20.60 21.80 
  5000 82.20 35.00 54.30 57.10 57.70 
Medium=0.5 1000 85.90 6.20 52.80 69.30 66.60 
  2500 89.50 24.30 97.60 98.90 98.70 
  5000 91.60 56.00 100.00 100.00 100.00 
Large=0.8 1000 89.40 5.90 68.60 97.50 98.70 
  2500 91.70 23.20 98.60 100.00 100.00 
  5000 93.20 52.50 100.00 100.00 100.00 
V. Large=1.5 1000 89.90 4.80 68.00 99.00 100.00 
  2500 92.10 20.60 98.90 100.00 100.00 
  5000 92.30 54.80 100.00 100.00 100.00 
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Table 8.3 – Simulation results for the IPD-IT method for Model C (Mixed-effect model) when there is small (0.1) between-study variation. Results 
display % of correctly identified final trees. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 91.80 22.30 85.00 89.70 91.50 
  2500 92.60 55.10 88.90 90.90 92.70 
  5000 93.20 80.40 91.60 91.60 92.40 
Small=0.2 1000 25.60 1.00 4.60 6.60 5.90 
  2500 51.10 9.40 21.90 23.10 24.20 
  5000 82.00 36.00 57.50 55.40 56.70 
Medium=0.5 1000 83.20 6.60 50.40 66.00 69.10 
  2500 90.40 21.40 98.30 98.70 98.80 
  5000 90.60 55.90 100.00 100.00 100.00 
Large=0.8 1000 90.30 6.60 70.70 97.50 98.70 
  2500 91.50 20.70 98.60 100.00 100.00 
  5000 91.20 55.40 100.00 100.00 100.00 
V. Large=1.5 1000 90.70 6.00 69.60 98.50 100.00 
  2500 91.60 21.90 98.90 100.00 100.00 
  5000 93.20 55.70 100.00 100.00 100.00 
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Table 8.4 – Simulation results for the IPD-IT method for Model A (Null model) when there is large (0.9) between-study variation. Results display % 
of correctly identified final trees. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 98.40 10.10 81.60 97.00 97.60 
  2500 98.20 39.50 97.30 97.10 98.40 
  5000 98.70 70.10 96.90 97.20 98.40 
Small=0.2 1000 11.00 0.10 2.20 1.30 1.50 
  2500 33.30 2.90 9.20 9.70 9.60 
  5000 72.70 18.00 28.90 32.40 29.90 
Medium=0.5 1000 82.10 1.80 28.90 45.00 43.00 
  2500 96.30 10.70 90.70 94.90 94.20 
  5000 97.20 30.60 99.90 100.00 99.90 
Large=0.8 1000 97.50 1.20 44.60 90.40 96.10 
  2500 98.20 9.40 94.30 100.00 100.00 
  5000 97.20 34.30 99.90 100.00 100.00 
V. Large=1.5 1000 96.90 1.50 45.50 94.20 100.00 
  2500 96.80 8.40 94.00 100.00 100.00 
  5000 97.60 33.00 100.00 100.00 100.00 
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Table 8.5 – Simulation results for the IPD-IT method for Model B (Fixed-effect model) when there is large (0.9) between-study variation. Results 
display % of correctly identified final trees. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 93.90 22.40 85.50 90.20 90.60 
  2500 93.20 53.30 90.90 91.30 90.80 
  5000 93.00 80.60 90.00 91.50 91.80 
Small=0.2 1000 22.50 1.40 5.80 5.40 5.70 
  2500 55.80 9.60 19.90 21.70 23.30 
  5000 80.60 37.60 54.20 53.70 55.40 
Medium=0.5 1000 87.40 4.00 52.00 67.50 65.90 
  2500 90.30 21.90 98.00 99.30 98.80 
  5000 91.40 56.60 100.00 100.00 100.00 
Large=0.8 1000 90.00 6.20 66.40 98.60 99.00 
  2500 90.90 24.50 98.60 100.00 100.00 
  5000 92.90 55.40 100.00 100.00 100.00 
V. Large=1.5 1000 90.90 6.50 66.30 98.40 100.00 
  2500 91.30 24.90 98.10 100.00 100.00 
  5000 92.40 51.70 100.00 100.00 100.00 
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Table 8.6 – Simulation results for the IPD-IT method for Model C (Mixed-effect model) when there is large (0.9) between-study variation. Results 
display % of correctly identified final trees. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 92.60 23.30 87.40 91.00 90.40 
  2500 93.90 56.30 89.20 91.90 90.80 
  5000 94.10 81.20 90.80 91.20 90.60 
Small=0.2 1000 22.70 0.60 6.40 6.30 6.00 
  2500 55.00 10.20 23.20 22.80 23.20 
  5000 82.00 37.40 55.50 55.30 55.80 
Medium=0.5 1000 86.70 5.90 51.20 67.10 67.50 
  2500 90.30 21.40 97.40 98.70 98.40 
  5000 92.20 55.10 100.00 100.00 100.00 
Large=0.8 1000 90.40 5.10 67.30 97.90 99.40 
  2500 90.80 21.00 98.30 100.00 100.00 
  5000 91.40 53.60 100.00 100.00 100.00 
V. Large=1.5 1000 89.70 5.30 69.60 98.80 100.00 
  2500 91.60 21.40 99.20 100.00 100.00 
  5000 92.70 52.60 100.00 100.00 100.00 
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Table 8.7 – Simulation results for the IPD-SIDES method for Model A (Null model) when there is small (0.1) between-study variation. Results display 
% of correctly identified final subgroups. 
 
  
T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 89.50 17.90 78.60 97.10 98.50 
 
2500 90.30 44.20 96.30 98.00 7.20 
 
5000 91.70 70.40 97.50 88.00 0.00 
Small=0.2 1000 19.40 15.00 26.70 21.30 13.60 
 
2500 46.40 43.10 54.30 45.50 97.40 
 
5000 73.00 74.50 78.30 76.60 100.00 
Medium=0.5 1000 82.60 23.40 83.70 89.30 82.60 
 
2500 96.40 49.10 100.00 99.70 100.00 
 
5000 98.30 79.00 100.00 100.00 100.00 
Large=0.8 1000 97.50 20.70 90.20 100.00 99.50 
 
2500 98.00 42.50 99.90 100.00 100.00 
 
5000 93.60 78.10 100.00 100.00 100.00 
V. Large=1.5 1000 98.70 14.10 82.20 99.80 100.00 
 
2500 55.60 68.90 100.00 100.00 100.00 
  5000 47.90 89.80 100.00 100.00 100.00 
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Table 8.8 – Simulation results for the IPD-SIDES method for Model B (Fixed-effect model) when there is small (0.1) between-study variation. Results 
display % of correctly identified final subgroups. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 88.50 19.10 77.40 95.90 98.30 
  2500 90.40 46.50 95.80 97.40 4.70 
  5000 90.10 70.60 97.60 82.30 0.00 
Small=0.2 1000 23.90 16.70 30.30 24.50 19.00 
  2500 45.70 46.30 56.70 46.90 99.30 
  5000 71.30 78.20 81.40 83.00 100.00 
Medium=0.5 1000 79.60 30.70 85.30 91.50 84.70 
  2500 97.20 53.20 99.90 99.70 100.00 
  5000 97.70 80.70 100.00 100.00 100.00 
Large=0.8 1000 96.00 23.60 91.00 99.80 100.00 
  2500 98.00 45.80 99.70 100.00 100.00 
  5000 89.10 83.90 100.00 100.00 100.00 
V. Large=1.5 1000 98.90 19.00 86.20 99.90 100.00 
  2500 52.10 75.60 100.00 100.00 100.00 
  5000 50.10 90.60 100.00 100.00 100.00 
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Table 8.9 – Simulation results for the IPD-SIDES method for Model C (Mixed-effect model) when there is small (0.1) between-study variation. 
Results display % of correctly identified final subgroups. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 88.70 21.00 74.50 95.90 97.10 
  2500 88.10 43.80 95.00 97.50 2.50 
  5000 89.10 70.70 97.00 78.30 0.00 
Small=0.2 1000 20.80 16.60 32.30 26.10 18.90 
  2500 43.70 43.30 55.10 48.20 99.40 
  5000 73.40 79.00 79.80 83.70 100.00 
Medium=0.5 1000 78.00 29.70 86.60 91.00 85.30 
  2500 95.50 55.40 99.70 99.90 100.00 
  5000 97.40 77.50 100.00 100.00 100.00 
Large=0.8 1000 95.10 22.80 90.90 99.70 99.70 
  2500 97.30 47.00 99.80 100.00 100.00 
  5000 87.10 82.90 100.00 100.00 100.00 
V. Large=1.5 1000 97.00 18.00 83.20 99.90 100.00 
  2500 52.10 77.40 100.00 100.00 100.00 
  5000 50.70 90.70 100.00 100.00 100.00 
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Table 8.10 – Simulation results for the IPD-SIDES method for Model A (Null model) when there is large (0.9) between-study variation. Results 
display % of correctly identified final subgroups. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 95.40 10.60 68.50 96.90 99.90 
  2500 95.90 28.10 96.30 99.40 68.70 
  5000 96.00 58.50 99.00 98.60 7.30 
Small=0.2 1000 14.90 8.20 21.80 12.20 7.00 
  2500 32.20 30.00 38.60 27.90 51.40 
  5000 61.00 60.60 62.60 59.50 98.10 
Medium=0.5 1000 70.00 17.30 70.80 79.00 67.,4 
  2500 98.00 36.90 99.20 99.20 98.50 
  5000 99.80 61.10 100.00 100.00 100.00 
Large=0.8 1000 98.00 10.90 75.60 99.50 99.10 
  2500 99.30 27.40 99.50 100.00 100.00 
  5000 99.30 55.90 100.00 100.00 100.00 
V. Large=1.5 1000 99.90 6.70 67.80 98.40 100.00 
  2500 82.40 37.90 98.70 100.00 100.00 
  5000 53.20 79.60 100.00 100.00 100.00 
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Table 8.11 – Simulation results for the IPD-SIDES method for Model B (Fixed-effect model) when there is large (0.9) between-study variation. 
Results display % of correctly identified final subgroups. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 90.50 22.20 79.80 96.20 98.00 
  2500 87.60 44.30 96.70 97.70 4.20 
  5000 88.60 70.60 97.60 82.50 0.00 
Small=0.2 1000 24.00 16.90 30.60 25.70 14.40 
  2500 45.00 45.90 56.40 47.20 98.70 
  5000 71.10 77.90 79.50 85.10 100.00 
Medium=0.5 1000 81.50 30.10 85.00 90.90 85.40 
  2500 95.20 52.50 99.90 99.80 100.00 
  5000 98.10 82.60 100.00 100.00 100.00 
Large=0.8 1000 95.70 21.20 90.80 99.60 99.40 
  2500 98.60 48.50 99.50 100.00 100.00 
  5000 90.20 82.40 100.00 100.00 100.00 
V. Large=1.5 1000 98.80 14.80 84.80 99.40 100.00 
  2500 50.50 70.50 100.00 100.00 100.00 
  5000 50.90 92.30 100.00 100.00 100.00 
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Table 8.12 – Simulation results for the IPD-SIDES method for Model C (Mixed-effect model) when there is large (0.9) between-study variation. 
Results display % of correctly identified final subgroups. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 88.60 20.30 77.80 96.40 96.00 
  2500 89.60 44.70 96.20 96.60 2.00 
  5000 89.50 72.00 97.40 76.00 0.00 
Small=0.2 1000 20.80 18.30 31.00 25.10 19.10 
  2500 44.70 44.40 54.80 46.50 99.60 
  5000 72.70 75.40 80.10 84.60 100.00 
Medium=0.5 1000 80.80 31.20 85.60 92.00 85.60 
  2500 95.40 54.00 100.00 99.60 100.00 
  5000 97.70 80.00 100.00 100.00 100.00 
Large=0.8 1000 95.90 24.00 90.50 99.80 99.70 
  2500 98.20 48.40 100.00 100.00 100.00 
  5000 87.60 81.10 100.00 100.00 100.00 
V. Large=1.5 1000 97.00 17.80 85.20 99.90 100.00 
  2500 48.40 75.40 100.00 100.00 100.00 
  5000 49.30 90.60 100.00 100.00 100.00 
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Chapter 9 
 
Further development of 
the IPD-SIDES method 
 
 
9.1 Introduction 
 
The previous chapter developed and evaluated the IPD-IT and IPD-SIDES methods for 
performing subgroup analyses in an IPD meta-analyses framework. Both of the 
methods seemed to perform rather well, especially when there is large between-study 
variance present. However, it was observed from the IPD-SIDES simulation results that 
there was a rather unusual decrease in the performance of the method when there is a 
single very large one-way interaction present. The consideration of much larger 
samples in the simulation study in the previous chapter may have magnified a problem 
that was not noticeable in the single trial scenario simulation presented in Chapter 7. 
 
Since the IPD-SIDES method works quite well in most of the scenarios considered in 
the simulation study, it is worth investigating how and why the methods performance 
is affected in the hope that a solution can be found. This chapter will therefore 
thoroughly investigate the issue to try and better understand why the drop in 
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performance occurs. Moreover, possible solutions to the problem will be sought and 
evaluated by re-running the simulation study conducted in the previous chapter.  
 
9.2 Investigating the drop in performance of the IPD-SIDES method 
 
The first step to better determine why the issue occurs is to observe what happens 
when applying the method to a single simulated dataset. The single dataset was 
generated (N=5000) with a very large single one-way interaction and the IPD-SIDES 
method was applied. Table 9.1 displays the final subgroups detected when applying the 
method. The method should only detect one subgroup (i.e. the first row only in Table 
9.1), however it goes on to split further and detect another subgroup. One of the 
possible reasons for this happening is because there is no restriction placed on the 
computed differential effect p-value i.e. the splitting criterion (final column in Table 
9.1). To recall how the method works, first the method evaluates the differential effect 
splitting criterion for all possible splits and retains the best single split i.e. split with the 
smallest p-value, for each covariate. These splits are then ordered in terms of the 
differential effect p-value from smallest to largest. Thereafter, only the top M splits 
with the largest differential effect are considered where M is pre-specified by the user. 
The ordered splits, though they may not be significant, are explored individually where 
only the subgroup with the more enhanced treatment effect is retained from each split 
provided it meets the continuation criterion. Hence, the differential effect splitting 
criterion is merely used to order the splits regardless of their significance. Therefore, it 
is possible for the method to detect a spurious subgroup resulting from a split with a 
non-significant differential effect. Thus, one possible solution to the problem would be 
to impose a restriction on the computed differential effect p-values such that the 
procedure only considers splits where the p-value is within a certain threshold e.g. 0.05 
or 0.10. If such a restriction is applied to the example in Table 9.1, then only one 
subgroup would have been identified. It is worth mentioning here that the splitting 
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criterion is used to aid the search process of the method to identify candidate 
subgroups. Therefore, the restriction placed on the splitting criterion p-value need not 
be that strict (p≤0.05), and instead a less stringent restriction can be imposed (p≤0.10) 
so that the method has the flexibility to identify subgroups that might be plausible.  
 
Another reason why the procedure goes on to detect additional subgroups is because 
of the continuation criterion used by the method. Recall from chapter 6 that the 
method only keeps a split provided it satisfies the continuation criterion 𝑝𝑐 ≤ 𝛾 ∙ 𝑝𝑝 i.e. 
that the one-sided treatment effect p-value of the newly formed child node must be less 
than or equal to the complexity parameter value multiplied by the one-sided treatment 
effect p-value of the parent node from which it came. As we are dealing with large 
sample sizes, the treatment effect estimates in the simulated datasets will have more 
precision i.e. smaller standard error. Therefore, if the effect size is large, then dividing 
by a very small standard error will produce an extremely small one-sided p-value for 
the treatment effect. Often the p-values are so small that computational limitations 
means that they are calculated or stored as zeros. Therefore, the first subgroup 
selected in Table 9.1 (first row) has a treatment effect of 0.808 and has a one-sided p-
value of zero. Subsequently, the method then goes on to select a second subgroup 
(second row in Table 9.1) because the one-sided p-value is equal to the p-value of the 
parent node from which it came; thus satisfying the continuation criterion. Thus, a 
solution to this problem would be to change the continuation criterion so that the one-
sided p-value of the child node should be strictly less than the one-sided p-value of the 
parent node i.e. 𝑝𝑐 < 𝛾 ∙ 𝑝𝑝. However, if we think about the aim of the method, the aim 
is to identify several candidate subgroups with enhanced treatment effect. Therefore, 
changing the inequality to being strictly less than will certainly disregard several 
candidate subgroups that are similar to the parent node from which they were formed. 
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Thus, changing the inequality might not be a suitable solution with regards to the 
objective of the method.   
 
From observing the output from the single simulated dataset, another issue with the 
method becomes apparent. Notice how the second subgroup identified by the method 
has a treatment effect of 0.843. This treatment effect is actually not that different from 
the treatment effect in the disregarded subgroup (0.773). The reason the method 
considers this split is because of the differential effect splitting criterion used by the 
method. Recall that this splitting criterion is of the form 
 
𝑝 = 2 ∙ [1 − Φ(
|𝑍𝐸1 − 𝑍𝐸2|
√2
)]                                                             (9.1) 
 
where 𝑍𝐸1 and 𝑍𝐸2 are the one-sided test statistics from the tests computed in child 
nodes 1 and 2 respectively. As explained earlier, the splitting criterion is only used to 
order all of the splits in terms of the differential effect p-value. Thereafter, the best M 
splits are considered from which the subgroups with larger treatment effect are 
retained (provided they meet the continuation criterion). Though the authors propose 
this splitting criterion to perform the differential effect search, it is probably not the 
most appropriate to directly evaluate the differential effect. As a result, it is quite 
possible that larger differential effects will go unnoticed. The reason why it is not the 
most appropriate splitting criterion is because it can give a significant p-value when 
the treatment effects in the two child nodes are similar and the standard errors are 
sufficiently different. In this case the difference in standardized Z statistics in (9.1) may 
be large even if the difference in (non-standardized) effect sizes is small. To consider 
an example, say a split is formed where both child nodes have a treatment effect of 4.0, 
however the SE in the left child node is 0.2 and the SE in the right child node is 0.9. 
Computation of the one-sided test statistics 𝑍𝐸1 =
4.0
0.2
= 20 and 𝑍𝐸2 =
4.0
0.9
= 4.4 would 
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suggest that there is a big differential effect between the two groups and thus the 
splitting criterion defined by equation (9.1) would indicate that the differential effect is 
highly significant. Now if the same split was evaluated using a regression model with 
the inclusion of an interaction effect, then the test statistic for the interaction effect 
would be very small thus being indicative of there being no differential effect present. 
What this means is that the current splitting criterion is more likely to select splits 
where there is a larger subgroup with more precision i.e. smaller SE, compared to a 
smaller subgroup with less precision i.e. larger SE, regardless of whether the treatment 
effects are the same or not. The current splitting criterion is therefore not an 
appropriate approach for performing the differential effect search for the objective we 
wish to use it for and so another alternative criterion is required. As mentioned earlier 
on in this thesis, the most appropriate method of directly evaluating a differential 
subgroup effect is to use a statistical test for interaction. Therefore, one approach to get 
the method to do what we require it to do is to define a new splitting criterion that uses 
the interaction effect estimate test statistic to obtain a differential effect p-value. We 
can define the new splitting criterion as follows 
 
𝑝 = 2 ∙ [1 − Φ(𝑍𝑖𝑛𝑡)]                                                        (9.2) 
 
where 𝑍𝑖𝑛𝑡 is the two-sided hypothesis test statistic computed for the interaction effect 
estimate that is obtained from fitting an appropriate regression model (linear, fixed or 
mixed model) with the inclusion of an interaction term and where Φ(𝑍𝑖𝑛𝑡) is the 
cumulative distribution function of the standard normal distribution. 
 
A closer inspection of the method coding provided by the authors identified yet 
another important issue with the method. It was found that having ordered the splits 
using the original splitting criterion; the method selects the subgroups with a larger 
one-sided test statistic i.e. smaller p-value rather than selecting the subgroups with the 
173 
 
largest treatment effect. Thus the method aims to find subgroups with the smallest p-
value rather than largest treatment effect, which is not what we want the method to do. 
Therefore, the code provided by the authors doesn’t actually do what we require it to 
do. In order for the method to do what we require, the coding can be changed such that 
the method selects the subgroup with the largest treatment effect instead of selecting 
the subgroup with the largest one-sided test statistic. In this way, the objective of the 
method changes to identifying subgroups with enhanced treatment effect rather than 
identifying subgroups with smallest p-value. From now onwards, this will be referred 
to as the modified IPD-SIDES method.   
 
9.3 Simulation Study 
 
The previous section investigated three issues with using the IPD-SIDES method to do 
what we want; firstly an issue highlighted in the previous chapter regarding the 
method’s performance when considering larger effect sizes, secondly an issue 
recognized in the previous section regarding the differential effect splitting criterion 
and thirdly an issue with the method coding in the way it selects subgroups. A possible 
solution for each of these issues was described in the previous section. In this section, 
we report the evaluation of the modified method using simulation studies. Two 
simulation studies were performed. Simulation study 1 evaluated the performance of 
the IPD-SIDES method proposed in the previous chapter with a restriction imposed on 
the p-values (p≤0.10) computed using the differential effect search splitting criterion. 
Simulation study 2 evaluated the performance of the modified IPD-SIDES method that 
uses a new splitting criterion defined by equation (9.2) and also selects the subgroup 
with the largest treatment effect (instead of the selecting the subgroup with smallest p-
value as done so by the original method). Moreover, a restriction was also placed on 
the p-values (p≤0.10) obtained from the interaction. Both of these simulation studies 
were set up in exactly the same way as described in the previous chapter. As there was 
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not much difference in the simulation study results of the method in the previous 
chapter when a fixed-effect or mixed-effect model was used, the simulation study in 
this chapter only considered the splitting criterion that utilizes a mixed-effect model. 
Moreover, simulation study 1 and 2 both investigated the performance of the method 
in the presence of small (0.1) and large (0.9) between-study variance.   
 
9.4 Simulation Study 1 results 
 
The results of simulation study 1 are presented in tables 9.2 (small (0.1) between-
study variation) and 9.3 (large (0.9) between-study variation) respectively. The results 
were quite similar in both of the results tables. When there are no subgroups to detect, 
the method detects the correct subgroup (full dataset) around 95% of the time. This is 
an improvement compared to the results in the previous chapter which observed a 
drop in the performance of the method when using either a fixed or mixed model when 
compared to the null model. The method detects the correct subgroup a majority of the 
time when there is a single medium, large or very large one-way interaction present. It 
can be observed from the results that imposing a restriction on the differential effect p-
value has resolved the issue highlighted in the previous chapter and the method now 
detects very large effects more than 90% of the time. When there are two one-way 
interactions present that are medium, large or very large, then the method detects the 
correct subgroups a majority of the time. When one of the interactions is small and the 
other interaction is medium, large or very large, then the method detects the correct 
subgroups a majority of the time provided the overall sample size is ≥5000. 
 
9.5 Simulation Study 2 results 
 
The results of simulation study 2 are presented in tables 9.4 (small between-study 
variation) and 9.5 (large between-study variation) respectively. The results in both 
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tables were quite similar and can be interpreted in the same way. When no interactions 
are present, the modified IPD-SIDES method detects the full dataset around 95% of the 
time. When there is a single medium, large or very large one-way interaction present, 
the method detects the correct subgroups the majority of the time. The modified 
method did not display any issues when detecting very large single interaction effects 
as was observed in the previous chapter. When two medium, large or very large one-
way interactions are present, the method detects the correct subgroups with large 
treatment effect the majority of the time. When one of the interactions is small and the 
other interaction is medium, large or very large, then the method detects the correct 
subgroups a majority of the time provided the overall sample size is ≥5000. In general, 
the results of the modified IPD-SIDES method are very promising in that it detects the 
correct subgroups with large treatment effect a majority of the time. 
 
9.6 Discussion 
 
This chapter set out to investigate an issue identified with the IPD-SIDES method 
proposed in the previous chapter. A restriction was imposed on the splitting criterion 
p-value as a solution to the problem and the results of the simulation study suggests 
that this resolves the issue. The method also does something different to what we 
require it to do i.e. it aims to identify subgroups with small p-values. Hence, the method 
was further developed to better suit the objective of the work in this thesis and thus 
the modified IPD-SIDES method was proposed and evaluated. The results of the new 
modified method were very promising in detecting subgroups with large or enhanced 
treatment effect.  
 
This chapter proposes the modified IPD-SIDES method as a useful tool for performing 
subgroup analyses in and IPD meta-analyses setting where the aim is to identify 
several candidate subgroups with large treatment effect. Having developed and 
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evaluated the modified IPD-SIDES method in a number of simulated settings, it is now 
of interest to apply this method to some real data. The next chapter will therefore apply 
both the IPD-IT and the modified IPD-SIDES methods to real individual patient data 
from several low back pain trials. Moreover, the IPD-SIDES method proposed in the 
previous chapter (using the original splitting criterion) and the modified IPD-SIDES 
method proposed in this chapter (using the restricted interaction test splitting 
criterion) will both be applied to the real data and compared to better demonstrate the 
difference between the two methods in terms of the subgroups they identify.   
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Table 9.1 – Simulation output for when there is a t*v1 interaction effect of 1.5 and total sample size N=5000. 
 
Selected subgroup Disregarded subgroup 
  
Subgroup n1 Trt1 SE Trt1 Trt1 p-value n0 Trt0 SE Trt0 Trt0 p-value 
Differential 
effect 
Split criterion 
p-value 
 x1 > -0.5  2500 0.808 0.041 0.000 2500 -0.760 0.040 1.000 1.571 0.000 
 x1 > -0.5 & x2 > -0.5  1250 0.843 0.058 0.000 1250 0.773 0.058 0.000 0.069 0.425 
 
 
Table 9.2 – Simulation results for the IPD-SIDES method with a restriction on the differential effect p-value (p≤0.10) when there is small (0.1) 
between-study variation. Results display % of correctly identified final subgroups. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 96.20 19.30 83.40 97.60 97.90 
  2500 94.70 48.30 96.80 97.90 93.00 
  5000 96.70 78.30 98.40 94.80 93.10 
Small=0.2 1000 17.70 4.30 17.70 17.80 17.20 
  2500 49.20 28.00 47.90 55.30 61.50 
  5000 77.30 64.90 78.80 82.80 86.10 
Medium=0.5 1000 84.10 16.40 84.50 86.20 85.80 
  2500 97.50 46.20 99.70 100.00 100.00 
  5000 98.10 78.00 100.00 100.00 100.00 
Large=0.8 1000 98.00 17.80 90.90 99.90 99.90 
  2500 98.30 44.60 100.00 100.00 100.00 
  5000 96.10 82.50 100.00 100.00 100.00 
V. Large=1.5 1000 98.10 18.60 91.30 99.80 100.00 
  2500 96.30 58.20 100.00 100.00 100.00 
  5000 96.70 86.10 100.00 100.00 100.00 
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Table 9.3 – Simulation results for the IPD-SIDES method with a restriction on the differential effect p-value (p≤0.10) when there is small (0.9) 
between-study variation. Results display % of correctly identified final subgroups. 
 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 96.30 18.60 86.60 97.90 97.20 
  2500 96.30 46.90 98.20 98.50 94.50 
  5000 96.20 76.30 98.20 95.90 94.20 
Small=0.2 1000 18.60 4.90 19.70 18.00 17.60 
  2500 47.40 29.10 47.20 55.30 61.10 
  5000 77.90 66.20 80.10 86.50 86.90 
Medium=0.5 1000 84.90 17.40 85.30 92.60 85.30 
  2500 98.00 48.40 99.70 100.00 100.00 
  5000 98.20 85.80 100.00 100.00 100.00 
Large=0.8 1000 96.70 22.50 90.60 99.90 99.70 
  2500 97.10 48.30 100.00 100.00 100.00 
  5000 95.90 83.40 100.00 100.00 100.00 
V. Large=1.5 1000 98.30 15.50 91.50 100.00 100.00 
  2500 95.60 51.30 99.90 100.00 100.00 
  5000 95.60 83.30 100.00 100.00 100.00 
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Table 9.4 – Simulation results for the modified IPD-SIDES with a restriction on the differential effect p-value (p≤0.10) when there is small (0.1) 
between-study variation. Results display % of correctly identified final subgroups. 
 
 
 
 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 96.80 20.50 83.40 97.50 98.40 
  2500 95.60 46.50 97.60 97.90 95.10 
  5000 95.60 72.80 98.40 95.60 94.40 
Small=0.2 1000 17.20 6.90 16.50 17.10 16.10 
  2500 49.00 38.80 50.80 44.80 61.60 
  5000 77.80 75.90 83.40 80.70 87.10 
Medium=0.5 1000 85.10 16.90 77.00 91.60 83.20 
  2500 97.90 54.60 100.00 100.00 100.00 
  5000 97.90 80.20 100.00 100.00 100.00 
Large=0.8 1000 97.70 16.70 83.70 99.80 99.50 
  2500 98.10 47.40 99.90 100.00 100.00 
  5000 96.10 81.80 100.00 100.00 100.00 
V. Large=1.5 1000 98.30 17.20 85.40 99.50 100.00 
  2500 95.60 53.00 100.00 100.00 100.00 
  5000 96.40 82.50 100.00 100.00 100.00 
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Table 9.5 – Simulation results for the modified IPD-SIDES with a restriction on the differential effect p-value (p≤0.10) when there is small (0.9) 
between-study variation. Results display % of correctly identified final subgroups. 
 
    T*X2 Standardized interaction effect size 
T*X1 Standardized interaction effect size N None=0 Small=0.2 Medium=0.5 Large=0.8 V. Large=1.5 
None=0 1000 96.60 21.30 86.50 98.20 96.90 
  2500 96.60 50.00 97.90 98.10 94.10 
  5000 95.90 78.30 98.60 94.50 94.60 
Small=0.2 1000 19.30 4.90 18.90 19.80 16.60 
  2500 48.40 35.90 46.40 48.20 57.70 
  5000 74.30 63.40 85.60 82.20 84.90 
Medium=0.5 1000 83.40 21.90 84.30 90.90 83.40 
  2500 98.60 44.60 100.00 99.70 99.90 
  5000 98.20 79.10 100.00 100.00 100.00 
Large=0.8 1000 97.90 28.10 83.60 99.70 99.80 
  2500 98.40 43.80 99.80 100.00 100.00 
  5000 96.80 87.00 100.00 100.00 100.00 
V. Large=1.5 1000 98.50 15.00 85.20 99.40 100.00 
  2500 96.40 54.40 100.00 100.00 100.00 
  5000 96.70 82.70 100.00 100.00 100.00 
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PART III 
 
Application and Summary 
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Chapter 10 
 
Application of IPD-IT 
and IPD-SIDES to real 
data 
 
 
10.1 Introduction 
 
The previous two chapters (Chapters 8 and 9) described and implemented a simulation 
study to evaluate the performance of the proposed IPD-IT, unmodified IPD-SIDES and 
the modified IPD-SIDES methods. The results suggest that the IPD-IT and modified IPD-
SIDES methods are promising approaches for performing subgroup analyses or 
subgroup identification in an IPD meta-analysis setting, particularly in detecting larger 
interaction effects. The choice of which model to use (linear regression, fixed model or 
mixed model) to estimate the splitting criterion depends on the degree of between-
study variability present in the dataset. If the between-study variability is small and 
negligible then it does not matter which model is applied. However, when there is 
considerable between-study variation present then it is recommended that either a 
fixed-effect or mixed-effect model be used to estimate the splitting criterion.   
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Having assessed the proposed extensions in a number of simulation settings, it is now 
of interest to apply these methods to some real data. Therefore, this chapter will 
present the results of the application of the proposed methods to a pooled dataset of 
data from a number of low back pain (LBP) acupuncture trials. Initially the data from 
the individual trials contained in the pooled dataset will be described. The statistical 
analysis methods applied to these data will then be detailed. Finally, the results from 
the analyses will be presented and discussed. Both the unmodified IPD-SIDES and 
modified IPD-SIDES methods will be applied to the real data in this chapter to better 
visualize the difference between the two methods in the subgroups they identify. 
 
10.2 Description of the pooled dataset 
 
The pooled dataset consists of data from 4 acupuncture trials with short-term follow-
up (8-13 weeks). The names of these trials will not be disclosed here and will be 
referred to as Trial 1, Trial 2, Trial 3 and Trial 4 respectively. In total, the pooled 
dataset consists of 4540 individuals; 298 from Trial 1, 1162 from Trial 2, 2841 from 
Trial 3 and 239 from trial 4. Though the data for each trial contained several 
demographic and baseline covariates, only three covariates were common to all four 
trials. All of the trials collected age and gender as demographic variables. In addition 
they also collected SF-36 data at baseline and short-term follow-up. The SF-36 is a 
questionnaire that measures health related quality of life (32). The items in the SF-36 
questionnaire are used to create two aggregated summary measures; a physical 
component score (PCS) and a mental health component score (MCS). These are 
measured on a scale of 0-100 where a lower score indicates poorer physical or mental 
functioning.  
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10.3 Methods 
 
Data formatting 
Prior to performing any analyses, it is important to specify an appropriate form for the 
continuous dependent variable to be used in the statistical analyses. There are a 
number of ways in which continuous outcome data can be used in analyses. One 
approach is to use the raw outcome data as the dependent variable and adjust for the 
baselines scores. Other common approaches include using change from baseline or 
percentage change from baseline as the dependent variable. The change from baseline 
approach from a clinical perspective is more appealing due to the ease of 
interpretability. However, an issue with this measure is that it has floor and ceiling 
effects. For example a patient with a high RMDQ score at baseline has more room for 
improvement in RMDQ score at post-treatment follow-up than a patient with a low 
score at baseline. For this reason, it might be more sensible to use the percentage 
change from baseline as a better measure of change. However, clinicians may find it 
more difficult to interpret a percentage change from baseline score compared to a 
change from baseline score. Furthermore, it has been shown that using the percentage 
change from baseline is statistically inefficient in terms of power when compared to 
using the change from baseline score (166). Thus, having described the limitations of 
these approaches, selecting which approach to take can be a difficult task. An obvious 
place to start is by observing the distribution of each of the different forms that the 
dependent variable can take since the models fitted by the tree methods to estimate the 
spitting criteria require the data be normally distributed. The outcomes of interest in 
the pooled dataset were the MCS and PCS scores from the SF-36 questionnaire 
measured at baseline and at around 8-13 weeks (short-term) follow-up. The different 
distributions for both the short-term MCS and PCS follow-up scores were compared i.e. 
the raw scores, the change from baseline scores and the percentage change from 
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baseline scores. It was observed that the distribution of the follow-up raw scores, in 
particular the MCS, were skewed. The percentage change from baseline MCS and PCS 
scores were even more skewed. However, both the change from baseline MCS and PCS 
scores were normally distributed. For this reason, it was decided to use the change 
from baseline MCS and PCS short-term follow-up scores as the dependent variables in 
the analyses. The change from baseline scores were computed by simply subtracting 
the baseline score from the short-term follow-up score, where a positive change score 
would indicate improvement.  
 
Both of the tree methods are designed to compare two arms e.g. intervention vs. 
control, therefore a binary treatment variable was created. Here, those who received 
GP care, usual care and sham acupuncture were classed as being in the control arm and 
those receiving acupuncture were classed as being in the intervention arm. The 
application of the tree methods requires that the dataset is complete. Therefore, 695 
individuals in the dataset with missing data were removed prior to performing the 
analyses. Though there are methods for dealing with missing data e.g. imputation and 
surrogate splits (used by the CART procedure) (130), these were not considered here 
as the objective was to simply demonstrate the application of the extended methods. 
Finally, the MCS and PCS baseline scores were rounded to one decimal place and the 
age covariate was rounded to a whole number to reduce the computational time 
searching all potential splits. Just to give an example, the original baseline MCS score 
has 3,432 unique split points that will need to be searched by both methods. Rounding 
the values of this covariate to one decimal place vastly reduces the number of unique 
split points to be searched to 512. 
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Assessing risk of bias of main trial 
The overall risk of bias in the main trial of each of the included trials was carried out 
using the Cochrane Collaboration risk of bias tool (167). The criteria used for the 
assessment were: 1) method of randomization, 2) allocation concealment, 3) blinding, 
4) incomplete outcome data, 5) selective reporting, 6) similarity of groups at baseline, 
7) sample size calculation, and 8) intention to treat analysis. 
 
Statistical analyses 
Prior to performing the main analyses, the demographic data, baseline data and 
outcome data were summarized for the pooled dataset. These summaries did allow for 
the clustering of the data. For continuous variables, the mean and standard deviation, 
median, range and frequency of missing data are presented. For categorical data, the 
frequency and percentage are presented for each category which also includes the 
frequency and percentage for missing data. Data were summarized by treatment arm 
as well as an overall summary.  
 
After removing all observations with missing data, a mixed-effect model was fitted to 
estimate the overall unadjusted treatment effect for both the change from baseline to 
short-term MCS and PCS outcomes. This was done so that the subgroups with 
enhanced treatment effect identified by both the unmodified and modified IPD-SIDES 
methods can be compared to the overall unadjusted treatment effect to see if the 
treatment effects actually are more enhanced. The IPD-IT, unmodified IPD-SIDES and 
modified IPD-SIDES methods were then applied to the pooled dataset for the primary 
analyses. Two sets of analyses were performed using each of these methods; one for 
the change from baseline to short-term follow-up MCS and the second for the change 
from baseline to short-term follow-up PCS. Application of these methods requires 
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certain parameters to be specified to control or aid the entire tree growing and 
selection procedure. The minimum number of individuals in any node at any given time 
was set to 30. The maximum number of levels or splits of the fully grown tree produced 
by the IPD-IT method was set to 10. The maximum number of levels for the unmodified 
IPD-SIDES and modified IPD-SIDES method was set to four since there are only four 
covariates to consider; thus any identified subgroups can only ever be defined by up to 
four covariates. Moreover, the maximum number of best splits to consider for each 
node was set the three for the unmodified IPD-SIDES and modified IPD-SIDES methods 
with a restriction of p≤0.10 placed on the splitting criterion. Prior to applying both the 
IPD-SIDES methods, a grid search was performed to select the optimum complexity 
control parameter sequence for the first four levels of the tree as described in Chapter 
6 (section 6.3.2). The grid search was performed considering all permutations of the 
values from 0 to 1 in steps of 0.2 at the first level, and then 0.2 to 1 in steps of 0.2 at 
levels 2, 3 and 4. The IPD-IT method used 5-fold cross-validation to evaluate the 
subtrees and select the final optimum tree. The resampling procedure was repeated 
1000 times for both the IPD-SIDES methods to adjust the p-values of the identified 
candidate subgroups; thus removing any possibly spurious subgroups. The final trees 
or subgroups identified by the three methods were then summarized.  
 
10.4 Results 
 
Risk of bias assessment of included trials 
The risk of bias assessment (Table 10.1) was based on the main results paper of each 
trial included in the pooled dataset. It was clear that all four trials used the method of 
randomization to allocate participants. Moreover, all four trials adequately concealed 
the allocation sequence. None of the trials were double blinded (participant or 
therapist). All trials adequately reported the completeness of outcome data including 
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exclusions from the analysis. Three of the four trials showed no signs of selective 
outcome reporting and provided a description of how the sample size was determined. 
All but one of the four trials performed the primary analysis on an intention to treat 
(ITT) basis.  
 
Table 10.1 - Cochrane collaboration Risk of Bias assessment of included trials 
 Risk of Bias Assessment (RoBA)* 
 1 2 3 4 5 6 7 8 
Trial 1 Y Y N Y Y Y Y Y 
Trial 2 Y Y N Y Y Y Y Y 
Trial 3 Y Y N Y U Y U N 
Trial 4 Y Y N Y Y Y Y Y 
* RoBA, 1. Random sequence generation, 2. Allocation concealment, 3. Blinding, 4. Incomplete outcome 
data, 5. Selective reporting, 6. Similarity of groups at baseline, 7. Sample size calculation, 8. Intention to 
treat analysis 
Y- Low risk of bias, N- High risk of bias, U- Unclear 
 
Summary of pooled dataset 
The pooled IPD dataset consisted of 4,540 individuals in total from four acupuncture 
trials. Table 10.2 presents a summary of the demographic and baseline data contained 
within the pooled dataset. The characteristics and baseline values of the individuals 
seem to be quite similar when comparing the control arm to the intervention arm. 
Overall, the sample has an average age of 52 with a slightly higher proportion of 
females (59%) than males (41%). The mean MCS scores and PCS scores are 45.7 (SD: 
12.2) and 35.4 (SD: 8.2) respectively.  
 
Summaries of the MCS and PCS component scores and the change from baseline to 
short-term follow-up MCS and PCS scores are presented in Table 10.3. On average, both 
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the MCS and PCS scores are greater in the intervention arm at short-term follow-up. 
Moreover, the mean change from baseline to short-term follow-up MCS and PCS scores 
are greater in the intervention arm as well. The positive sign for the mean change 
suggests that those in receipt of the intervention (acupuncture) improve more in terms 
of both the mental and physical components compared to those in the control arm. This 
is consistent with published meta-analyses. 
 
Table 10.2 – Summary of demographic and baseline data from pooled dataset 
  
Control 
(N=2397) 
Intervention 
(N=2143) 
Total  
(N=4540) 
Age N 2397 2143 4540 
  Mean (SD) 52 (13.4) 52 (13.3) 52 (13.3) 
  Median 53.0 53.0 53.0 
  Range 18 – 88 18-91 18 – 91 
  Missing 0 0 0 
Gender Male 981 (41%) 891 (42%) 1872 (41%) 
  Female 1416 (59%) 1252 (58%) 2668 (59%) 
  Missing 0 0 0 
MCS N 2199 1956 4155 
  Mean (SD) 46 (11.9) 45.4 (12.4) 45.7 (12.2) 
  Median 48.2 47.2 47.7 
  Range 11.3 - 70.5 9.5 - 71.3 9.5 - 71.3 
  Missing 198 187 385 
PCS N 2199 1956 4155 
  Mean (SD) 35.2 (8.3) 35.7 (8.2) 35.4 (8.2) 
  Median 34.5 35.1 34.8 
  Range 12.4 - 67.7 13.7 - 61.3 12.4 - 67.7 
  Missing 198 187 385 
 
 
 
In total, 3845 were included in the final dataset for analyses. The demographic and 
baseline data were again summarized and observed for the reduced dataset and the 
covariates were stilled well balanced across both arms. The overall mean treatment 
effect estimate for the change from baseline to short-term MCS outcome was 2.50 (SE: 
0.342). The overall mean treatment effect estimate for the change from baseline to 
short-term PCS outcome was 3.75 (SE: 0.282). 
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IPD-IT results 
The IPD-IT method did not identify any moderators of treatment effect when the 
outcome was the change from baseline to short-term follow-up MCS or when the 
outcome was the change from baseline to short-term follow-up PCS.  
 
Table 10.3 – Summary of short-term outcome data and change from baseline to short-
term follow-up outcome data 
  
Control 
(N=2397) 
Intervention 
(N=2143) 
Total 
(N=4540) 
MCS N 2106 1920 4026 
  Mean (SD) 47.4 (11.7) 49.1 (11.0) 48.2 (11.4) 
  Median 50.4 52.2 51.3 
  Range 14.4 - 71.1 8.1 - 69.7 8.1 - 71.1 
  Missing 291 223 514 
PCS N 2106 1920 4026 
  Mean (SD) 39.0 (9.8) 43.0 (10.0) 40.9 (10.0) 
  Median 38.3 43.9 40.6 
  Range 13.5 - 69.4 14.0 - 65.9 13.5 - 69.4 
  Missing 291 223 514 
MCS CHANGE  N 2026 1819 3845 
 FROM BASELINE Mean (SD) 1.4 (10.6) 3.7 (10.3) 2.5 (10.5) 
  Median 0.5 2.3 1.3 
  Range -38.1 - 44.6 -39.2 - 42.3 -39.2 - 44.6 
  Missing 371 324 695 
PCS CHANGE  N 2026 1819 3845 
 FROM BASELINE Mean (SD) 3.9 (8.2) 7.3 (8.9) 5.5 (8.8) 
  Median 2.4 6.1 4 
  Range -23.4 - 33.7 -18.6 - 37.6 -23.4 - 37.6 
  Missing 371 324 695 
 
 
Unmodified IPD-SIDES results 
The unmodified IPD-SIDES method found two subgroups when the outcome was the 
change from baseline to short-term follow-up MCS (Table 10.4). Recall from chapter 7 
that the method aims to identify candidate subgroups where each of the candidate 
subgroups can be thought of as a separate tree. Therefore, the first candidate subgroup 
or tree suggests that individuals with baseline MCS≤60.5 (n=3464) and the second 
 191 
 
candidate subgroup suggests that individuals aged>34 (n=3422) have greater 
treatment benefit. When the outcome was the change from baseline to short-term 
follow-up PCS, the unmodified IPD-SIDES method identified 39 subgroups with 
enhanced treatment effect (Table 10.5). As there are so many candidate subgroups 
identified in this table, they will not be interpreted here and can be interpreted in the 
same way as those subgroups identified in Table 10.4. Just to give one example, the 
third subgroup identified in Table 10.5 suggests that individuals with baseline 
MCS<=60.5, aged>34 and have baseline PCS>25.3 have on average a treatment benefit 
of 3.718 in terms of the physical component score. The fact that so many candidate 
subgroups were identified makes the overall interpretation of the results quite difficult. 
Moreover, if required, reducing the number of subgroups to a select few meaningful 
subgroups could prove to be quite difficult especially when many of the subgroups 
have similar treatment effects.  
 
Modified IPD-SIDES results 
The modified IPD-SIDES method found one subgroup with enhanced treatment effect 
when the outcome was the change from baseline to short-term follow-up MCS (Table 
10.6). Individuals with baseline MCS≤54.5 (n=2701) have greater treatment benefit. 
When the outcome was the change from baseline to short-term follow-up PCS, the 
modified IPD-SIDES method identified 4 subgroups with enhanced treatment effect 
(Table 10.7). Those with a baseline MCS>51.4 (n=1531) have an average treatment 
benefit 4.340, those with baseline MCS>51.4 and baseline PCS <= 35.9 (n=919) have an 
average treatment benefit of 5.436, those with baseline MCS>54.5 (n=1144) have an 
average treatment benefit of 4.609 and finally those with Age<=43 at baseline have an 
average treatment benefit of 4.929. 
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Unmodified IPD-SIDES results vs. modified IPD-SIDES results 
There is a clear distinction between the unmodified IPD-SIDES method and the 
modified IPD-SIDES method in the subgroups identified when we observe the results. 
First and foremost, our objective and hence the objective of the modified IPD-SIDES 
method is to identify subgroups with enhanced treatment effect i.e. subgroups that 
have a treatment effect that is greater than the overall treatment effect. When we 
observe the results of the unmodified IPD-SIDES method, we can clearly see that this is 
not true for many of the subgroups. For example, the first subgroup identified in Table 
10.5 has a mean treatment effect of 3.716 which is less than the overall treatment effect 
(3.75) for the change from baseline to short-term PCS outcome. On the other hand, the 
results of the modified IPD-SIDES method indicate that all of the identified subgroups 
actually do have an enhanced treatment effect compared to the overall mean treatment 
effect of the data. This observation clearly shows the distinction between the two 
methods and provides positive evidence that the modified IPD-SIDES method does 
actually identify subgroups with enhanced treatment effect. 
 
Another observation is that many of the treatment effects of the subgroups identified 
by the unmodified IPD-SIDES method are not that different to their comparator. For 
example, the first selected subgroup in Table 10.5 has a mean treatment effect of 3.716 
and its comparator subgroup has a treatment effect of 3.614. Moreover, there are also 
subgroups that have been selected that have a treatment effect that is smaller than the 
comparator subgroup e.g. the second subgroup identified in Table 10.5. As discussed in 
the previous chapter, the reason this happens is because the original splitting criterion 
does not directly evaluate the differential effect. For example, the test statistics for the 
first subgroup in Table 10.5 are 𝑍𝐸1 =
3.716
0.293
= 12.683 and 𝑍𝐸2 =
3.614
0.939
= 3.849. The 
difference between the test statistics suggests that there is a big differential effect 
between the two groups and thus the original splitting criterion will indicate it as being 
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highly significant. Evaluating the same subgroup using a mixed-effect model with 
random trial effect, a fixed treatment effect, a fixed binary indicator for the subgroup 
and a fixed interaction effect, then the test statistic for the interaction effect is 0.240 
which is indicative of there being no differential effect present; yet the unmodified IPD-
SIDES splitting criterion suggests otherwise. This therefore provides empirical 
evidence that the new splitting criterion (equation (9.2) in Chapter 9) used by the 
modified IPD-SIDES method better evaluates the differential effect and does what we 
require it to do when compared to the original splitting criterion proposed by the 
authors.  
 
10.5 Discussion 
 
This chapter demonstrated the application of the proposed IPD-IT, unmodified IPD-
SIDES and modified IPD-SIDES methods to real individual patient data. There were no 
subgroups or moderators of treatment effect identified by the IPD-IT method. The 
difference between the unmodified IPD-SIDES and modified IPD-SIDES methods was 
clearly demonstrated having applied it to real data. The modified method identified 
subgroups with enhanced treatment effect and thus demonstrated that it actually does 
what we require it to do.  
 
The fact that no subgroups were found by the IPD-IT method does not necessarily 
imply a negative result. Recall from Chapter 3 that one of the reasons for performing 
exploratory subgroup analyses is to assess the internal consistency of a main effect 
found in a trial within subgroups. Therefore the fact that no subgroups were found by 
the IPD-IT method could suggest that the treatment effectiveness found from the 
primary trial analyses is consistent across subgroups. However, on the other hand, 
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such a conclusion may not be believable given that the modified IPD-SIDES method did 
find some subgroups. 
 
The application of these methods to real data bought to light several issues associated 
with conducting IPD meta-analyses. Although IPD were provided for each of the trials, 
the data are only of use for subgroup analyses if there are several demographic and 
baseline covariates that are common to all trials. In the example in this chapter, only 
four covariates were common to all trials. This may contribute towards the fact that no 
subgroups were identified by the IPD-IT method because there were not enough 
covariates that could have been used to define potential subgroups. Moreover, this 
could also mean that the modified IPD-SIDES method could have missed out on 
identifying more subgroups defined by a greater number of covariates with larger and 
more enhanced treatment effect.  
 
Missing data was another issue faced when applying these methods; a problem 
experienced with most statistical analyses. Observations with missing baseline or 
outcome data had to be dropped from the analyses. Although there are methods for 
dealing with missing data e.g. imputation, analysing data with imputed values would 
only serve as a form of sensitivity analyses.  
 
Typically when performing such analyses, the ICC value is computed beforehand to 
determine what analyses method to use. The ICC values for the MCS and PCS outcome 
data were 0.002 and 0.03 respectively. These values are very small, hence the 
application of the original IT and SIDES methods may have sufficed. To verify this, the 
original methods were applied to the data and the same results were observed. 
Nonetheless, the main analyses in this chapter did adjust for clustering effects by 
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applying the proposed IPD-IT and modified IPD-SIDES methods with the aim of 
demonstrating the application of these methods to real data. 
 
This chapter concludes the proposal of the IPD-IT and modified IPD-SIDES procedures 
by demonstrating their application to real individual patient data from several similar 
trials. The next chapter will thus provide a detailed discussion of the work contained in 
this thesis along with several recommendations for further work. Finally, the 
conclusions of this work along with its contributions to LBP research, statistical 
methodology and medical research will also be presented.  
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Table 10.4 – Subgroups identified by the unmodified IPD-SIDES method when applied to the change from baseline to short-term MCS outcome data. 
 
 
Selected subgroup Disregarded subgroup 
  
Subgroup n1 Trt1 SE Trt1 Trt1 p-value n0 Trt0 
SE 
Trt0 
Trt0 p-value 
Differential 
effect 
Split criterion 
p-value 
 MCS <= 60.5  3464 2.768 0.361 8.77E-15 381 0.647 0.691 0.1748 2.122 1.93E-06 
 Age > 34  3422 2.756 0.363 1.60E-14 423 0.013 1.000 0.4947 2.743 8.44E-08 
 
 
Table 10.5 – Subgroups identified by the unmodified IPD-SIDES method when applied to the change from baseline to short-term PCS outcome data. 
 
 
Selected subgroup Disregarded subgroup 
  
Subgroup n1 Trt1 
SE 
Trt1 
Trt1  
p-value 
n0 Trt0 
SE 
Trt0 
Trt0  
p-value 
Differential 
effect 
Split criterion  
p-value 
 MCS <= 60.5  3464 3.716 0.293 0.000 381 3.614 0.939 5.95E-05 0.102 4.46E-10 
 MCS <= 60.5 & Age > 34  3071 3.658 0.307 0.000 393 3.894 0.944 1.87E-05 -0.236 3.72E-08 
 MCS <= 60.5 & Age > 34 & PCS > 25.3  2755 3.718 0.314 0.000 316 3.597 1.109 0.000666 0.121 1.25E-09 
 MCS <= 60.5 & Age > 34 & PCS > 28.2  2456 3.552 0.329 0.000 615 4.341 0.738 2.05E-09 -0.789 0.000503 
 MCS <= 60.5 & Age > 34 & PCS <= 47.1  2764 3.752 0.326 0.000 307 3.166 0.661 8.24E-07 0.585 2.02E-06 
 MCS <= 60.5 & PCS > 25.5  3114 3.713 0.298 0.000 350 4.163 1.079 5.71E-05 -0.450 1.26E-09 
 MCS <= 60.5 & PCS > 25.5 & Age <= 63  2519 3.755 0.339 0.000 595 3.470 0.610 6.25E-09 0.285 0.000137 
 MCS <= 60.5 & PCS > 25.5 & Age > 33  2790 3.740 0.312 0.000 324 3.373 0.988 0.000319 0.367 1.38E-09 
 MCS <= 60.5 & PCS > 25.5 & Age <= 68  2827 3.721 0.316 0.000 287 3.318 0.861 5.82E-05 0.403 2.07E-08 
 MCS <= 60.5 & Age <= 69  3154 3.817 0.311 0.000 310 2.369 0.832 0.002197 1.448 2.46E-11 
 MCS <= 60.5 & Age <= 69 & PCS > 25.8  2839 3.706 0.314 0.000 315 5.249 1.144 2.24E-06 -1.544 3.32E-07 
 MCS <= 60.5 & Age <= 69 & PCS <= 43.7  2524 4.047 0.355 0.000 630 3.039 0.525 3.53E-09 1.008 7.18E-05 
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 MCS <= 60.5 & Age <= 69 & PCS <= 47.9  2847 3.963 0.328 0.000 307 2.759 0.679 2.45E-05 1.204 1.48E-08 
 PCS > 25.2  3449 3.909 0.288 0.000 396 3.047 1.000 0.001158 0.862 1.09E-13 
 PCS > 25.2 & Age <= 68  3106 3.941 0.307 0.000 343 3.361 0.810 1.68E-05 0.580 7.43E-10 
 PCS > 25.2 & Age <= 68 & MCS > 28.1  2790 3.776 0.323 0.000 316 5.219 0.921 7.39E-09 -1.443 2.14E-05 
 PCS > 25.2 & Age <= 68 & MCS > 32.8  2484 3.907 0.346 0.000 622 4.058 0.647 1.82E-10 -0.151 0.000368 
 PCS > 25.2 & Age <= 68 & MCS <= 59.9  2801 3.818 0.320 0.000 305 4.630 0.981 1.19E-06 -0.812 3.52E-07 
 PCS > 25.2 & Age > 33  3101 3.946 0.301 0.000 348 3.458 0.973 0.000190 0.489 1.49E-11 
 PCS > 25.2 & Age > 33 & MCS > 28.1  2791 3.826 0.317 0.000 310 4.812 0.909 5.99E-08 -0.986 1.76E-06 
 PCS > 25.2 & Age > 33 & MCS > 32.9  2469 3.957 0.341 0.000 632 3.903 0.623 1.84E-10 0.055 0.00016 
 PCS > 25.2 & Age > 33 & MCS <= 60.3  2795 3.812 0.314 0.000 306 4.782 1.002 9.02E-07 -0.970 1.91E-07 
 PCS > 25.2 & MCS <= 60.2  3112 3.814 0.301 0.000 337 4.321 0.945 2.42E-06 -0.506 1.04E-08 
 PCS > 25.2 & MCS <= 60.2 & Age > 33  2789 3.825 0.315 0.000 323 3.604 1.009 0.000177 0.222 1.25E-09 
 PCS > 25.2 & MCS <= 60.2 & Age <= 63  2513 3.899 0.343 0.000 599 3.410 0.604 8.22E-09 0.489 5.32E-05 
 PCS > 25.2 & MCS <= 60.2 & Age <= 68  2822 3.816 0.319 0.000 290 3.537 0.857 1.85E-05 0.279 3.09E-08 
 Age <= 69  3480 3.881 0.299 0.000 365 2.329 0.788 0.001550 1.552 1.49E-12 
 Age <= 69 & PCS > 25.4  3129 3.888 0.304 0.000 351 4.363 1.077 2.56E-05 -0.475 6.11E-10 
 Age <= 69 & PCS > 25.4 & MCS <= 59.9  2819 3.754 0.317 0.000 310 4.725 0.980 7.14E-07 -0.972 6.94E-07 
 Age <= 69 & PCS > 25.4 & MCS > 28  2816 3.703 0.320 0.000 313 5.384 0.923 2.76E-09 -1.681 4.93E-05 
 Age <= 69 & PCS > 25.4 & MCS > 32.8  2503 3.831 0.342 0.000 626 4.083 0.646 1.31E-10 -0.252 0.00055 
 Age <= 69 & PCS <= 47.6  3137 3.981 0.317 0.000 343 3.056 0.645 1.07E-06 0.925 3.22E-08 
 Age <= 69 & PCS <= 47.6 & MCS <= 57.3  2522 3.874 0.344 0.000 615 4.234 0.755 1.01E-08 -0.360 6.67E-05 
 Age <= 69 & PCS <= 47.6 & MCS > 28.8  2816 3.871 0.336 0.000 321 4.793 0.925 1.11E-07 -0.922 7.11E-06 
 Age <= 69 & PCS <= 47.6 & MCS <= 60.6  2823 3.932 0.330 0.000 314 3.958 1.035 6.53E-05 -0.026 1.10E-08 
 Age <= 69 & MCS <= 60.4  3135 3.816 0.312 0.000 345 4.061 0.976 1.57E-05 -0.244 1.25E-08 
 Age <= 69 & MCS <= 60.4 & PCS > 25.9  2813 3.706 0.316 0.000 322 4.986 1.137 5.76E-06 -1.279 2.12E-07 
 Age <= 69 & MCS <= 60.4 & PCS <= 43.7  2510 4.040 0.357 0.000 625 3.038 0.528 4.41E-09 1.002 8.28E-05 
 Age <= 69 & MCS <= 60.4 & PCS <= 47.9  2831 3.961 0.330 0.000 304 2.806 0.685 2.09E-05 1.154 2.35E-08 
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Table 10.6 – Subgroups identified by the modified IPD-SIDES method when applied to the change from baseline to short-term MCS outcome data. 
 
 
Selected subgroup Disregarded subgroup  
  
Subgroup n1 Trt1 
SE  
Trt1 
Trt1  
p-value 
n0 Trt0 
SE 
Trt0 
Trt0 
p-value 
SMD* of 
selected 
subgroup 
Differential 
effect 
Split criterion 
p-value 
MCS <= 54.5 2701 3.285 0.415 1.22E-15 1144 0.635 0.430 0.0700 0.28 2.650 0.0009 
 * SMD – Standardized mean difference 
 
Table 10.7 – Subgroups identified by the modified IPD-SIDES method when applied to the change from baseline to short-term PCS outcome data. 
 
 
Selected subgroup Disregarded subgroup  
  
Subgroup n1 Trt1 
SE 
Trt1 
Trt1 
p-value 
n0 Trt0 
SE 
Trt0 
Trt0 
p-value 
SMD* of 
selected 
subgroup 
Differential 
effect 
Split criterion 
p-value 
MCS > 51.4 1531 4.340 0.463 0.000 2314 3.403 0.348 0.000 0.56 0.937 0.086 
MCS > 51.4 & PCS <= 35.9 919 5.436 0.609 0.000 612 3.054 0.591 0.000 0.70 2.382 0.016 
MCS > 54.5 1144 4.609 0.544 0.000 2701 3.378 0.324 0.000 0.59 1.230 0.029 
Age <= 43 1170 4.929 0.527 0.000 2675 3.237 0.330 0.000 0.63 1.692 0.005 
* SMD – Standardized mean difference 
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Chapter 11 
 
Discussion, Further 
Work & Conclusions 
 
 
11.1 Introduction 
 
In Chapter 8 and Chapter 9, the IPD-IT and modified IPD-SIDES methods were 
developed and proposed for application in an IPD meta-analysis setting. The previous 
chapter, Chapter 10, was the final stage of the methodological development 
demonstrating the application of the proposed IPD-IT and modified IPD-SIDES 
methods to real life data from several trials of acupuncture for non-specific low back 
pain. The objective of this chapter is to provide a detailed summary of the work carried 
out in this thesis. Firstly, a detailed discussion will be presented along with 
recommendations for further work. Finally, a structured conclusion of the work in this 
thesis will be presented.  
 
11.2 Discussion and Further Work 
 
The work presented in this thesis contributes towards the advancement of subgroup 
analyses methodology within the area of LBP. Moreover, it further contributes towards 
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statistical methodology for identifying subgroups in an IPD meta-analyses framework. 
The detailed discussion in this section brings to light a number of important research 
questions that need investigating. These research questions will thus form the 
recommendations for future work and will also be presented in this section.  
 
Simulation studies 
A simulation study was performed in Chapter 7 to evaluate the performance of the IT, 
STIMA and SIDES methods in a number of very simple scenarios in a single trial setting. 
The IT and SIDES methods performed well particularly in detecting large and very 
large interaction effect sizes for a variety of sample sizes. On the other hand, the STIMA 
method didn’t perform well and was therefore dropped from further investigation. In 
theory the STIMA method sounds quite plausible and one ought to expect that it should 
perform as described; however this was not the case. Therefore, further work should 
consider extensively evaluating the STIMA method to investigate why it performed the 
way it did in the simulation study. Overall, the single trial simulation study provided 
confidence that the IT and SIDES methods work well in a number of different settings 
having considered a variety of sample sizes and interaction effect sizes. 
 
A simulation study was also performed in Chapter 8 to evaluate the performance of the 
two proposed extended methods (IPD-IT and IPD-SIDES) considering a variety of 
sample sizes, interaction effect sizes and varying between-study variance. The 
simulation study highlighted an issue with the performance of the IPD-SIDES method 
when detecting subgroups with very large treatment effects. This issue was thoroughly 
investigated and resolved in Chapter 9; however, the investigation gave rise to a 
number of other important findings associated with the method. In particular, the 
method identifies subgroups with the smallest p-value and thus doesn’t actually do 
what we require it to do. Therefore the method was further developed in Chapter 9 to 
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do what we require it to do by proposing a new splitting criterion that directly 
evaluates the interaction effect and also with a restriction imposed on the interaction 
p-value; hence the modified IPD-SIDES method was proposed. The modified method 
was then evaluated using a simulation study. Both the IPD-IT and the modified IPD-
SIDES methods performed well in detecting interaction effects using either a fixed-
effect or mixed-effect model to estimate the splitting criterion to account for the 
between-study variability. Again, the performance of these methods was assessed in a 
number of scenarios where the simulated data were generated from a linear model 
assuming a normally distributed outcome. Having demonstrated the methods work in 
several simple settings, it would be good to further evaluate their performance under 
slightly more complex settings such as when the data deviate from normality or when 
there are imbalances in the data. An advantage of recursive partitioning based methods 
compared to linear regression is that they do not make any assumptions about the 
distribution of the outcome variable or any assumptions of linearity. These methods 
have been shown to perform well in different scenarios when the continuous outcome 
data are non-normal. For example, Su et al demonstrated in a single trial setting that 
the IT procedure works well in detecting interactions when there are deviations from 
normality (136). Therefore, it would be good to evaluate the proposed methods and 
demonstrate how they perform in the event that data are non-normal. For example, we 
could evaluate the methods using a simulation study where data are generated as 
described in Chapter 7 but instead using a non-normal error distribution e.g. an 
exponential distribution. Other than continuous outcome data, future work should also 
consider the extension of the methods to other data types such as binary outcome data 
using a logistic regression model. Moreover, it is also of interest to evaluate the 
performance of the proposed methods considering varying degrees of imbalance in the 
data and also considering data with different types of covariates e.g. categorical and 
continuous. Hence, future work should consider performing a simulation study to 
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assess the IPD-IT and modified IPD-SIDES methods in more complex scenarios. 
Furthermore, it would also be of interest to perform a simulation study to evaluate the 
performance of the modified IPD-SIDES method using varying restrictions on the 
splitting criterion p-value. This will help assess how much we can relax the restriction 
without greatly affecting the performance of the method. 
 
Missing data 
The handling of missing data is a limitation of the original IT and SIDES methods as 
well as the IPD-IT and modified IPD-SIDES methods. Application of these methods to 
real data requires that the dataset is complete i.e. all observations with missing data 
need to be removed prior to the analyses. This could result in a loss of a large amount 
of information if there are several observations with one or more pieces of data 
missing i.e. missing covariate or outcome data. Not much emphasis was placed on 
handling missing data in this thesis as the objective of the work was to develop a 
method(s) and demonstrate its application. One option for handling missing data is to 
use surrogate splits; an approach proposed by Breiman et al and commonly used by the 
CART type approach (130, 131). If we assume a best split s* is found during the tree 
growing process having ignored all the missing values, then a surrogate split approach 
basically searches for the next best split s using another covariate that produces a split 
that is most similar to s* e.g. it has a similar splitting criterion value. The observation 
with the missing value is then sent to the node corresponding to its allocation from the 
surrogate split. Another option to consider is the use of multiple imputation techniques 
to handle missing data. Whichever approach is taken, analyses of a dataset with 
imputed values would only serve as a form of sensitivity analyses. However, of the two 
approaches for handling missing data, it has been shown that multiple imputation 
outperforms the surrogate split approach in terms of predictive accuracy (168).  
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Application to empirical data 
In Chapter 10, the proposed IPD-IT and modified IPD-SIDES methods were applied to a 
real IPD dataset consisting of data from four acupuncture trials. The purpose of this 
was simply to demonstrate the application of the methods. In general for both of these 
methods, if no subgroups are identified then this does not suggest a negative result. 
Such a result could be inferred as being confirmation of internal consistency which is 
one of the reasons for performing exploratory subgroup analyses as discussed in 
Chapter 3 i.e. confirmation that the treatment effect is consistent across subgroups. 
However there may be instances, as displayed in the application of the methods in 
Chapter 10, where one method finds subgroups whereas the other method doesn’t. In 
such an instance, both methods cannot be right. Observation of the simulation study 
results suggest that the IPD-IT method is more likely to get a false negative than 
modified IPD-SIDES is to get a false positive, so out of the two, we would probably 
prefer to believe the modified IPD-SIDES method. Both of these methods were only 
applied to a single pooled dataset in Chapter 10. However, it would also be nice to 
demonstrate the application of these methods to other real datasets as well. Hence, 
further work should consider the application of these methods to more real datasets. 
 
Several trials may test similar interventions using similar outcome measures however 
they may not have recorded the same or similar baseline measures or demographic 
data. This would result in very few common covariates being investigated and thus 
quite likely contributing towards the reason why no subgroups are found. Hence, a 
lesson learned here is that the commonality of covariates is a very important factor to 
consider during the planning stages of an IPD meta-analyses in the context of subgroup 
analyses where the aim is to investigate patient level covariates.  
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Computational efficiency  
Data mining techniques and machine learning algorithms are commonly associated 
with a reputation of being computationally intensive, in particular when dealing with 
large datasets. The same is also true for the IPD-IT and modified IPD-SIDES methods. In 
the simulation studies presented in this thesis, the computational time of these 
methods was quite short due to only a small number of binary variables being 
considered. However, when the data contain several more covariates with many more 
potential split points to consider, the computational time is amplified. This was 
experienced during the application of the methods to the real dataset in Chapter 10 and 
is thus noted here as a limitation of these methods. Both of the methods were 
investigated to see where the time lapse occurs when compared to the original IT and 
SIDES methods by applying them to the real data in Chapter 10 using the change from 
baseline to short-term follow-up PCS as the outcome. It was observed that the time 
taken to evaluate the splitting criterion for a single split was greater for the proposed 
methods; hence the overall time taken to grow a tree was greater. For example, the 
original IT method took 6.3 seconds to grow a single tree, the IPD-IT method that uses 
a fixed-effect model to estimate the splitting criterion took 105.3 seconds to grow a 
single tree and the IPD-IT method that uses a mixed-effect model to estimate the 
splitting criterion took 459.1 seconds to grow a single tree. Furthermore, the original 
SIDES method took 9.3 seconds to grow a single tree, the IPD-SIDES method that uses a 
fixed-effect model for estimating the splitting criterion took 16.2 seconds and finally 
the IPD-SIDES method that uses a mixed-effect model took 51.8 seconds to grow a tree. 
The reason for this is that the splitting criteria of the original methods directly compute 
the splitting criterion i.e. the t-test statistic, using the data whereas the proposed IPD-
IT and modified IPD-SIDES methods fit a model first to account for the clustering and 
then extract the test statistic thereafter from the fitted model. Direct computation of 
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the splitting criterion is evidently quicker than obtaining the splitting criterion having 
fitted a model. As a result, the use of the splitting criterion obtained from a fitted model 
has a cumulative effect on the time taken for the tree growing process. Consequently, 
this also lengthens the time taken for any of the cross-validation or resampling 
components of the methods; thus increasing the overall computational time. This 
therefore raises a question about whether or not the computational efficiency can be 
improved for both methods by developing a splitting criterion that can be directly 
computed without affecting the performance of the methods. One possible option to 
consider, as briefly discussed in Chapter 8, is to use a two-stage approach by evaluating 
the original IT and modified SIDES splitting criteria in each trial separately and then 
synthesizing them using some weighted average as done so in conventional meta-
analyses. Although such an approach sounds plausible, it does have an obvious 
drawback that was also discussed in Chapter 8. Nonetheless, having highlighted the 
increased computational time of the proposed methods, the two-stage approach is 
something worth investigating. Therefore, future research should develop and evaluate 
the performance of the two-stage approach that directly computes the splitting 
criterion to see if it improves the computational efficiency without any loss of the 
methods performance. 
 
11.3 General recommendations 
 
Conventional approach vs proposed methods 
An IPD meta-analysis framework is ideal for exploring patient level covariates and 
performing subgroup analyses. The conventional approach to subgroup analyses in this 
framework involves testing a limited number of subgroups one at a time. Considering 
the resource intensiveness associated with the entire process of forming an IPD 
repository, it would be a shame to waste these efforts by just exploring a limited 
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number of covariates one at a time instead of exploring the entire covariate space to 
identify subgroups defined by multiple covariates. For this reason, the IPD-IT and IPD-
SIDES methods have been developed and proposed in this thesis as two novel tools for 
subgroup analyses or subgroup identification that make best use of an IPD meta-
analysis framework. It is thus recommended that these methods be considered when 
performing subgroup analyses in an IPD meta-analyses setting.  
 
Choice of method 
The choice of which method to use out of the two simply depends on the objective of 
the researcher. To be more precise, it depends on whether the researcher wants to use 
the individual patient data to identify moderators of treatment effect or if they want to 
identify subgroups with enhanced treatment effect i.e. subgroups with a treatment 
effect greater than the overall treatment effect. Thus, when the research objective is to 
identify moderators of treatment effect, it is recommended that the IPD-IT method be 
used. If however, the objective is to identify subgroups with enhanced treatment effect, 
then it is recommended that the IPD-SIDES method be used.  
 
Splitting criterion estimation 
The results of the simulation studies presented in Chapter 8 and Chapter 9 suggest that 
the performance of the methods are quite similar when using either a fixed-effect or a 
mixed-effect model to estimate the splitting criterion. Hence, there is no particular 
preference as to which is used when applying these methods. However, the application 
of these methods can become computationally intensive when applied to larger 
datasets with many more variables, as discussed in section 11.2. Therefore, when the 
datasets are very large with a lot of variables, it is recommended that the methods be 
applied using a fixed-effect model to estimate the splitting criterion in order to save 
computational time.  
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11.4 Conclusions 
 
11.4.1 Addressing the research objectives of this thesis 
 
The primary and secondary research objectives were clearly presented in Chapter 1. 
The results and findings presented in this thesis fulfill the primary and secondary 
research objectives and will now be specified.  
 
Primary research objective 
The primary research objective of this thesis was to develop and evaluate innovative 
approaches for performing subgroup analyses in IPD meta-analyses within the area of 
low back pain. This thesis satisfies the research objective by proposing two novel 
approaches to subgroup analyses or subgroup identification, namely the IPD-IT and 
modified IPD-SIDES methods, in an IPD meta-analyses setting. As mentioned in 
previous chapters, the aims of these methods are different but are both very important 
clinically. To be more precise, the IPD-IT method aims to identify subgroups defined by 
one or more characteristics that are moderators of treatment effect, whereas the 
objective of the modified IPD-SIDES method is to identify subpopulations defined by 
one or more characteristics that have enhanced treatment effect. Both of these 
methods can aid a clinician’s decision making allowing them to better target 
treatments to patients presenting with LBP in the hope to maximize the treatment 
benefit.  
 
Secondary research objectives 
Secondary research objectives were required to systematically work towards 
answering the primary research objective. This thesis presented a review of the 
current recommendations for performing subgroup analyses in RCTs in Chapter 3, 
highlighting some important issues regarding how subgroups are typically defined and 
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evaluated. A systematic review in Chapter 4, published in the Spine Journal, found that 
the quality of subgroup analyses in the low back pain literature was of poor quality and 
that alternative statistical approaches are required. Finally, several alternative 
statistical methods were described in Chapter 5 from which tree based methods were 
highlighted as a promising alternative to overcome the associated issues with current 
guidelines and conventional subgroup analyses. The identified tree methods were thus 
developed and extended to address the primary research objective.  
 
11.4.2 Contributions to the literature 
 
The work contained in this thesis provides several strengths that contribute to the 
existing literature. These strengths will now be presented. 
 
Subgroup analyses in the area of LBP 
For many years, subgroup analyses have consistently been a key topic of discussion in 
the LBP research community. Though much effort has been made to undertake 
subgroup analyses in a single trial setting, the quality of the analyses and the reliability 
of the results are highly questionable (Chapter 4). Conventional methods used for 
subgroup analyses in the area of LBP in both a single trial setting and an IPD setting 
have several issues; one of them being the statistical approach used i.e. testing 
subgroups individually rather than identifying subgroups defined by multiple 
characteristics. This thesis identified tree based methods (IT and SIDES) used in other 
research disciplines as an alternative statistical approach for identifying subgroups 
defined by multiple characteristics. Hence tree methods provide an alternative 
approach for performing subgroup analyses in a single LBP trial setting. Moreover, the 
proposed extensions of the identified methods (IPD-IT and modified IPD-SIDES) now 
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provide two new novel approaches to subgroup analyses of LBP data in an IPD meta-
analyses setting.  
 
Statistical contributions 
Subgroup analyses in general in an IPD meta-analyses framework typically test 
subgroups one at a time using either a one-stage or a two stage-approach. Considering 
the resource intensiveness of IPD meta-analyses, it would be a shame to collect all of 
the data only to perform one or a small number of subgroup analyses of pre-specified 
subgroups with a pre-defined and justified cut-point. Rather, it would be better to 
make full use of the data and explore the entire covariate space to identify subgroups 
defined by multiple characteristics. Therefore, this thesis proposes two statistical 
approaches to subgroup analyses in an IPD meta-analyses setting. 
 
Medical contributions 
Although the problem originated from an important research priority in the LBP 
community, this does not restrict the identified and proposed statistical methods to the 
field of LBP only. The proposed methods are easily applicable to any field of research 
where the aim is to perform subgroup analyses in an IPD meta-analyses framework. 
Identifying subgroups in this manner could be extremely useful in any medical 
research area so that treatments can be targeted accordingly to maximize benefit and 
quite possibly to reduce any associated harms. 
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Appendix A: Systematic review paper published in the Spine Journal 
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Appendix B 
 
Appendix B: Systematic review search terms 
Listed below are the specific keywords used to conduct the literature search: 
1     Low Back Pain/ (11231) 
2     "low* back pain".m_titl. (6615) 
3     1 or 2 (12932) 
4     randomized controlled trial.pt. (309096) 
5     controlled clinical trial.pt. (82630) 
6     randomized.ab. (215472) 
7     clinical trials as topic.sh. (154789) 
8     randomly.ab. (155983) 
9     trial.ti. (92244) 
10     4 or 5 or 6 or 7 or 8 or 9 (693954) 
11     3 and 10 (1993) 
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Appendix C 
 
Appendix C: Matrix form of the general expressions required to generate data for the simulation study 
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